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 Abstract 
      Chronic pain is a condition that is thought to affect roughly 8 million people in the UK. It is 
classified as pain that persists for more than 6 months. Chronic pain is commonly associated 
with depression, insomnia, anxiety and poor quality of life. Many treatments for chronic pain 
are accompanied by numerous debilitating side-effects, this in combination with insufficient 
pain relief means that approximately 50% of patients will discontinue their treatment.  Most 
sufferers choose to live with the pain rather than deal with numerous adverse-effects. There 
is a great need for new therapeutics that are specifically designed to target the underlying 
mechanisms of chronic pain, therefore providing safer and more effective treatments.   
    One such mechanism is the down-regulation of strychnine-sensitive glycine receptors 
(SSGRs) localised in the dorsal horn. Glycinergic activity is known to be inhibitory and artificial 
stimulation can produce analgesia. Positive allosteric modulators acting on α1 SSGRs may able 
to compensate for the inhibitory glycinergic activity that is reduced in chronic pain. Previous 
work within the group lead into the identification of propofol analogues designed to be novel 
positive allosteric modulators of α1 SSGRs. 
    Work presented in this thesis describes the generation and optimisation of these analogues 
with a focus of drug metabolism and pharmacokinetics. The hit to lead process has resulted in 
the development of a lead compound that is highly potent at the target, has excellent 
pharmacokinetic and safety profiles and is able to produce high levels of analgesia in an 
animal model of neuropathic pain. 
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1.1 Pain 
1.1.1 Nociception 
      Pain is an unpleasant sensation that occurs when contact is made with noxious stimuli or 
when tissues, nerves or organs are damaged. Although uncomfortable, pain serves a 
protective purpose; it warns us of potential dangers and encourages us to guard injuries 
whilst they heal. Throughout history opium, in varying forms, has been used as a go-to for 
analgesia (pain relief)1. From the 1800s onwards, analgesic drugs such as morphine and 
aspirin have become more widely used.  Improved understanding of how pain is processed 
has led to creation of therapies that target the inflammatory and neurological aspects of pain, 
as well as the varying degrees of pain severity1. Recently, chronic dysfunctional pain has 
emerged as legitimate disease and traditional therapies no longer provide sufficient relief. 
There is a serious need for new analgesics that are designed to specifically target the 
underlying mechanisms of chronic pain.  
     Nociception is the processing of sensory information stemming from contact with painful 
stimuli. In the early-1900s, specialised sensory neurons (nociceptors) transmitting noxious 
signals from the periphery into the spinal cord, where they synapse with projection neurons 
that feed into the central nervous system (CNS), were identified2. Nociceptive neurons are 
categorised into two groups, Aδ and C-fibres3. The cell bodies of these fibres originate in the 
dorsal root ganglion (DRG) of the spinal cord. Aδ-fibres are thin and lightly myelinated, a 
structure that allows for swift conduction of sensory transmissions2. They are commonly 
believed to be responsible for ‘first’ pain; the sharp, spike of pain that accompanies a quick 
  
retreat of the injured appendage. ‘Second’ pain is a throbbing or burning ache that often 
arises from tissue damage. The conduction for this type of pain is much slower and perfectly 
suited to smaller, unmyelinated C-fibres2; 3. Both nociceptive neurons can be further 
differentiated by the types of stimuli they react to; some Aδ-fibres are exclusively activated by 
mechanical (i.e. touch) and others by thermal (i.e. heat), whilst C-fibres may be activate by 
mechanical, thermal and additional chemical (i.e. spice) stimuli3. Nociceptors all have much 
higher activation thresholds than their normal sensory counterparts and contain highly 
specialised transducers.  
    Many of nociceptive ion channels belong to the large, diverse transient receptor potential 
(TRP) non-specific cation channel family2. Vanilloid receptors (TRPV1-4), responding to heat 
and chemical stimuli were the first nociceptive transducers to be identified2; 4. Channel 
opening is temperature dependant, similar to what is seen in normal heat sensory neurons 
only with a higher temperature threshold (43°C)5. Vanilloid receptor-like channels (VRL) are 
another type of transducer that responds to heat. These channels have a higher temperature 
threshold than standard vanilloid channels (52°C) and are not responsive to vanilloids; 
vanilloids, such as capsaicin, are compounds that primarily activate TRPV channels. It is 
believed VRLs are most commonly expressed on large type I Aδ nociceptors, usually 
responsible for detecting intense heat3; 4. 
    Response to painful cold is not as well defined as noxious heat. Only in the last decade have 
two transducers, TRPM8 and TRPA1, been identified. The role these channels play in the 
sensation of noxious cold is still not conclusive6; 7. The receptors that respond to painful touch, 
such as pressure and tissue distortion, and noxious chemicals (e.g. toxins, irritants and 
  
flavonoids) have yet to characterised but it is likely that TRPs involved in nociception of 
temperature (e.g. TRPA1) play a key role2; 6.  Exposure to noxious stimuli is frequently 
accompanied by physical damage.  In an attempt to heal damage, an inflammatory response is 
triggered, causing the nervous system to become sensitised to pain (algesia)8; 9.  
 
1.1.2 Inflammatory Pain     
    Activation and increased sensitivity of nociceptive cation channels is caused by natural 
chemical mediators released following injury of nerves and tissues. The role of inflammation 
in pain propagation is a vast, complex process, that largely involves the production and 
release inflammatory mediators from immune cells that sensitise surrounding nerves to pain 
and promote regeneration 10.  
     Following trauma there is an influx of calcium ions (Ca2+) into the neuron. Increased Ca2+ 
concentration initiates a series of intracellular events, including the release of nociceptive 
neurotransmitters, glutamate and substance P, and the activation of m-calpain and UPS 
(ubiquitin-proteasome system)8; 10.  M-calpain promotes the release of more inflammatory 
mediators and, along with UPS, assists in the breakdown of the cytoskeleton, causing further 
damage and prompting additional inflammation11; 12. Sensory neurons also release adenosine 
triphosphate (ATP) that triggers Schwann cells to release free radicals and inflammatory 
proteins, for instance chemokines, cytokines and neurotrophins9; 10. The release of chemical 
mediators leads to the recruitment of more immune cells (e.g. Mast cells, neutrophils and 
macrophages) that also contribute to inflammation and alter permeability of the blood-nerve 
  
barrier, allowing easier access of the injured site8; 9. As a result the excitability of injured 
neurons and surrounding uninjured neighbouring nerves is increased, often by changes in ion 
channel expression and function. For example, the activation of mast cells prompts the 
release tryptase and bradykinin, which induce pain hypersensitivity via protease-activated 
receptors (PARs). Activation of PARs sets off an intracellular cascade that cumulates in the 
increased activity and expression of cation channels, such as TRPV113. Thus lowering the 
activation threshold of the neuron, as well as reducing the cool-down  time for subsequent 
impulses. With less intense stimuli needed to trigger action potentials at a greater frequency, 
the nerve becomes hyperexcitable. In another example, potassium-channels are the down-
regulated by RE1-silencing transcription factor (REST), which has been shown to be increased 
during inflammatory pain14.  Potassium-channels are responsible for generating an inhibitory 
M-current that counteracts firing of action potentials. Decreasing the availability of functional 
potassium channels will lessen the effect of the M-current and increase neuronal 
excitability15. The role of inflammation in pain hypersensitivity is summarised in Figure 1.1. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Injury 
Inflammatory Response 
Genotypic Shift 
Phenotypic Shift 
Pain Hypersensitivity  
 Activation of m-calpain/UPS 
 Release of glutamate/substance P 
 Activation of inflammatory cells 
(e.g. Schwann cells) 
 Release of inflammatory mediators 
(e.g. cytokines, chemokines and 
bradykinin) acting on PARs 
Increased intracellular 
calcium 
 Increased glutamate 
synthesis/release 
 Up-regulated Na+/Ca2+ channels 
 Increased NMDA receptor 
expression 
 Down-regulated K+ channels 
 Reduce GABAergic and glycinergic 
activity 
 Triggered intracellular 
kinase pathways (e.g. 
JNK, MAPK and ERK1/2) 
 Activation of 
transcription factors 
(e.g. REST, SOX-11 and 
AP-1) 
 
Figure 1.1. Inflammatory response, after injury, leads to pain hypersensitivity: Following injury, 
increased intracellular Ca2+ leads to the activation of m-calpain and UPS, initiating cellular 
breakdown. M-calpain also causes the release of algesic agents, ATP, glutamate and substance P 
and activates nearby immune cells. Inflammatory proteins, such as chemokines and bradykinin act 
on protease-activated receptors (PARs). This sets off a series of intracellular kinase pathways, 
including JNK, MAPK and ERK1/2 that trigger regulatory transcription factors, REST, SOX-11, AP-1, 
etc. The end result is up-regulation of Ca2+/Na+ channels and NDMA receptors, as well as the down-
regulation K+ channels and GABA/glycine receptors. Changes in expression of ion channels lower 
the activation threshold of neurons, making them more excitable. While altered expression of 
neurotransmitter receptors allow for easier communication between nociceptors. Adapted from 
Üçeyler et al. 200610. 
  
1.1.3 Neuropathic Pain  
         Neuropathic pain (NP) describes hypersensitivity that follows injury within the 
somatosensory system16. Neuronal trauma in the peripheral nervous system (PNS) may occur 
as the result of physical trauma (e.g. surgical, poisoning, sports injury) or as a by-product of 
underlying disease (e.g. tumours, diabetes, degenerative disorders); trauma in the PNS drives 
maladaptive changes in the CNS17. If the trauma occurs in the CNS, commonly in the spinal 
cord, a permanent dysfunction of the somatosensory system is likely to develop. Damage in 
the CNS can be also caused by direct injury, stroke and degenerative diseases (e.g. multiple 
sclerosis)17; 18.  
    The nature of the nerve that experiences damage has a profound effect on the 
development of neuropathic pain. As expected, damage to larger nerves, such as the sciatic 
nerve is 6x times more likely to cause NP than the damage to a smaller nerve19. Due to the 
nature of neuronal injury, particularly in the CNS, the restorative aspects of inflammation 
commonly aggravate the damaged nerve (i.e. formation of a glial scar), resulting in the 
maladaptive plasticity of the nervous system and often the development of chronic pain20; 21.  
    Although increased sensitivity to pain is not ideal, it encourages us to ‘protect’ the 
effected site and many aspects of the immune response play a vital restorative role. Schwann 
cells promote the removal any debris that may disrupt tissue or nerve regeneration and the 
release of growth factors, vital for repair8. In the later stages of inflammation, leukocytes 
release anti-inflammatory proteins that supress production of inflammatory mediators22. It is 
important to note that regeneration only occurs when damage happens in the periphery; 
  
injury in CNS results in glial scar around the site. The scar, formed through astrogliosis, 
prevents the restorative aspects of the immune response from reaching the site, 
simultaneously, trapping the destructive aspect21. As result the entire nociceptive pathway 
begins to destructively adapt, causing malfunction of the nervous system (neuropathic pain)19; 
20.  
 
1.1.4 Chronic Pain 
      Chronic pain can be described as pain persisting for more than half a year or as pain that 
lasts past the point of projected healing. As with functional pain, chronic pain can be 
nociceptive, inflammatory or neuropathic however it serves no practical or restorative 
purpose19. As a disorder, chronic pain is often used to  describe numerous pain related 
conditions including complex regional pain syndrome and common back pain23. Chronic pain 
can arise due to previous injury (e.g. nerve lesions during surgery), degenerative diseases (e.g. 
multiple sclerosis), functional disorders (e.g. Inflammatory Bowel Disease, IBD) or even as a 
side effect of long term treatments such as chemotherapy17; 23; 24.  
    Roughly about 16% of the world’s adult population suffer from chronic pain, with almost 8 
million of them living in the United Kingdom25; 26. Unfortunately, despite its prevalence, 
chronic pain is severely mismanaged; one third of sufferers either refuse or discontinue 
treatment, due to misinformation, adverse-effects and insufficient pain relief24.  Numerous 
genetic and environmental factors can contribute to the development of chronic pain, making 
it difficult to produce a ‘one size fits all’ treatment. Living with chronic pain seriously 
  
decreases an individual’s quality of life27. For people suffering from chronic pain, even getting 
dressed can be an excruciating experience and many cannot lead a normal healthy lifestyle; 
this in turn causes problems with weight gain and substance abuse28; 29. Not surprisingly 
chronic pain is part of a neurotic triad that encompasses depression and insomnia27.  
      Patients suffering from chronic pain are often prescribed a combination of drugs, including 
existing analgesics and non-traditional analgesics. The main of aim treatment is to 
compensate the maladaptive changes in the nervous system by reducing functional 
nociception. Targeting aspects of the nervous system that are functioning normally often 
leads to dose-dependent adverse effects23. Meaning that as analgesic effect lessens over time; 
the dose cannot simply be increased. In an attempt minimise the side-effects without 
comprising on analgesia drugs are given in combination at lower doses30. For many patients, 
taking multiple drugs for chronic pain, in addition to any other medication is disheartening 
and a common reason behind withdrawing from treatment24. 
 
 
 
 
 
 
  
1.2 Managing Chronic Pain 
1.2.1 Antidepressants and Anticonvulsants 
    Antidepressants are drugs initially used to treat major depression but have become popular 
treatments for various neurological disorders including addiction, anxiety, insomnia and pain. 
The use of antidepressants in the management of chronic pain is effective, not only because 
of the analgesic effect but also positive impact on mood and sleep behaviours; both of which 
are key grievances of chronic pain sufferers27; 31. There are numerous closely related drug 
classes that fall under the umbrella of antidepressants. In chronic pain management the most 
commonly prescribed class are tricyclic antidepressants (TCAs) (e.g. amitriptyline). These are 
non-specific re-uptake inhibitors of neurotransmitters, serotonin (5-HT) and noradrenaline 
(NA)23; 32.      
     In the CNS, 5-HT and NA play an inhibitory role in the descending pain pathway; the 
pathway that feeds information from the brain to the periphery. TCAs, along with other 
antidepressants, increase the levels of 5-HT and NA in the synaptic space by preventing up-
take by presynaptic neurons and glial cells32; 33; 34. Higher levels of inhibitory neurotransmitters 
will lead to greater inhibition of descending pain signals.  It has been demonstrated however, 
that the onset of analgesia is much quicker than that of mood improvement, suggesting that 
TCAs produce analgesia through an assisted mechanism33.  Although the exact mechanism is 
not known, it has been suggested that TCAs may act as antagonists at Na+ and Ca2+ channels, 
thereby reducing neuronal excitability35. In addition, they may block the glutamate receptor 
NMDA (N-methyl-D-aspartate)33; 36. Serotonin–noradrenaline re-uptake inhibitors (SNRIs) 
  
and selective serotonin re-uptake inhibitors (SSRIs) specifically target serotonin (SERT) and 
noradrenalin (NET) transporters and may also be prescribed to treat chronic pain; although 
the adverse effects associated with SNRIs and SSRIs are not as severe, they are not as effective 
as TCAs37. SNRIs have been known to be slightly more effective than SSRIs, suggesting that 
sufficient analgesia is not entirely dependent on serotoninergic activity38. Even though 
antidepressants are capable of producing a substantial amount of pain relief, some patients 
(approximately 10%) will discontinue taking them due to unpleasant side-effects37. The 
mechanism of action of antidepressants used to treat chronic pain is shown in Figure 1.2. 
  
    
Figure 1.2. Structures and action of antidepressants: Serotonin (represented as purple circles) and 
noradrenaline (blue squares) are released into the synaptic cleft, where they act on post-synaptic 
receptors (not shown). Transporters up-take excess neurotransmitter back into the pre-synaptic 
neuron. TCAs (e.g. amitriptyline and nortriptyline) and SNRIs (e.g. Duloxetine) block both serotonin 
(SERT) and noradrenaline (NET) transporters. While SSRIs (e.g. Fluoxetine) are selective for SERT37. 
  
 The second major drug class used to manage chronic pain are anticonvulsants. Originally 
intended to treat epilepsy, they are able to attenuate the neuropathic aspect of chronic pain, 
much like antidepressants. Anticonvulsants are typically cation channel blockers and are 
considered ‘second-line’ treatments due to an increased rate of patient withdrawal39. The 
most commonly prescribed anticonvulsant is carbamazepine, as it is better tolerated than its 
counterparts37. Carbamazepine (Figure 1.3) is sodium channel blocker that causes voltage-
gated Na+ channels (e.g. Nav1.7) to become ‘locked’ in their inactive state. Decreasing the 
abundance of functional Nav channels will make depolarisation harder to achieve and reduce 
the excitability of the nerve40. This is a useful countermeasure for increased Nav channel 
expression seen during chronic pain. While most anticonvulsants target Nav channels, some 
do have activity at voltage-gated Ca2+ channels, such as gabapentin and pregabalin (Figure 
1.6)39; it is not unusual to prescribe two anticonvulsants, acting on different channels, 
together for maximum efficacy41.  
 
 
 
 
 
 
 
Figure 1.3. Chemical structures of anticonvulsants: Carbamazepine (left), a sodium channel blocker, is 
a common treatment for chronic pain. Clonazepam (right) is a member of the benzodiazepine family. 
Benzodiazepines are not as effective in treating pain as other anticonvulsants39. 
  
     In addition to cation channel blockers, another type of anticonvulsant that has been used 
to treat pain is benzodiazepines (e.g. Clonazepam, Figure 1.3). Benzodiazepines enhance 
GABAergic activity in the nervous system42. GABA (γ-aminobutyric acid) is one of two 
neurotransmitters that modulate the body’s natural inhibitory mechanism in the ascending 
pain pathway43. GABAA receptors are ligand-gated chlorine channels (Cl
-), which upon opening 
allow an influx of Cl- and cause hyperpolarisation of a neuron. Clonazepam and other drugs of 
its class allosterically modulate GABA receptors, resulting in improved effectiveness of 
GABA42. The major pit fall of benzodiazepines is there powerful effect on the CNS, often 
leading to the development of psychosis. Heavy sedation and cognitive impairment are also 
common side-effects and are considered to outweigh the analgesic effect of 
benzodiazepines37; 44. As a result these drugs become extremely unpopular therapeutic 
options for chronic pain, as move effective alternatives have become available. 
 
1.2.2 Non-Steroidal Anti-inflammatory Drugs and Opioids 
      Non-steroidal anti-inflammatory drugs (NSAIDs) are the world’s most common treatment 
of functional pain. Over-the-counter NSAIDs, such as aspirin and ibuprofen, are effective pain 
relievers, whilst more potent prescription NSAIDs, e.g. Naproxen, are welcomed alternatives 
to opioids 38. NSAIDs inhibit the synthesis of prostaglandins (PGs) by targeting the catalytic 
enzyme, cyclooxygenase (COX, Figure 1.4). PGs are released, typically by mast cells, during 
inflammatory. Not only do they increase the inflammatory response, but they also act directly 
on neurons to alter ion channel expression45. There are two types of COX enzymes; the first is 
  
COX-1, a widely expressed enzyme involved in maintaining good gastrointestinal (GI) function. 
COX-2 is less commonly expressed than COX-1 and is up-regulated during inflammation. It has 
also been known to play a role in cardiovascular function38; 46. In addition to inhibiting COX 
enzymes, there is some evidence to suggest NSAIDs may have some antagonistic activity at 
NMDA receptors45.  
 
 
    As reducing inflammation in the peripheral nervous system is the main mechanism of 
NSAIDs, they are usually used to treat musculoskeletal disorders that have a large 
inflammatory pain competent (e.g. rheumatoid arthritis).  Although they are not as useful in 
treating non-inflammatory  degenerative diseases like osteoarthritis47. Acetaminophen or 
paracetamol (Figure 1.4) is often used to treat pain arising from osteoarthritis. While 
Arachidonic Acid  
COX -1 COX-2 X 
Prostanoids (e.g. prostaglandins) 
Homeostasis  Inflammation 
Aspirin (NSAID) 
Ibuprofen (NSAID) 
Naproxen (NSAID) 
Paracetamol 
Figure 1.4. Mechanism of action of NSAIDs and paracetamol: COX-1 and COX-2 catalyse the 
conversion of arachidonic acid into prostanoids. Prostanoids are a family of inflammatory signalling 
chemicals that include prostaglandins, thromboxanes and the prostacyclins. Prostaglandins, in 
particular, play a key role in inflammatory pain45. 
  
paracetamol does inhibit COX-2 it is not considered a NSAID due to its minor anti-
inflammatory effect. This is because paracetamol acts in the CNS, reducing pain sensitisation 
rather than in PNS, reducing over-all inflammation46. By acting in the CNS, paracetamol also 
has far less side effects and is a more favourable overall. In comparison, inhibition of COX in 
the periphery by NSAIDs, leads to a great number of side-effects that vastly decrease the 
practical use of these drugs in chronic pain management38; 46.  
    Another traditional analgesic used to treat chronic pain are opioids acting on inhibitory 
receptors within the descending pain pathway48. Endogenous opioids, such as endorphins, are 
considered the body’s natural morphine and not only alleviate pain but are also associated 
with positive feelings49. Synthetic opioid-like drugs can activate opioid receptors with greater 
efficacy than their natural occurring counterparts. Opioid receptors are G-protein couple 
receptors (GPCRs) and can be categorised into four types; µ- (MOR), δ- (DOR), κ- (KOR) and 
nociceptive- (NOR)50. They are all widely expressed throughout the nervous, gastrointestinal 
and immune systems. MOR, targeted by morphine, is the most common opioid receptor and 
is responsible for the greatest analgesic effect; however it is also the most associated with 
dependence and respiratory disorders. KOR is closely linked with sedation, whilst DOR and 
NOR have less analgesic activity they do not cause dependence and sedation to the same 
extent38. Activation of these receptors triggers multiple mechanisms by which analgesia is 
produced.  
        Opioids promote analgesia through various mechanisms; the first is inhibition of 
inflammatory mediator production (e.g. bradykinin). Activation of opioid receptors triggers a 
conformational change49. The receptor disbands and the G-protein component inhibits 
  
activity of adenylyl cyclase (AC); an enzyme responsible for conversion of ATP to cAMP (cyclic 
adenosine monophosphate). Normally cAMP triggers a protein kinase cascade that ends in 
increased transcription of inflammatory proteins. Inhibition of this process by opioids leads to 
an anti-inflammatory effect51. Secondly, opioids raise activation thresholds and prevent 
frequent neuronal firing. Opioid binding increases the activity of Na+/K+ pumps 48. This 
enhances the inhibitory M-current and causes the neuron to become hyperpolarised more 
easily. Finally, opioids can indirectly block Ca2+ channels, reducing the release of substance P 
and glutamate50. This is prevents stimulation of surrounding nerves. Some opioids, such as 
methadone, have additional activity, acting as NMDA antagonists and 5-HT/NA re-uptake 
inhibitors49. Despite powerful analgesic effects, opioids are one of the least favourable chronic 
pain treatments due to adverse effects. Three common opioids, used in pain management, 
are morphine, methadone and tramadol (Figure 1.5) 
 
 
 
 
Morphine Methadone Tramadol 
Figure 1.5: Structures of three opioids used to treat chronic pain49. 
  
1.2.3 Adverse-effects  
      Adverse effects that develop during treatment of chronic pain through antidepressants 
and anticonvulsants can be attributed to the effect of the drugs on the nervous system. Drugs 
acting on the parasympathetic system result in a wide range of side-effects such as dizziness, 
nausea, dry mouth and cardiac arrhythmias23; 34; 37. Anticonvulsants, in particular, have an 
affect the cardiovascular system, something that will can complications in patients with 
additional heart problems44. Although there is no apparent evidence that suggests 
anticonvulsants have a worse benefit risk relationship than antidepressants, it has still been 
reported that more than twice as many patients will stop using anticonvulsants37. 
    Most antidepressants increase the presences of neurotransmitters (e.g. 5-HT and NA) in the 
nervous system, however in the most cases of chronic pain; the normal activity of these 
neurotransmitters is not hindered. Over-saturation of the CNS, predominantly by 5-HT, will 
result in adverse neurological effects such as sedation, nightmares and dysphoria33. 5-HT, 
along with opioid receptors, also plays a part in the reward pathway, so repeated use of 
antidepressants and opioids may cause addiction and dependence. Prolonged use of such 
drugs may lead to the development of withdrawal-like symptoms, e.g. headaches and 
agitation52.  Many of these side-effects are dose-dependent; while a lower dose will results in 
less side-effects, it will also mean a reduction in analgesia. In order to maintain a sufficient 
level of pain relief, many drugs are given in combination with other analgesic drugs acting via 
different mechanisms. 
  
   The adverse effects of NSAIDs are linked directly to their mechanism of action. Both COX-1 
and COX-2 play roles in vital homoeostasis. COX-1 is required for correct functioning of the GI 
system. Inhibition of COX-1 may result in renal impairment, ulceration and GI bleeding. Not 
only may these side-effects contribute to chronic pain but they can be fatal; in the past it has 
been reported that 12% of patients that develop NSAID driven GI diseases will die  as a 
result38. Chronic pain is common amongst the elderly, who will be at greater risk of developing 
adverse effects in the GI tract.  In an effort to prevent this, NSAIDs were re-designed to be 
selective for COX-2. Unfortunately COX-2 plays an important regulatory role in the 
cardiovascular system, therefore they are not suitable for patients with existing heart 
problems44. Painful indigestion (dyspepsia) is the most common reason for treatment 
withdrawal and is seen with both selective and non-selective NSAIDs38; 53. Changing the 
formulation of NSAIDs and combining them with protein pump inhibitors (PPIs) poses a 
possible solution. Napratec combines naproxen and a PPI (for its GI protective function) in an 
attempt to maintain efficacy while reducing risk53; 54. However, at present NSAIDs, along with 
opioids, are not considering for long term management of chronic pain. Instead they are used 
for brief symptomatic relief when needed53.  
      As seen with other pain treatments, opioid use is usually accompanied by headaches, 
sedation, dizziness, and problems relating to GI tract (e.g. nausea and constipation)46. There is 
also a danger of hypoventilation if dosing is not corrected to be proportional to pain severity. 
Many of these side effects will lessen as treatment goes on or they can be counteracted with 
other drugs44. The most harmful side effects, tolerance and dependence, arise from prolonged 
use. The mechanism underlying these adverse effects is not clear although there are a number 
  
of theories55. Firstly, it has been shown that upon receptor binding naturally occurring opioids 
will promote the expression of more receptors. This does not occur with opioid drugs, so 
quicker saturation of available receptors occurs38. Secondly, reduction in cAMP will cause the 
body to re-compensate by increasing ATP, AC and cAMP so receptor activation has less of an 
effect. In both cases, higher doses will be required to reach the same analgesic level and 
ultimately prolonged use of opioids will be needed for normal function55. It is also possible 
that taking high doses, long-term will contribute to chronic pain itself.  Hyperalgesia may 
occur as NMDA receptors become sensitised due to increase opioid activity38; 55. If this occurs 
and opioid us is discontinued, patients can develop withdrawal symptoms. This is common 
with powerful opioids like morphine and methadone44. Some weaker opioids (e.g. Tramadol) 
are less likely to cause tolerance or dependence and can be used to prop up other drugs46. 
Despite this, the addictive nature of opioids often leads to substance abuse, making them a 
last resort for managing chronic pain. 
 
1.2.4 Gabapentin and Pregabalin 
      Gabapentin and pregabalin are a distinctive type of anticonvulsants used in the 
management of chronic pain. Not only is gabapentin effective but it is also has less serious 
adverse effects; however common side-effects do include dizziness and sedation56. As Cav 
antagonists they are the only drug type in their class and are prescribed for a number of 
neurological related illnesses. Whilst their ability to alleviate pain falls just short of other 
psychoactive drugs, they do produce the least harmful side-effects44; 56. As adverse effects is 
  
the main reason for switching or stopping a drug course, slight loss of efficacy is sometimes 
considered a minor sacrifice. Both drugs are often prescribed in combination with a lower 
dose of other treatments to counteract the loss of analgesia.  
 
 
 
 
 
 
   Gabapentin and pregabalin are both analogues of the neurotransmitter γ-aminobutyric acid 
(GABA, Figure1.6). Initially these drugs were used as anticonvulsants but they have become a 
common treatment for chronic pain. Initially designed to cross the blood brain barrier (BBB) 
and mimic GABA, neither gabapentin nor pregabalin actually acts via directly on the 
GABAergic system56. Gabapentin acts on the α2-δ-1 subunit of voltage-gated Ca2+ channels. 
The purpose of α2-δ subunit is to assist the integration of the channel into the membrane. 
Binding of gabapentin impairs incorporation into the membrane and causes destabilisation of 
the pore57. There is some evidence to suggest that gabapentin may act on an additional 
auxiliary subunit, β4a, which also helps translocation to the membrane and compete with 
thrombospondin, a protein associated with synapse formation, although neither is believed to 
been the main mechanism of action56; 58.  
Figure 1.6. The structures of GABA, gabapentin and pregabalin56. 
  
    In chronic pain there is known to be an up-regulation of calcium channels. Gabapentin 
appears to have no effect on the normal expression of calcium channels but rather prevents 
the integration of the up-regulated channels. As a result there is a reduction in excess levels of 
intracellular calcium. As mentioned earlier, a rise in intracellular calcium is the trigger for 
numerous events that lead to increased transmission of nociceptive signals10. Decreasing the 
number of active Cav channels will interrupt some of the mechanisms that are responsible for 
pain hypersensitivity. There is some evidence that gabapentin also inhibits the synthesis of 
NF-κB, which is required for cytokine production59. It is likely that gabapentin reduces pain 
through a number of mechanisms working alongside one another. Pregabalin acts via the 
same major mechanism of action as gabapentin and has been shown to have greater potency 
and a quicker on-set of action57.  
    The side-effects of both drugs include swelling, fatigue, and dizziness. Gabapentin has also 
been associated with depression and increase in suicidal thoughts. As with all therapies for 
chronic pain, lower doses are given in combination to diminish adverse-effects without 
comprising on analgesia.  Non-steroidal anti-inflammatories (NSAIDs) and opiates are often 
used as initial treatments for acute pain; as pain becomes chronic, these traditional analgesics 
become unsuitable and patients are prescribed antidepressants and anticonvulsants60; 61. The 
most common drugs used to manage chronic pain are summarised in Table 1.1 
    Treatments currently prescribed may be effective for specific aspects of pain (i.e. NSAIDs for 
inflammatory pain and psychoactives for neuropathic) however, chronic pain is a complex 
condition with many contributing factors and mechanisms. Therefore, managing pain is 
difficult. Maximising analgesia and reducing adverse effects, takes effort and careful planning 
  
on behalf of the clinician and the patient. Treatments usually work short-term but they are 
not suitable for long-term use. For many patients the neurological and physical side-effects, in 
addition to the requirement of take numerous drugs daily become too much, with roughly 
about 10% of patients24 giving up on treatment and choosing to live with chronic pain. As such 
there is a serious need for more effective means of treating and managing chronic pain. The 
key to creating an effective treatment for chronic pain is to focus on what specifically causes 
dysfunctional pain. A greater understanding and utilisation the mechanisms that cause 
malfunction of the nervous system and contribute to chronic pain, present an opportunity for 
novel, more efficient treatments.  
 
 
 
  
 
 
Drug Class Primary Mechanism of Action Adverse Effects 
Antidepressants   
Amitriptyline (TCA) Inhibits re-uptake of 5-HT/ NA 
Sedation, dry mouth, 
tinnitus, constipation, 
impaired vision, 
dizziness, 
discontinuation 
syndrome (anxiety, 
nausea, headaches). 
Nortriptyline (TCA) Inhibits re-uptake of NA/5-HT 
Desipramine (TCA) Inhibits re-uptake of NA/5-HT 
Fluoxetine (SSRI) SERT antagonist 
Duloxetine (SNRI) SERT and NET antagonist 
Venlafaxine (SNRI) SERT and NET antagonist 
Anticonvulsants   
Carbamazepine Sodium channel blocker 
Arrhythmias, migraines, 
dizziness, drowsiness, 
nausea, fatigue, 
depression, diarrhoea. 
Oxcarbazepine Sodium channel blocker 
Topiramate Sodium/calcium channel blocker 
Gabapentin Calcium channel binding antagonist 
Pregabalin Calcium channel binding antagonist 
NSAIDs   
Aspirin COX1/2 inhibitor 
Gastric 
ulceration/bleeding, 
indigestion, increased 
blood pressure, 
diarrhoea, nausea. 
Ibuprofen COX1/2 inhibitor 
Naproxen COX1/2 inhibitor 
Diclofenac COX1/2 inhibitor 
Opioids   
Tramadol µ-opioid receptor agonist 
Dependence, tolerance, 
nausea, drowsiness, dry 
mouth, constipation.  
Morphine µ-opioid receptor agonist 
Methadone µ-opioid receptor agonist 
Oxycodone κ-opioid receptor agonist 
Miscellaneous   
Lidocaine (topical 
anaesthetic ) 
Sodium channel blocker Rash 
Paracetamol COX2 inhibitor Overdose hepatoxicity  
 
Table 1.1. Most common drugs used to treat chronic pain: Adapted from Jay et al. 201417. 
  
1.3 Mechanisms of Chronic Pain 
1.3.1 Peripheral and Central Sensitisation  
    Chronic pain has three unique symptoms, painful response to innocuous stimuli (allodynia) 
that may manifest as burning or itching sensation, increased sensitivity to noxious stimuli 
(hyperalgesia) and the pain in the absence of stimuli (spontaneous activity)62. These 
behaviours come about as a result of a complex series of interconnecting events that cause 
sensitisation of the nervous system21. In most cases, these changes are driven by the 
compensatory immune response that is triggered by neuronal injury. After healing, 
inflammation usually dissipates and the sensory circuitry involved to returns to normal, 
however in chronic pain the peripheral and central nervous system become permanently 
sensitised19.   
     Sensitisation is caused by changes in ion channel expression and activity. Of particular 
interest is the up-regulation of Nav1 channel family. Several attempts have been made to pin-
point the major Nav1 subtype involved in hyperexcitability. Through the use of channel 
blockers and knock-down (KD) mouse models, Nav1.3, Nav1.7 and Nav1.8, have all been 
implicated in neuron hypersensitivity; KD models involve a reduction in the expression of a 
vital genes 19,63. Another cation channel, that has been attributed to sensitisation, is the HCN 
(hyperpolarisation-activated cyclic nucleotide-gated) channel. HCN channels are non-specific 
cation channels that are activated close to the threshold and help achieve depolarisation 
required for action potentials. These are known to be up-regulated during chronic pain and 
HCN antagonists are able to reduce spontaneous activity 64. Down-regulation of K+ channels 
  
and up-regulation of Ca2+, also play central roles in membrane hyperexcitability. In the case of 
temperature dependant channels (e.g. TRPV1-4), the activation threshold can be lowered so 
significantly that nociceptors are triggered by normal body temperature, thus giving the 
illusion of pain without a stimulus3.  
    Altered expression and function of ion channels is the end-point of transcriptional events 
that are driven by restorative inflammation22. Pro-inflammatory mediators (e.g. ATP, 
bradykinin, PGE2, etc.) trigger a series of calcium-dependant intracellular events, usually 
involving protein kinases, that lead to the activation of transcription factors65. 
 
 
 
 
 
 
   
   These events are complex and not well understood however a number key transcription 
factors have been identified, including SOX-11 (Sry-related HMG box), AP-1 (activator protein 
1) and ATF3 (Activating transcription factor 3)
19. Inflammatory mediated up-regulation is not 
just limited to activation of transcriptional pathways. Inflammatory proteins can aid the 
Figure 1.7. Structures of prostaglandin E2 (PGE2) (top left), adenosine triphosphate (ATP) (top right) 
and bradykinin (bottom). 
  
trafficking and integration of ion channels, as well as direct or indirect agonism. For example, 
TRPV1 opening is mediated by inhibitory PIP2 (phosphatidylinositol 4, 5-bisphosphate). 
Bradykinin acting on bradykinin receptor (B2) receptors triggers the breakdown of PIP2 by PLC 
(phospholipase C) into DAG (diacyl glycerol) and IP3 (inositol 1, 4, 5-trisphosphate). IP3 
increases intracellular Ca2+, while DAG activates protein kinase C (PKC) which can down-
regulate potassium channels (Figure 1.8)66. Bradykinin, may also trigger the conversion of 
arachidonic acid into 12-HPETE (hydroperoxyeicosatetraenoic acid). 12 HPETE mimics the 
effect of vanilloids on TRPV channels67; 68. While, NF-κB acts on PAR2, triggering a kinase 
cascade, that involves ERK1/2 (extracellular-signal-regulated kinases) and JNK (c-Jun N-
terminal kinases). This ultimately leads to activation of the previously mentioned PIP2-PLC 
pathway33.  
       
 
 
 
 
 
     
 
Phosphatidylinositol 4, 5-bisphosphate (PIP2) 
Diacyl glycerol (DAG) 
Inositol 1, 4, 5-trisphosphate (IP3) 
PLC 
Figure 1.8. Breakdown of PIP2into IP3 and DAG via the enzyme PLC: This pathway is triggered by 
bradykinin acting on B2 receptors. PIP2 regulates the opening of TRPV1, while IP3 increases 
intracellular Ca2+ and DAG down-regulate potassium channels66. 
 
  
     Another prominent inflammatory mediator in sensitisation is brain-derived neurotrophic 
factor (BDNF). This neurotrophin is released from affected neurons and immune cells during 
inflammatory pain and is heavily involved in the sensitisation of the nervous system65. BDNF 
increases glutamate activity via phosphorylation of NMDA subunits, NR1; more activate 
subunits means more functional receptors. Blocking BDNF production has been shown to 
reduce both hyperalgesia and allodynia69.  
    Spontaneous activity is likely to be caused by the activation thresholds of nociceptive 
neurons lowering to that of normal body temperature70. Allodynia is the perception of pain 
following an innocuous stimulus (i.e. light touch). Malfunction of non-nociceptive neurons 
usually occurs at the site of injury (e.g. sensitisation) or in the dorsal horn (e.g. disinhibition), 
where sensory neurons from the PNS and CNS synapse. In most cases this type of pain occurs 
following mechanical stimuli (e.g. pressure, contraction, distension and sound), so allodynia is 
often referred to as mechanical allodynia71.  
      Normally, neurons specialising mechanoreception are large, fast conducting myelinated 
Aβ-fibres3. Intracellular kinase cascades, such as the MAPK/ERK (mitogen-activated protein 
kinase/ extracellular signal-regulated kinases) pathway that is normally seen in noxious 
signalling has be revealed to occur in Aβ-fibres after neuronal injury72. Pro-inflammatory 
proteins (e.g. BDNF) are known to upregulate mechanosensory ion channels, PIEZO and TRPC. 
PIEZO2 (Piezo-type mechanosensitive ion channel component 2) is the pore forming subunit 
of cation channels found in sensory neurons and has been implicated in the development of 
allodynia73; 74. It is probable that increased sensitivity of both primary nociceptive and sensory 
fibres may influence projection neurons across the dorsal horn, i.e. activation of peripheral 
  
mechanosensory neurons creates nociceptive inputs in the CNS.  In addition, the activation 
threshold of, mechanically insensitive, TRPV channels may become so low that they respond 
to mechanical stimulus73. As well as neuronal sensitisation, it was a suggested that growth 
factors, released during inflammation, act on uninjured Aβ-fibres causing them to sprout new 
axons that grow into laminae II75. Recently it has been shown that these ‘sprouts’ may be an 
undiscovered sub-class of nociceptive neurons that become far more pronounced following 
nerve injury, the precise nature of these neurones remains a mystery76.  
     Hyperexcitability of the nervous system is just one of the two major contributors to 
dysfunctional pain. The other is a malfunction of natural pain regulation between the PNS and 
CNS. Loss of inhibitory activity in the dorsal horn of the spinal cord is different from the 
descending pathways that involve 5-HT, NA and opioids77. Inhibition of the ascending pain 
pathway is heavily involved in regulation of signals from the PNS to the CNS and the 
interactions between nociceptive and non-nociceptive neurons.  
 
1.3.2 Disinhibition 
    The dorsal horn is sub-divided into laminae I-V, where primary mechanosensory neurons 
terminate in the nucleus proprius (laminae III-V), while nociceptive neurons input into the 
marginal nucleus (laminae I) and substantia gelatinosa (laminae II)(Figure 1.9)77; 78. Small 
inhibitory interneurons synapse with neurons from the periphery and projection neurons than 
transmit signals to the brain (Figure 1.9). They regulate input between sensory neurons 
through GABAergic and glycinergic activity79. GABA/glycine, released from inhibitory 
  
interneurons, acts post-synaptically on projection neurons43. These interneurons can be 
activated via inputs from descending nociceptive and non-nociceptive neurons, as well as 
inhibitory NA and 5-HT neurons80. Introduction of antagonists into this system are able to 
create an effect similar to allodynia and hyperalgesia19. This emphasises the importance of 
GABA and glycine in correct pain processing and role of disinhibition in chronic pain 
progression. GABA receptor type A (GABAAR) and glycine receptors (GlyR) are both ligand-
gated ion channels that allow chloride ions (Cl-) to cross the membrane and cause 
hyperpolarisation43. Loss of functional GABAergic and glycinergic has been directly linked to 
the development of spontaneous activity, hyperalgesia and allodynia81.   
 
 
 
 
 
 
 
 
 
    
Figure 1.9. Simplified schematic of synapsing neurons in the dorsal horn: The dorsal horn is divided 
into laminae I-V. Nociceptive, C-fibres and Aδ-fibres synapse in laminae I and II. They interact with 
projection neurons, leading up to the thalamus and with inhibitory interneurons. Inhibitory 
interneurons regulate input into projection neurons through GABAergic or glycinergic activity. During 
chronic pain states, this mechanism is reduced87,93. 
  
One potential mechanism of disinhibition is a chlorine gradient shift from hyperpolarisation to 
depolarisation. The chlorine gradient relies on correct function of the potassium-chloride 
transporter 2 (KCC2). BDNF stimulates the  down-regulation of  KCC282. In addition KCC2 relies 
on the Na+/K+ pump for homeostasis of potassium. Increased expression of Na+ channels will 
alter the potassium gradient, which in turn impacts the chlorine gradient82. Another source of 
disinhibition is the down-regulation of post-synaptic GlyR. The prostaglandin, PGE2 released 
during inflammation, acts on the EP2 (prostaglandin E2 receptor). PGE2 increases intracellular 
cAMP and triggers a protein kinase A (PKA) cascade80. PKA phosphorylates GlyRs and prevents 
successful ligand binding. EP2 agonists can directly inhibit glycine activity and cause allodynia 
but they have no effect GABA, suggesting that glycine activity alone is an important part of 
ascending pain inhibition81. Apoptosis of inhibitory interneurons has also been reported, 
however the reasoning behind this remains unknown19. Although disinhibition plays a major 
role in chronic pain, many of the contributing mechanisms remain unclear. It certain that 
disinhibition is important to the development of allodynia and hyperalgesia, as one of the 
major features of inhibitory interneurons in the DRG is to prevent miscommunication 
between sensory and nociceptive neurons and the CNS.  Rescuing inhibition offers an 
excellent therapeutic opportunity for chronic pain. GABAAR receptor already exists as a target 
for various anaesthetics and analgesics (i.e.  Benzodiazepines) however due to a strong 
hypnotic side-effects, it is would not make a suitable therapeutic target46. In comparison GlyRs 
have largely been over-looked by the pharmaceutical industry.  
       Understanding the some of the process underlay chronic pain has led to the development 
of new drug targets. Drugs acting to mitigate the changes that lead to malfunction of pain 
  
Table 1.2. Novel compounds for the treatment of chronic pain in Phase II/III development: Taken 
from Gilron et al. 201483.  
pathways, offer potentially more effective and safer treatments than those available 
currently. Many drug targets, that in the past have been overlooked, are now known to play 
vital roles in the development of both inflammatory and neuropathic chronic pain. Validation 
of these targets has inspired a new wave of potential treatments and the discovery of new 
analgesic properties of existing drugs (Table 1.2)83 
 
 
 
 
 
 
 
 
 
 
Compound Company Mechanism of Action 
Stage of 
Development 
DS-5565 Daiichi Sankyo Calcium channel blocker Phase II 
CNV-2197944 
Convergence 
Pharmaceuticals 
T-type calcium channel 
blocker  
Phase II 
Z-160 Zalicus 
N-type calcium channel 
blocker 
Phase II 
ABT-639 AbbVie 
T-type calcium channel 
blocker 
Phase II 
GRC-17536 Glenmark TRPA1 antagonist Phase II 
DWP-05195 Daewoong TRPV1 antagonist Phase II 
GRC-15300 Glenmark TRPV3 antagonist Phase II 
ICA-105665 (Icagen) Pfizer 
Potassium channel 
agonist 
Phase II 
CNSB-015 (Flupirtine) 
Relevare 
Pharmaceuticals  
Potassium channel 
agonist 
Phase III 
REL-10 xx (d-
Methadone) 
Relmada 
Therapeutics  
Opioid receptor agonist Phase II 
CNV-1014802 
Convergence 
Pharmaceuticals 
Voltage-gated sodium 
channel blocker 
Phase II 
TD-9855 Theravance 
5-HT/NA re-uptake 
inhibitor 
Phase II 
BND-11624 Brane Discovery NMDA antagonist Phase II 
NXN-462 NeurAxon 
Cannabinoid CB2 
receptor agonist  
Phase II 
 
  
1.4 Novel Therapeutic Targets  
1.4.1 M-Current 
    Pharmacological enhancers of the M-current are growing increasingly popular as analgesics. 
The Im is an inhibitory current controlled by the opening of voltage-dependant K
+ channels 
(Kv) and can be described as a voltage-dependant non-inactivating K+ current15. For most 
neurons, resting potential lies at -70mV and when the membrane potential surpasses -55mV, 
an action potential occurs. The Kv channels that are responsible for the M-current open at 
approximately -60mV 84.  During depolarisation, M-current is generated and acts as an 
opposing force to prevent the activation threshold from being achieved. In addition, it 
generates the refractory period, a period of hyperpolarisation following successful firing of an 
action potential that prevents successive stimulation of a neuron85. 
     The Kv channels that produce M-current belong to the Kv7.1-5 family. Kv7.3 is the only 
type that is able exist in combination with the other subtypes, however only Kv7.2 has been 
known to generate M-current 15. Many established mechanisms of dysfunctional pain, lend 
themselves to the reduction of the M-current. For example, bradykinin is able to close Kv7 
channels via PKC, while PIP2 is a vital co-factor for Kv7.2 function. A number of pain 
transmitters, such as glutamate, have also been shown to inhibit the M-current85; 86. Loss of 
M-current will mean that the activation threshold is reached much quicker and a reduction in 
the refractory period allows for repetitive firing of action potentials. The overall result is 
intense pain response following a weak stimulus; a key component in the development of 
  
spontaneous activity and hyperalgesia. Drugs acting on Kv7.2/3 channels may be able to 
rescue normal M-current function and attenuate chronic pain.  
  
 
 
 
 
     Many emerging treatments are based on existing drugs such as the anticonvulsants, 
retigabine and flupiritine (Figure 1.10)87. In an artificial hyperexcitability model, made to 
mimic sensitisation seen during chronic pain, both retigabine and flupiritine were able to 
diminish neuronal excitation88. Retigabine, like many anticonvulsants, was originally designed 
as modulator of GABAARs; however it has shown to have a much higher affinity for Kv7 
channels89. Administration of a Kv7.2/3 blocker, linopirdine, is able to reverse the analgesic 
effect of retigabine suggesting that Kv7.2/3 and the potentiation of M-currents is indeed the 
mechanism of action15. Retigabine can attenuate pain in neuropathic and inflammatory pain 
models. Intact nociceptive fibres do not response to retigabine, indicating that normal 
nociceptive processing will not be altered by retigabine, a positive attribute for an analgesic89. 
Flupiritine is the parent compound on which retigabine was based. For a long time, flupiritine 
was classified as a non-opioid analgesic and its mechanism of action was unknown87. It was 
believed that flupiritine may act on NMDA or GABAARs; it is now known that Kv7.2/3 is the 
Figure 1.10: Anticonvulsants, retigabine (left) and flupiritine (middle) are being considered as new 
treatments for chronic pain. Linopirdine (right) is a Kv7.2/3 blocker used to reverse the effect of 
retigabine87. 
  
major target90. Both flupiritine and retigabine are slowly becoming popular treatments for 
chronic pain, particularly pain arising from chemotherapy and fibromyalgia15; 90. As more 
research is carried out on Kv7.2/3 and the M-current, it is likely that flupiritine and retigabine, 
as well as new drugs of the same class will become prominent players in the management of 
chronic pain.    
 
1.4.2 Sodium and Calcium Channels  
      Up-regulated Na+ and Ca2+ channels are the crux of neuronal hyperexcitability. Not only 
does increased function of these channels result in greater frequency of action potentials but 
they also act as a trigger of numerous cellular events that affect other aspects of nociception. 
Decreasing the activity of these ion channels will inevitably lead to a reduction in pain, making 
them an obvious drug target. Unfortunately, many Na+ and Ca2+ channels are vital for normal 
nociception so there is a danger that blocking these channels will negatively impact functional 
pain processing91. Regardless, investigating the effect of cation channel blockers on pain may 
pave the way for a new class of analgesics.   
    Non-selective cation ion channels involved in nociceptive present a good starting point. 
Novel antagonists acting on TRP channels, for example TRPV1, TRPA1 and TRPM8, are able to 
reduce varying pain behaviours in different pain models92. However, the results of the these 
studies are reliant on the pain model and the nature of analgesia achieved, due to direct role 
some channels play in development of pain92; 93. Thereby the usefulness of non-selective TRP 
antagonists does not translate well into patients, whom have numerous factors contributing 
  
to their pain. Optimistically, the analgesic properties of TRP antagonist present a basis for the 
development of more viable treatments.  
      Recently research into the potential for Nav1 specific antagonists has been carried out63. 
Of particular interest is Nav1.7, where loss of function mutations effect normal nociception 
and KD mice models exhibit reduced pain behaviours19; 63. Lidocaine, a topical analgesic, and 
some anticonvulsants act as weak antagonists at Nav1 channels91. Most of the research of 
Nav1.7 antagonists is in its infancy, but the results are promising.  
    The use of Ca2+ channels blockers as analgesics is also being explored. N-type calcium 
channels (Cav2) are known to play role in the development of neuropathic and inflammatory 
pain through the use of KD mice models94. Ziconotide is an atypical drug used to treat severe 
pain. It is Cav2.2 channel antagonist that can only be administered via CSF infusion 
(cerebrospinal fluid) and causes crippling motor neuron effects95. While it is not suitable for 
the management of chronic pain, ziconotide has inspired the production of leconotide, a 
novel drug that has shown to be effective in pain models with little side effects96. Studies into 
novel blockers of Cav3.2 channels have also shown a reduction in allodynia in animal pain 
models97.  
 
 
 
 
  
1.4.3 Glutamate 
     As the major neurotransmitter involved in nociception, glutamate and its receptors have 
much potential as novel treatment targets. Many of the phenotypic changes that occur in 
neuropathic and inflammatory pain will increase glutamatergic activity, either through 
increased levels of glutamate itself or the expression and efficacy of its receptors. Glutamate 
plays an important role in sensory processing including functional nociception, therefore 
targeting the synthesis and release of glutamate does carry risk98. The alternative is to target 
the receptors that interact with glutamate and are up-regulated during chronic pain.  
     The most obvious target is NMDA receptors; NMDA receptors are an inotropic cation 
channel that opens upon binding of glutamate and various co-factors99. It has been well 
documented that NMDA receptors are up-regulated during chronic pain25. The concept of 
NMDA antagonists has existed for a number of decades, although very little research has 
been carried out in regards to creating a clinically approved analgesic100. Most current NMDA 
antagonists are used as anaesthetics and for veterinary purposes. Not only are they highly 
sedative but they cause a number of psychoactive side effects101. They provide some use in 
the treatment of motor neuron degenerative diseases and hyperalgesia stemming from 
opioid withdrawal, although this is a rare occurrence102. Like opioids, many NMDA antagonists 
are commonly used as drugs of substance abuse. The most well-known NMDA antagonist is 
ketamine (Figure 1.11).  
 
 
  
 
 
     
   
     
      Ketamine is a NMDA antagonist that binds to NMDA receptor subunits and prevents 
proper formation of the receptor101. While ketamine is considered non-selective it is believed 
that it favours binding to the NR2A/D subunits (i.e. binding site of glutamate)100; 101. The 
antiviral, amantadine (Figure 1.11) is also a weak NMDA antagonist. While less potent than 
ketamine; amantadine is useful in treating a number of neurological conditions, although this 
is likely due to its dual dopaminergic effects102. Recently novel NR2 selective antagonists have 
shown to reduce analgesia without effecting cognitive or motor function103. This suggests that 
any analgesic effect of ketamine or amantadine is the result of preventing glutamate binding 
to NMDA. Ifenprodil (Figure 1.11) is a novel analgesic that directly targets N2B subunits and 
reduces pain without side-effects104.  
      NMDA receptors are not the only potential drug target that may reduce glutamatergic 
activity. Glutamate also acts on its other receptor, mGluR (metabotropic glutamate 
receptor)105. These receptors are different from inotropic GluRs, which include NMDA 
amongst their ranks106. mGluRs are GPCRs that have 8 subtypes, one of which, mGluR1 has 
been implicated in neuropathic pain via KD mice models. Interest in these receptors is 
Figure 1.11. Structures of NMDA antagonists, ketamine (left), amantadine (middle) and ifenprodil 
(right)102-104. 
  
mounting and in the past five years a series of studies have been carried out measuring the 
effect of novel allosteric antagonists in various pain models105; 106; 107. So far, these compounds 
have shown promise and may lead the way for new class of drugs that can be used to manage 
chronic pain. 
 
1.4.4 Glycine 
     Glycine plays important excitatory and inhibitory roles in how the nervous system 
processes pain43; 99. In the past, little research into role of SSGRs as an analgesic target has 
been carried out. Now as more information comes to light about the importance of glycine, it 
is becoming an increasingly attractive drug target. Glycine has duel functions in nociception 
and both offer potential treatment targets.  
    While glycine plays a vital inhibitory role in nociception, it is also has a mild excitatory 
function. Glycine, along with D-serine, is a vital co-factor of NMDA receptors. Binding of 
glycine to the NR1 subunit allows glutamate to bind to the NR2 subunit, which opens the 
channel pore48. The NR1 binding site can be easily oversaturated, so the levels of glycine need 
to be carefully regulated. Glycine transporters, GlyT1 and GlyT2, harvest excess glycine from 
synaptic spaces to prevent oversaturation. GlyT1 and GlyT2 are members of the SLC6 family 
(sodium dependant solute carrier family 6) that are expressed both pre-synaptically and on 
glial cells108. GlyT1 is localised predominantly close to NMDA receptors, while both types are 
found near inhibitory interneurons. Inhibition of GlyT1 has been shown to attenuate 
allodynia. This is most likely due to increased levels of glycine at inhibitory synapses, as co-
  
administration of GlyR antagonist, strychnine can reverse the effect99. It is also possible that 
increased glycine levels cause saturation of the NMDA binding site. Oversaturation of the 
binding site may trigger endocytosis of the receptor, thus decreasing the number of 
functional NMDA receptors and neuronal excitability. However such an effect would need 
prolonged exposure at high concentrations55; 99. In addition, GlyT1 inhibition does not affect 
normal nociceptive, so the effect on NMDA is likely to play a very minor role in analgesia99. 
Increasing the levels of glycine acting on GlyRs is able to relieve pain to a greater extent than 
gabapentin, the ‘gold standard’ of analgesic agents. So it is highly probable that targeting the 
receptor itself will also produce an analgesic effect109.  
    Drugs acting on GlyRs have the potential to produce a superior analgesic than those that 
exist currently. It is known that simply increasing glycine levels can attenuate pain and there is 
evidence to show that agents acting allosterically on GlyRs are more effective at increasing 
glycinergic activity than direct agonists110. This provides further basis for the GlyR as drug 
target. Some research has been conducted using cannabinoids as analgesics. Cannabidiol 
(CBD) and its analogue DH-CBD (dehydroxyl-CBD) are non-psychoactive cannabinoids that are 
able to increase inhibitory currents mediated by glycine (Figure 1.12). DH-CBD was also seen 
to restore function to GlyRs that had been affected by PGE2. The reduction of inflammatory 
and neuropathic pain by CBD and DH-CBD through glycinergic activity was confirmed using 
strychnine and GlyR KD models; in both cases the analgesic effect as reversed111. The role of 
GlyRs as a drug target will be discussed further in Chapter 2.  
 
  
 
 
 
 
          Allosteric modulators of GlyRs are promising analgesic agents. In comparison to other 
novel analgesics, such as retigabine, NMDA antagonists and cation ion channels, GlyR agonists 
have a more favourable pharmacologic response/side-effect relationship. As a bonus, the 
unique role that α1 SSGRs play in the spinal cord means that it is unlikely that they cause 
major on-target toxicity. Positive allosteric modulators (PAMs) of SSGRs have been shown to 
alleviate pain better gabapentin, a drug commonly used to treat chronic pain (see Chapter 3).  
As such PAMs of GlyRs, have the potential to become innovative, safe and effective 
analgesics.     
 
1.5 Project Aims 
     The goal of this project is to carry out lead optimisation of positive allosteric modulators 
of glycine receptors expressing the α1 subunit, with the ultimate aim of generating a new 
treatment for chronic pain; glycine receptors containing the α3 subunit are known to be 
downregulated during the development of pain hypersensitivity. Restoring inhibitory 
glycinergic activity in nociceptive signalling presents a novel approach to treating chronic 
pain. The desired target profile for these compounds is shown in Table 1.3.  
Figure 1.12. Structure of cannabidiol111. 
  
  This thesis will be focussed on the optimisation on pharmacokinetics, particularly 
microsomal stability, in vivo rat metabolism and cytochrome P450 enzyme inhibition of 
propofol analogues. The ideal drug candidate should meet all criteria in outlined in Table 1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Target 
Physiochemical  
Aq. Sol (mg/mL) 0.01- 0.5mg/mL (pH7.4) 
LogP ≤4 
LogD 1-3 
MW (Da) ≤450 
TPSA (Å) 40-90 
HBD ≤3 
pKa 3-9 
MPO 4≥ 
Selectivity  
GlyRα1 EC50 ≤1µM 
GABAAR EC50 ≥ 100x GlyRα1 EC50 
Pharmacokinetics  
Oral Bioavailability (%) ≥20 
T1/2 (Rat Liver Microsomes)  ≥60 min 
T1/2 (Human Hepatocytes)  ≥30 min 
Brain CSF 
3x GlyRα1 EC50 
(at 2/3 hrs, 1-3mg/Kg) 
Protein Binding  ≤99.5% 
Toxicity   
hERG toxicity  IC50 ≥ 10µM 
HepG2 toxicity 
No tox at 50x GlyRα1 
EC50 
AMES genotoxicity negative 
CYP Inhibition  IC50 ≥ 10µM 
 
Table 1.3. Lead optimisation target profile for this project.  
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2.1 Targeting the Glycine Receptor 
2.1.1 Strychnine-Sensitive Glycine Receptors 
     Chronic pain is currently treated using a combination of traditional painkillers and 
psychoactives. Many of these therapeutic strategies result in numerous adverse-effects and 
patients often experience a decline in pain relief over time. There is an urgent need for new 
analgesics that target the underlying mechanisms of dysfunctional pain. One prospective 
approach is restoring the glycinergic activity, reduced in chronic pain, through modulation of 
GlyRs.  
     These receptors are inotropic chloride channels expressed post-synaptically on nerves in 
the dorsal horn1. They respond to glycine released by inhibitory interneurons and when 
activated trigger hyperpolarisation. When glycine binds to the receptor a conformational 
change is triggered and the ion channel becomes permeable to Cl- ions1. 
        It is thought that GlyRs mediate a much faster inhibitory current than GABAARs. Many 
nociceptors, particularly in laminae I, appear to predominantly interact with glycinergic 
interneurons2.  Typically, neurons that express GlyRs are found in the spinal cord, most 
abundantly in the cervical and lumbar regions, and the brain stem3.  A number of GlyRs also 
appear in the brain, however they are small in number and their exact role in pain processing 
is uncertain4. GlyRs were originally differentiated from GABAARs by the relationship with the 
toxic alkaloid, strychnine. Strychnine allosterically binds to a site near the ion channel pore 
and is able to antagonise the receptor, although it is readily displaced by the binding of 
glycine3.  Administration of strychnine is able to induce allodynia, signifying that GlyRs are 
  
contribute to dysfunctional pain behaviours5. Strychnine is often used to determine if a 
compound is interacting with GlyRs3.       
       GlyRs belong to the cysteine-loop (Cys-loop) ligand-gated ion channel (LGIC) receptor 
family. LGICs are a common receptor type for many neurotransmitters including GABA and 5-
HT2. All LGICs subunits share similar structural features, notably a long extracellular N-
terminal binding domain (ECD) containing the highly conserved Cys-loop, four transmembrane 
segments (TM1-4) with an intracellular loop between TM3-4 and a small extracellular C-
terminal6; 7; 8.  Based on structurally similar LGICs, it is believed that TM2 domains form the 
channel pore and upon ligand binding rotate, opening the channel. There is evidence to 
suggest that the arginine residues in the TM2 domains become  charged in such a way that 
repels cations but allows the flow of anions6.  
      The SSGR itself has five subunits, α1-4 and β1, that can form homomeric and heteromeric 
pentamers9. All homomeric pentamers are can be formed by small α-subunits, while 
heteromeric pentamers must contain the larger β-subunit at a ratio of 2α:3β4. The β-subunit is 
a supportive subunit, vital for trafficking, agonist binding and receptor clustering at the 
synapse. The subunit contains a cytoplasmic loop that binds to the scaffolding protein, 
gephyrin and interacts with transporter proteins, Vps35 and neurobeachin to help integration 
into the membrane10; 11; 12. The α-subunits are usually categorised into α1-3, with α4 being a 
pseudo-gene. Out of all the subunits, α1 is the most abundant and is a major component of 
many heteromers. In the embryo, α2 is the dominant subunit, however during early postnatal 
development many GlyRα2s are replaced with the α1β heteromers9. The α3 subunit was once 
considered to the least abundant, however it is now know that heteromers containing α3 are 
  
densely localised in the laminae I-II and have been directly implicated in sensitisation of the 
PNS during inflammatory pain4.  
 
2.1.2 Role of GlyRα3 in Chronic Pain 
    Once considered a minor subunit of adult GlyRs, GlyRα3 are now known to play a 
substantial part in the development of peripheral sensitisation and allodynia13; 14. GlyRα3, 
along with GlyRα1, are believed to regulate signalling between first-order nociceptors and 
projection neurons in dorsal horn15. While both subunits are found in the laminae I-II only α3 
has been implicated in disinhibition. As mentioned earlier, in a study by Xiong et al., two 
cannabinoids CBD and DH-CBD were able to attenuate analgesia via GlyRs, more specifically 
through modulation of GlyRα314. The properties of CBD and DH-CBD were not as prominent in 
mice lacking GlyRα3 (Glra3-/- )14, further verifying that α3 is the major contributor to glycine 
disinhibition. In addition, normal nociception is not changed in Glra3-/- mice, suggesting that 
the α3 subunit only plays a role in dysfunction pain behaviours13.  Application of PGE2 was 
shown to reduce glycine mediated currents and trigger pain sensitisation in wild type mice but 
not in Glra3-/- mice13. In the same study, administration of PKA inhibitor peptides was able to 
reverse the effect on glycine currents by PGE2, whilst strychnine reversed the effect of DH-
CBD  
    While the structure of the two subunits is highly conserved (80-90%)6, there is a difference 
in the conformational change that occurs following glycine binding. This difference is thought 
to be the result of the serine residue within the intracellular loop between TM3-4 that can be 
  
phosphorylated by PKA16. A mutation in this sequence (Ser346Ala346) is able to obstruct the 
effect of PGE2
 on GlyRα313.  It is likely that PGE2, causes a distortion of the glycine binding site 
in α3 subunits through PKA phosphorylation16. A loss in functional GlyRα3 has a major impact 
on the normal glycinergic activity in the dorsal horn. To compensate, the activity of GlyR 
containing the α1 subunit would need to be increased by pharmacological intervention.  
 
2.1.3 Allosteric Modulation of Glycine Receptors 
      From a pharmaceutical perspective, little research has been conducted into utilising GlyRs 
as a drug target. A great deal compounds including Zn2+, anaesthetics, alcohols and 5-HT 
antagonists have been known to potentiate glycine response17; 18. Mutations at Ser267 residue 
in the TM2 domain can significantly reduce the effect of abuse solvents, such as toluene, and 
anaesthetics, suggesting that major allosteric sites lie within the membrane, close to the 
channel pore19; 20.  Extracellular allosteric sites close to the ligand-binding site have also been 
identified for Zn2+21. 
   PAMs have a number of advantages over direct agonist. Unlike direct agonists, PAMs do not 
have to compete for a binding site, as many receptors have multiple, highly conserved 
allosteric sites22. They also rely on natural release of the neurotransmitter, meaning that 
normal physiological signalling is not disrupted; PAMs may even be able to reset biological 
functions that have become hindered, something that  would be advantageous in restoring 
lost glycinergic activity. Furthermore if pharmacological intervention is dependent on the 
availability of the biological ligand and receptor, the likelihood of target-based toxicity will be 
  
lessened23. Finally, receptors can become oversaturated if exposed to a potent agonist, 
leading to internalisation or inactivation24; 25.  
        In the case of LGICs, repeated exposure to a highly concentrated agonists can lead to 
desensitisation of the receptor26. Many compounds that antagonise GlyRs only do so at high 
glycine concentrations, whereas at low concentrations they increase affinity for glycine. In the 
prolonged presence of a ligand, many GlyRs shift between open and desensitised states18; 27. 
This implies that the GlyR is vulnerable to desensitisation. It has been proposed that many 
positive modulators increase the rate of state transition and the duration of ligand effect 
rather than boost glycine affinity27. While some allosteric modulators do allow for greater 
strychnine displacement by glycine28. Allosteric modulators are more effective at potentiating 
glycine currents than direct agonists through a various mechanisms29. 
    Unlike GABAAR agonists, anaesthetics acting via GlyRs are able attenuate pain without any 
hypnotic side effects. This provides further evidence that positive allosteric modulators of 
GlyRs have the potential to become novel analgesics. One of most potent allosteric 
modulators of GlyR is the anaesthetic propofol30. 
 
2.1.4 Propofol and Glycine Receptors 
      Over a century after the introduction of surgical anaesthetics, propofol (Diprivan) has 
become one of the most extensively used anaesthetics during short surgical procedures31. 
Administered intravenously, due to its poor solubility, propofol (2,6-di-isoprophylphenol) is a 
  
highly lipophilic phenol whose alky groups at the 2 and 6 positions are vital for its hypnotic 
effect (Figure 2.1)32. Propofol is popular because of its rapid on-set of activity (less than 
minute) and the smooth transition between anaesthesia and wakefulness (i.e. no nausea or 
respiratory issues)31.   
 
 
 
 
     The ease of surfacing from sedation is largely related to the quick distribution and rapid 
metabolism of propofol. Propofol also has few serious side-effects making it a standard choice 
for commonplace procedures31; 33.  The foremost grievance of patients treated with propofol 
is pain upon injection; with a high incidence (80%) of patients report a burning sensation 
following administration34. At therapeutic levels propofol is able to activate peripheral 
nociceptors through TRPV1 and TRPA1, leading to pain after initial dosing34; 35. Certain 
formulations of propofol, such as fospropofol (a pro-drug), does not elicit pain and are 
becoming common means of inducing anaesthesia36. 
      Propofol produces anaesthesia by activating GABAA receptors. The binding site is found in 
β subunits of GABAARs and lies between the extracellular and transmembrane domains, close 
to sites in TM1-2 that determine sedation37. Specific mutations in the subunit β3 are able to 
block the sedative effect of propofol38; 39. As well as enhancing inhibitory chloride currents, 
Figure 2.1. The structure of 2, 6-di-isoprophylphenol (Propofol)31. 
  
propofol is able to block the release of acetylcholine (ACh) in the hippocampus and frontal 
cortex; this is thought to be independent to sedation by means of an alternative binding site40. 
Propofol is purely used as a sedative and has no intrinsic analgesic properties; however 
reports show patients treated with propofol have been shown to experience less intense post-
operative pain when compared to isoflurane and some minor analgesia is experienced during 
propofol infusion41; 42. It is possible that propofol may inhibit the phosphorylation of NR1, 
however this effect only occurs at higher than therapeutic concentrations42.  Another effect of 
high propofol concentrations  is the amplification of glycine facilitated currents39. 
 
   2.1.5 GlyRα1 as a Drug Target 
    As with many anaesthetics, propofol is a non-selective low-affinity modulator of GlyRs30. 
Propofol, despite having specificity for GABAA, has established dose-dependent activity at 
GlyRα1, both in the presence and absence of glycine30; 39. At low glycine concentrations, 
propofol is thought to slow the transition of open receptors to their deactivated states43. In 
the presence of partial agonists, taurine and β-alanine, propofol is able to increase affinity and 
response to exceed that of a full agonist, glycine17. Propofol also has a negative modulatory 
effect at very high glycine concentrations, possibly due to inhibitory receptor-receptor 
interactions43. It has been reported that propofol has mild activity at GlyRα2, although the 
modulation is much stronger in GlyRα144.  
     Mutations in the α1 subunit have varying effects on propofol modulation. For instance 
changes in the large intracellular will decrease propofol enhancement, while mutations in 
  
transmembrane domains have the opposite effect45; 46. Water-filled cavities within TM2-3 
domains of α1 subunits are thought to be a major binding site for propofol45. Structural 
changes triggered by agonist binding have no influence on the activity of propofol, suggesting 
that effects of propofol and glycine binding within the receptor are unrelated47. Hyperekplexia 
(startle disease) is a rare hereditary condition that is associated with mutations in the α1 
subunit of GlyRs46. It has been directly linked to an arginine residue (Arg271) in the TM2 
domain. This mutation effects agonist binding and channel opening48. Surprisingly, propofol 
emits a greater response on mutated α1 subunits in comparison to wild type. Propofol is also 
able to increase agonist affinity to normal levels in mutated subunits46. It is likely propofol 
mediates sedation through GABAA and analgesia through the GlyR. As such propofol presents 
a good starting point for the development of a novel analgesic. 
    A number of studies have demonstrated that propofol analogues are able to potentiate 
glycine currents to a greater extent than propofol itself30. Particularly, halogen substitutions at 
the 4-position have a much higher efficacy at GlyRs in comparison to propofol49; 50. In addition, 
these analogues show little to no activity for GABAARs
51. A series of novel analgesics based 
around the core structure of propofol may prove to an effective way to target the GlyR.  
 
 
 
 
  
2.2 Propofol Analogues 
2.2.1 Substituted Phenols  
   Propofol and its halogenated analogues have been shown to produce analgesia without 
sedation through the activation of GlyRs. This same phenomenon is also seen with other 
commonly used anaesthetics, most of which are halogens themselves52. In order to focus the 
direction of structural modification, it must be determined what structural aspects have the 
largest impact on specificity for GlyRs over GABAARs. Many halogenated anaesthetics do not 
show significant specificity for either receptor, so it is possible that the phenolic core of 
propofol is responsible for greater selectivity towards GABAARs. 
    A series of phenol derivatives have previously been tested at GlyRα1s to investigate the 
influence of propofols phenolic group on glycine modulation. Testing was carried out in the 
presence of glycine (10µM) and modulation was determined as changes in the chloride 
current53. The structures and EC50 values of the compounds is presented in Table 2.1.  The 
results show that the basic phenolic structure is not sufficient to potentiate glycine mediated 
currents. All of the compounds failed to achieve a lower EC50 than propofol. It is already 
known that the alky groups at the 2 and 6 positions in propofol are needed for activity at 
GABAARs
32, and the  data suggest that this is also true of GlyRs. Therefore when designing 
propofol analogues, the core structure should be maintained. As seen in previous literature, 
halogenation at the para-position appeared to boost efficacy glycine receptors. It is likely that 
para-halogenation propofol analogues would prove to be more effective than the parent 
compound.  
  
 
 
 
2.2.2 Testing at GlyRα1 
        Propofol analogues acting on GlyRs to produce analgesia has been thoroughly 
investigated. From this point a series of compounds or ‘hits’ can be synthesised with the 
intention of increasing efficacy at the tar. The activity at GlyRα1 of potential hits as tested in 
an efficient but ‘low-throughput’ electrophysiology assay54. Whole cell voltage-clamp 
electrophysiology was used to measure the activity of hit compounds at GlyRα1. Cells were 
transfected with cDNA to express recombinant GlyRα1β1 on the cell surface. Cells were 
treated with 10µM glycine and the test compound at varying concentrations, and the voltage 
Table 2.1. The EC50 values of phenol derivatives acting at GlyRα1: Phenol derivatives were tested in 
the presence of glycine (10µM) at recombinant GlyRα1s. The effect on chloride currents was 
recorded and the EC50 values were determined as 50% of the maximal potentiation of the current
52. 
 
 
   
EC50 = 4.8µM EC50= 8µM EC50 = 13µM EC50 = 59µM 
 
   
 EC50= 70µM EC50 = 226µM EC50 = 254µM 
 
 
  
response was recorded (Figure 2.2). Compounds that showed no activity at 1µM were not 
investigated further due limitations of unstable cell lines. These studies were carried out 
under the supervision of Prof. Bodo Laube at the University of Tübingen, Germany. To ensure 
selectivity for the target, compounds were also tested against GABAARs at BioFocus DPI 
Limited (Saffron Walden, UK). The experimental methods for these assays are presented in 
Appendix II and IV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Potentiation of glycine response by 4-chloropropofol.  
Left, Top: Representative current traces produced by a glycine at 1000μM (maximal concentration) and 
10μM (sub-maxima concentration). 
Left, Bottom: Current traces demonstrating the effect of glycine (10μM) with an increasing 
concentration (1-100nM) of 4-chloropropofol.  
Right: Dose-response curve of 4-chloropropofol acting on glycine receptors in the presence of glycine 
(10μM). EC50 values were determined as 50% of the maximal potentiation of glycine current. 
*GlyRα1 EC50 experiments were carried out under the supervision of Prof. Bodo Laube at the University 
of Tübingen, Germany. 
  
2.2.3 Halogenated Propofol Analogues 
   The EC50 values for phenols derivatives at GlyRα1 suggests that the core structure of 
propofol must be maintained for functionality, but the addition of a halogen at the para- 
position may increase affinity. A number of halogenated propofol analogues have previously 
demonstrated selectivity for GlyRs over GABAARs
40; 49; 50. One halogenated analogue, 4-
iodopropofol acts on GABAARs and is able to inhibit ACh release but is not hypnotic 
40. This 
suggests that incorporation of halogens can have a drastic effect on which binding site is 
targeted by a compound. 4-bromopropofol can prevent the firing of action potentials, an 
effect that is reversed by strychnine50. Finally, 4-chloropropofol is able to augment glycine 
mediated chloride currents in an artificial model of hyperekplexia49. 
     Based on previous literature, three halogenated propofol analogues were tested against 
GlyRα1 at the University of Tübingen. The physiochemical properties of each compound were 
also generated in silico, as an indicator for good absorption and solubility (Table 2.2). 
Compounds with low molecular weight (MW), ClogP and ClogD are more likely to cross the 
BBB and have adequate exposure at the target; consequently it is advantageous to estimate 
the physiochemical properties as early as possible.  
     The halogenated analogues were able to increase glycine response at low concentrations 
(nM) and were approximately 1000 fold more potent than propofol at GlyRα1. This data 
validates para-substitution of propofol as an approach for increasing affinity for GlyRs over 
GABAAR, as it is unlikely that such low concentrations will be sufficient for activation of 
GABAARs
55. All the compounds had ClogP (<5) and MW (<450Da) within an acceptable range 
  
for a drug. ClogD for each compound was higher than desired and the estimated aqueous 
solubility (Aq. Sol.) was poor56. It is recommended that drugs have solubility close to 50µM to 
ensure good absorption and permeability, which will contribute to bioavailability and CNS 
penetration56. As a result of its high efficacy at the target, as well as having the most ‘drug-
like’ physiochemical properties (i.e. lowest ClogP, ClogD, MW and highest Aq. Sol.), 4-
chloroprofol was chosen for testing in an animal model of chronic pain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2. GlyRα1 EC50 data and in silico physiochemical properties of halogenated propofol 
analogues. 
 *GlyRα1 EC50 data provided by the University of Tübingen. 
 
Compound EC50 (µM) ClogP ClogD 
Aq. Sol. 
(µM) 
MW 
4-chloropropofol 
 
0.00066 ± 0.0038 
 
4.49 4.4 18.37 212 
4-bromopropofol 
 
0.00062 ± 0.0018 
 
4.63 4.67 10.81 257 
4-iodopropofol 
 
0.00067 ± 0.0033 
 
4.82 4.82 14.85 304 
 
  
2.3 Biological Testing of  4-Chloropropofol  
2.3.1 Metabolism of 4-Chloropropofol  
    Before 4-Chloropropofol could be validated in a neuropathic pain model, a pharmacokinetic 
(PK) profile had to be determined. Studying the in vivo metabolism of a compound not only 
ensures satisfactory levels of free drug are available at the target site but also provides brief 
insight into potential toxicities. Early metabolic testing can reduce number of animals used in 
proof of concept studies and acts as an indicator for success at later stages of development; it 
is estimated that roughly half drug candidates will fail to enter pre-clinical testing as a result 
of poor absorption, distribution, metabolism and excretion (ADME)57. 
    Pharmacokinetics of 4-chloropropfol (Table 2.3) was investigated via in vivo rat metabolism. 
Rats were dosed orally (p.o) at 8 mg/kg and intravenously (i.v) at 1 mg/kg. Blood samples were 
taken from the tail vein at time points 0 min, 30 min, 1 hr, 2 hrs, 4hrs and 6hrs (p.o) and 0 min, 15 
min, 30 min, 1 hr, 2 hrs and 6hrs (i.v). The final time point (6hrs) was taken by cardiac puncture 
following termination. The experiments were carried out in triplicate by the DMPK Group at 
ChemPartners Ltd, Shanghai, China.  
 
 
 
   
 
 
Parameters 
I.V P.O Bioavailability 
F (%) 1mg/Kg 8mg/Kg 
AUC (min*µg/mL) 7.39 42.8 
72.4 
Cmax (µg/mL) 0.11 0.1 
Tmax (min) 15 30 
t1/2 (min) 48.8 398 
Cl (mL/min/Kg) 14.8 146 
Vd (L/Kg) 11.8 79.6 
 
Table 2.3: Pharmacokinetic parameters of 4-chloropropfol. 
 *Data provided by ChemPartners Ltd, China.  
 
 
 
  
       The clearance rate (146 mL/min/kg) and volume of distribution (80.6 L/kg) for 4-
chloropropofol, following oral dosing was much higher than the desired value in rats (Cl=10-
45 mL/min/kg, Vd=0.5-10 L/kg)
58. However, the half-life (398min) of the compound was also 
quite long, with a short Tmax (30mins) and a reasonable Cmax (100ng/mL). This indicates that 4-
chloroporpofol is rapidly absorbed although it appears to be widely distributed within tissue. 
The oral bioavailability (72.4%) exceeded the recommended value of 30% in rats58. Although 
the overall PK profile is not ideal, the data suggest that 4-chloropropofol is quickly absorbed 
with relativity high plasma concentrations, meaning drug exposure at the target should be 
sufficient to elicit a response.  
 
2.3.2 4-Chloropropofol in a Neuropathic Pain Model 
    Testing 4-chloropropofol in a neuropathic pain model not only endorses modification of the 
para-position but also provides proof that the GlyR is a viable analgesic target. The effect of 4-
chloropropofol in the Chung Lesion model of neuropathic pain was carried out by Dr Laiche 
Djouhri in the Department of Pharmacology, University of Liverpool59.  
     As with the parent drug, 4-chloropropofol also had poor solubility and was formulated as a 
pro-drug, similar to fospropofol. Both 4-chloropropofol and the formulated pro-drug were 
tested to observe the effect of solubility. Neuropathic pain was induced following spinal nerve 
ligation (SNL).  A period of 7 days was left between surgery and dosing in order for 
neuropathic pain to develop. Animals were dosed orally at 8mg/kg. Heat hyperalgesia was 
tested as paw withdrawal latency from a hot plate and mechanical allodynia (MA) was 
  
measured as paw withdrawal threshold (PWT) in response to gradually increasing pressure. 
The results are shown in Figure 2.3. 
   
 
 
 
 
 
 
 
Figure 2.3. Effects of oral administrations of 4-chloropropofol and pro-drug in Chung lesion model of 
neuropathic pain: Rats were habituated for one week prior to experiment. A comparison was made 
between the pre-SNA base-line (t=0) and 7 days post-surgery using one way ANOVA with Dunnets 
multiple comparison to ensure neuropathic pain had developed. The rats were dosed orally at 8mg/Kg 
with 4-chloropropofol (n=6) or pro-drug (n=6). A vehicle control and positive control (gabapentin, 
30mg/Kg, i.p.) included. The data is expressed as mean (± SEM). Comparisons between post drug 
values and vehicle values were made using two way ANOVA followed by Bonferroni corrections (* = P 
≤ 0.05, ** = P ≤ 0.01, *** = P 0.001) 
*Data provided by Dr Laiche Djouhri, University of Liverpool. 
 
 
  
      At both post-dose time points (2-3hrs and 6-7hrs), 4-chloropofol was more effective than 
gabapentin in attenuating hyperalgesia. As expected the prodrug had a slower on-set of 
action due to its dependence on metabolic activation. At 6-7hrs post-dose, the pro-drug was 
more effective than gabapentin but not as effective as 4-chloropropofol. No sedation was 
observed following administration of 4-chloropropofol, suggesting that the analgesic effect is 
mediated through GlyRs rather than GABAA 
31. 
     While 4-chloropropofol was able to attenuate hyperalgesia, the same effect was not seen 
for mechanical allodynia; 4-chloropropofol and its pro-drug had very little impact on PWT. At 
2-3hrs, gabapentin was able to significantly reduce allodynia but this effect was not seen with 
4-chloropropofol. Attenuation of hyperalgesia but not allodynia has been noted before in this 
particular pain model, with retigabine60; 61.  This suggested that heat hyperalgesia and 
mechanical allodynia are developed through different mechanisms and that GlyRs are 
predominately involved in the development of hyperalgesia. 
        To summarise, analogues of propofol acting at GlyRs rather than the traditional target 
GABAARs, possibly present a new class of analgesics. Halogenation at the para-position is 
thought to have an effect on target selectivity of propofol. A halogen analogue, 4-
chloropropofol underwent various biological tests that that ended with validation in an animal 
neuropathic pain model. 4-chloroprofol has shown to have greater affinity for GlyRs compared 
to propofol. In addition, it is able to attenuate hyperalgesia to a greater extent than the ‘gold-
standard’ gabapentin in a neuropathic animal pain model. Unfortunately the physiochemical 
properties and pharmacokinetic profiling of 4-chloroprofol were not acceptable for a potential 
  
drug candidate. To improve the physiochemical properties of the analogue, it was decided that 
further modification at the para-position would be investigated.  
 
2.4 Bi-Phenyl Analogue Series  
2.4.1 Bi-Phenyl Analogues 
     It has previously been established that substitution at the para-position can increase 
selectivity of GlyR over GABAA and that ‘large’ compounds with a high molecular volume, such 
as 4-iodopropofol, can be accommodated at the binding site. On this basis, it was decided 
that the limitations of side chain complexity and size would be explored through the addition 
of a phenyl ring.  There is a vast list of possible substitutions that can be incorporated to the 
second ring. In order to narrow down the possibilities, a Craig plot was used. 
     The Craig plot is a tool, commonly used by medicinal chemists, that categorises 
substitutions by their electronic and hydrophobic effects in comparison to hydrogen62. 
Electron donating structures with high hydrophobic values are usually metabolically unstable, 
while highly electrophilic structures may form toxic metabolites63; 64; as such these side-chains 
are often dismissed. Electron withdrawing substitutions, such as halogen, carbonyl and 
trifluoromethyl, are stabilising and are frequently used to improve the physiochemical 
properties of a compound65. The use of the Craig plot, analogue synthesis and in silico 
physiochemical predication was all carried out in the Department of Chemistry at the 
University of Liverpool. 
  
       A series of bi-phenyl analogues, constructed around a common scaffold were synthesised 
(Figure 2.4).  Many of the compounds included chlorine and fluorine at the ortho, meta and 
para-positions. Each compound demonstrated improved potency at GlyRα1 (EC50 at low 
picomolar concentrations) and as seen with halogenated phenols the compounds with 
chlorine at the para-position were the most effective. Although all compounds showed 
excellent activity at the desired target, the physiochemical properties in particular ClogP was 
higher that desired (≥6).  
 
 
2.4.2 Physiochemical Properties  
       The early generation of hit compounds is a time-consuming process. With unlimited 
chemical possibilities, it is difficult to identify a compound that has ideal drug-like properties. 
Generally a series of guidelines are followed to single out compounds with the highest chance 
of being developed into an approved drug66. Built upon Lipinski's ‘rule of five’, drugs especially 
those acting in the CNS must meet certain criteria; i) ClogP below 5, ii) ClogD below 3, iii) MW 
below 450Da, iv) no more than 3 hydrogen bond donors (HBD), v) topological polar surface 
Figure 2.4. Bi-phenyl propofol analogue scaffold. 
 
 
  
area (TPSA) between 40-90 Å, vi) pKa below 8-1067; 68. These parameters can be used as an 
indicator of predict solubility, absorption and distribution.  Compounds with physiochemical 
properties outside of these recommended ranges are unlikely to transition well into a 
therapeutic agent that can be used by patients. These guidelines are often used as measures 
of ‘drug-likeness’ and it is essential that analogues in this project fall within these ranges. 
 
2.4.3 Bi-phenyl Amide Analogues 
      The addition of larger sider-chains at the para-position increased potency at the target 
receptor, unfortunately at the cost of other drug-like attributes. In an attempt to improve the 
physiochemical properties of the analogues while maintaining efficacy at GlyRα1, it was 
decided that heterocyclic amides would be incorporated into the bi-phenyl analogue 
structure. Heterocyclic amides are often used to improved TPSA and solubility of a structure69. 
      
 
 
 
 
      The bi-phenyl amide analogues all showed a marked improvement in ClogP and ClogD, 
however the values were still outside of optimal values. The other physiochemical properties, 
Figure 2.5. The bi-phenyl amide scaffold. 
  
TPSA, MW, HBD and pKa were closer to acceptable levels. While the drug-like properties of 
the analogues has improved, the efficacy at the target receptor was considerably poorer. 
Most of these analogues were unable to activate GlyRα1 below the cut-off concentration 
(1µM). 
   The only compound in the series that was able to successfully activate (EC50<1µM) glycine 
receptors was LT-01-45 (2, 6-diisopropyl-4-(6-(trifluoromethyl) pyridin-3-yl) phenol). 
Unfortunately some activity was also seen at GABAAR (EC50=0.12µM) but this was higher than 
what was seen at GlyRα1, signifying specificity for the drug target (Table 2.4).  
 
 
 
 
 
 
 
 
 
 
 
LT-01-45 
 
GlyRα1 EC50 = 0.0001µM 
GABAAR EC50 = 0.12µM 
ClogP = 5.55 
ClogD = 3.70 
TPSA = 33.12Å 
MW = 322.35Da 
HBD = 1 
pKa = 9.22 
 
Table 2.4: GlyRα1 EC50 data, CNS MPO score and in silico physiochemical properties of LT-01-45. 
*Compounds synthesis and in silico testing were carried out in the Department of Chemistry, University of 
Liverpool (UK) and GlyRα1 EC50 data provided by the University of Tübingen. 
 
  
   Due to poor physiochemical parameters and lack of constant activity at the target, the bi-
phenyl series was terminated. However before dismissal, the effect of a large para side-chain 
on metabolic stability was considered. As the most successful analogue in the series, LT-01-45 
was selected to be tested for metabolic resistance against cytochrome P450 enzymes (CYPs).   
 
2.5 Metabolic Stability of LT-01-45 
2.5.1 Microsomal Stability 
     Determination of a good metabolic profile is an essential aspect of early drug discovery. In 
addition to being active at the target, having drug-like properties and a favourable PK/PD 
profiles, a candidate compound must also be metabolically stable. In particular, candidates 
must be resistant to phase I metabolism by CYPs. These enzymes are responsible for the 
metabolism of more than 70% of drugs currently on the market, including, propofol70; 71. 
      Understanding how a compound is metabolised by CYPs is useful for a number of reasons. 
CYP mediated metabolism is often considered the ‘modification’ stage, in which a functional 
group is introduce to allow further metabolism. Drugs that undergo excessive CYP metabolism 
are usually excreted quickly and have reduced exposure at the target site72. In addition the 
induction or inhibition of CYPs by other drugs, supplements or food can increase the levels of 
toxic drugs or their metabolites73. While these analogues are not designed to form non-toxic 
metabolites, it is important to recognise the extant by which a candidate will be metabolised 
by CYPs, as this can offers insight into future drug-drug interactions. 
  
Microsomal stability testing in lead generation and optimisation is common practice. The use 
of microsomes for measuring CYP mediated metabolism allows for a high-throughput 
screening, which is useful at early stages of development where there is a  high number of 
test  compounds74. Accessible and inexpensive, microsomes are ideal for determining which 
lead candidates are likely to have favourable drug-like ADME properties75. They also give 
greater control over the testing environment, in that specific co-factors can be used to single 
out metabolising enzymes, like CYPs or UGTs (uridine 5'-diphospho-glucuronosyltransferases). 
In this project, microsomes were used to investigate CYPs; phase II metabolism was carried 
out by ChemPartners using whole hepatocytes. It is expected that the propofol analogues will 
show increase microsomal stability over the parent drug.  
 
2.5.2 Metabolism of Propofol 
      Propofol undergoes rapid hepatic metabolism with almost all (80%-90%) of the 
administered dose excreted in the urine as conjugated metabolites76. As a phenolic 
compound, propofol does not require the introduction of a polar functional group for 
conjugation, however some phase I metabolism does occur. The two major routes of 
metabolism for propofol are glucuronide conjugation of the phenol and hydroxylation at the 
para-position. Just less than half of the dose is thought to undergo CYP metabolism71; 76. CYP 
mediated metabolism results in the formation of 4-hydroxypropofol (Figure 2.6). This 
intermediate can be further oxidised or conjugated through glucuronidation  and to some 
extent, sulfation77. Many CYP isoforms may take part in the hydroxylation of propofol but 
  
members of CYP2B, and to a lesser extent CYP2C, sub-families appear to have the greatest 
impact on propofol biotransformation71; 77; 78. 
       Propofol exhibits a substantial amount of pharmacokinetic and pharmacodynamic 
variation between individuals. Inter patient variation usually manifests as recovery time from 
sedation. Patients that gain consciousness quicker are likely to metabolise propofol by the 
quickest route, direct glucuronidation79. It is thought that 4-hydroxypropofol formed during 
CYP metabolism may have some hypnotic activity, which can also prolong the sedative 
effect80. Metabolic efficiency is probably caused by the high incidence of polymorphisms with 
metabolising enzymes (e.g. CYPs are highly polymorphic) or differences in expression, relating 
to gender and race79;81. Polymorphic CYPs appear to contribute greatly to inter-patient 
variability, despite being lesser metabolisers of propofol81.  
 
 
    
 
 
 
 
 Figure 2.6. Metabolism of propofol: Propofol undergoes CYP mediated phase I metabolism into 4-
hydroxyprofol, which can be further oxidised or conjugated via glucuronidation. CYP (Cytochrome 
P450), UGT (uridinediphosphate  glucuronosyl transferase), GLU (Glucuronic acid)21. 
  
    Phase I metabolism of propofol predominately occurs at the para-position. The addition of 
a large side-chain should block hydroxylation, while the introduction of a trifluoromethyl 
group is a popular means of increasing resistance to CYP oxidation82 (Figure 2.7). This should 
reflect in a prolonged half-life and reduced clearance.  
 
 
 
 
 
 
 
 
2.5.3 Microsomal Stability Assay 
    Microsomal stability assay was carried using rat and human liver microsomes. The assay 
was incubated at 37°C for 60 min (n=6). Samples were taken at time points 0, 10, 30 and 60 
min. The drug samples were extracted from the microsomal fractions and prepared for 
analysis by liquid-chromatography mass-spectrometry (LC-MS). Microsomal stability was 
determined as a percentage remaining of 0 min. PK parameters, half-life and intrinsic 
clearance were calculated using microsomal stability-time plots. 
Site of CYP 
hydroxylation 
in propofol 
Nitrogen is stabilised 
by electron 
withdrawing CF3 
group 
Figure 2.7. The site of CYP mediated metabolism is blocked by the side-chain in LT-01-45. 
  
2.5.4 Results and Discussion 
    A series of bi-phenyl propofol analogues were created with the intention to produce a new 
analgesic acting through GlyR modulation. Within this series, only one compound, LT-01-45, 
showed satisfactory activity at GlyRα1. LT-01-45 also exhibited some activity at GABAAR 
making it an unsuitable choice for further development. In addition the compound also 
demonstrated poor drug-like properties. Before the bi-phenyl amide scaffold was rejected 
outright, it was decided that the impact on metabolism of a side-chain at the para-position 
would be tested. CYP mediated metabolism of propofol usually occurs at this position, 
therefore blocking the site should increase metabolic stability.  
     Metabolism of LT-01-45 by CYPs was tested using rat and human liver microsomes (RLM 
and HLM). LT-01-45 (1µM) was incubated with the microsomes for 60 minutes. Samples were 
taken at appropriate time points and analysed using LC-MS. The data is represented as time 
plots in Figure 2.8. Statistical analysis was performed using one-tailed T-Test in Microsoft 
Excel. 
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Figure 2.8.Microsomal stability data for LT-01-45 in rat (above) and human (below) liver 
microsomes:  LT-01-45 (1µM) was incubated for 60 minutes in rat and human liver microsomes 
(1mg/mL protein). Each individual experiment was carried out in duplicate. A control without 
essential co-factor, NADPH was also carried out. The data is expressed as mean (± SEM) (n=6). Data 
comparison between drug and control incubation was carried out using one tailed T-Test (RLM 
P=0.06 and HLM P=0.07).  
  
       The data shows that LT-01-45 undergoes approximately 20% (±0.16) turnover in rat 
microsomes. The turnover in humans was slightly higher at roughly 25% (±0.09) metabolism 
in comparison to the control. Following statistical analysis, there was no significant difference 
seen between the test incubations and the control lacking co-factor NADPH in both rat 
(P=0.06) and human (P=0.07) liver microsomes. The data was used to calculate microsomal PK 
parameters, T1/2, ClCYP and Clint. In the following equations the rate constant K, was the 
gradient of microsomal stability-time plots. It was converted to half-life (T1/2) using the 
correction factor, 0.693. T1/2 was then used to calculate the clearance by CYPs (ClCYP). A scaling 
factor, taken from a protocol provided by ChemPartners83, was used to calculate the intrinsic 
clearance per Kg (Clint): 
T1/2 = 0.693/K 
ClCYP = (volume/microsomal protein concentration) * (0.693/T1/2) 
Clint = ClCYP * Scaling Factor 
83 
   The PK parameters for LT-01-45 are shown in Table 2.5. LT-01-45 had a long half-life in both 
rat (150 minutes) and human (144 minutes) microsomes. The microsomal clearance was low 
(RLM = 4.6µL/min/mg and HLM=4.8µL/min/mg). These values are within the desirable range 
for metabolically stable drugs (RLM ≤ 13.32mL/min/mg and HLM ≤8.6 mL/min/mg)84. After 
scaling up the intrinsic clearance was also favourable (RLM = 8.3mL/min/Kg and HLM = 
6mL/min/Kg). In human microsomes the intrinsic clearance of propofol has been estimated to 
be around 11-15mL/min/Kg85; 86. This value is significantly higher compared to LT-01-45. This 
  
provides evidence that the major site of CYP hydroxylation of propofol occurs at the para-
position and blocking of this site can greatly improve the metabolic stability of the compound.  
 
 
 
 
 
 
        
The introduction of side-chains into propofol not only increases potency at the target 
receptor but also improves metabolic stability. Although these are clear advantages over the 
parent structure, there is still the pressing issue of poor physiochemical properties. 
     Maintaining good physiochemical properties of the analogues is a vital part of the 
candidate selection process. Using these parameters as a stringent measure of success is 
restrictive and wasteful. For example while ClogP is an important gauge for absorption and 
metabolism, all the analogues generated at this point were rejected based on high Clog. 
However, many of these compounds showed excellent efficacy at the target and LT-01-45 
(ClogP=5.5) had a good metabolic profile. Rejection of these compounds based on ClogP value 
is wasteful, as helpful information about structure in relation to favourable attributes is 
dismissed.  
 RLM HLM 
T1/2 (min) 150 144 
ClCYP(µL/min/mg) 4.6 4.8 
Clint(mL/min/kg) 8.3 6 
 
Table 2.5. Microsomal pharmacokinetic parameters of LT-01-45: Parameters were calculated using 
microsomal stability-time plots and equations taken from ChemPartners protocol. 
 
 
  
     In addition It has been reported that 44% of approved CNS drugs have ClogP above 587. If 
the guidelines utilised here had been followed, these drugs would have never been 
developed. This shows that judging potential candidates on their individual properties and 
strictly following the ranges outlined in the ‘rule of five’ is not the most efficient way to 
determine potential leads.  
      Fortunately, a new method of high-throughput in silico screening has recently been 
introduced by Pfizer. This method is referred to as multi-parameter optimisation (MPO). MPO 
is designed to rate compounds on their overall drug-likeness and has been specifically geared 
towards drugs that penetrate the CNS. It was decided that MPO would be used to determine 
which analogues would be developed further.  
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 3.1 Early Drug Development  
3.1.1 Multiparameter Optimisation 
     The early generation of hit compounds is a time-consuming process. With unlimited 
structural possibilities, it is difficult to identify which compounds will have ideal drug-like 
properties. In this project, Lipinski’s rule of five was used to evaluate each hit. Many 
compounds were dismissed due to high ClogP, regardless of their activity at the target.  This 
method was considered restrictive and slow; it was decided an alternate means of assessing 
new hits was greatly needed. Fortunately, a new system for evaluating novel drugs 
(Multiparameter optimisation), had just recently been introduced by Pfizer and others, and 
has quickly gaining in popularity1. 
      MPO is an algorithm that predicts in silico, six main physiochemical properties featured in 
the ‘rule of five’; ClogP, ClogD, MW, HBD, TPSA and pKa2. Each property is measured on a scale 
(T0-1) and the sum of these values is the MPO score (0-6)1. For CNS drugs, the recommended 
MPO is 4-62. The key advantage of this system is that, an acceptable MPO can be reached in a 
variety of ways. For instance, a compound with a low ClogP score (e.g. LT-01-45) may have 
high scores in other categories, meaning that it can still be accepted based on its overall MPO 
score. Unfortunately, LT-01-45 achieved a MPO score of 3, too low for drugs capable of 
penetrating into the CNS. However two parameters, MW and HBD, were within the acceptable 
range (Table 3.1), illustrating that MPO can be used to identify the strengths and weaknesses 
of a hit. The inclusion of individual scores highlights areas that may be tweaked to improve 
drug-likeness.  
  
 
 
 
 
 
 
 
 
     In a study by Segall et al. (2012), the MPO algorithm was applied to FDA approved drugs 
and Pfizer drug candidates. A high correlation (74%) of approved CNS drugs had a MPO score 
above 4. Analysis was also carried on drug candidates currently being developed by Pfizer, 
where it was found that 60% of these compound had a MPO above 42. Many of these 
candidates had less than optimal individual scores and would have been dismissed based on 
traditional guidelines. High MPO scores can also be suggestive of good ‘absorption, 
distribution, metabolism, excretion and toxicity’ (ADME-T) properties. Drugs that work in the 
CNS must have high passive apparent permeability (Papp) and low glycoprotein (p-gp efflux) 
liability in order to pass through the BBB. They must also have low intrinsic clearance (Clint) 
and show little to no toxicity3; 4; 5. In MPO validity studies, favourable ADME-T traits correlated 
 
LT-01-45 
 
Parameter T0 Score 
ClogP = 5.55 0.00 
ClogD = 3.70 0.15 
TPSA = 33.12 Å 0.65 
MW = 322.35Da 1.00 
HBD = 1 0.83 
pKa = 9.22 0.39 
CNS MPO = 3.0 
 
Table 3.1. MPO score of LT-01-45: Breakdown of MPO score for LT-01-45. The analogue has poor ClogP 
and ClogD. The TSPA and pKa values were adequate, while MW and HBD were excellent. Overall the 
compound failed to achieve the recommended score of 4. Colour coded T0 scores: red = poor, orange = 
average, green = good. 
*MPO data was provided by the Department of Chemistry.  
 with high MPO scores2. This suggests that MPO is not only able to measure the drug-likeness 
of a compound but may be used to predict ADME, safety and, more importantly the likelihood of 
CNS penetration.   
 
3.1.2 CNS Penetration   
    The failure rate of neurotherapeutic candidates proceeding into pre-clinical development is 
almost twice as high as that of non-CNS drug candidates. Furthermore, drugs acting in the CNS 
are also far less likely to be approved for clinical and commercial use6. Difficulties in 
developing CNS drugs arise from the complex and high risk nature of treating neurological 
diseases. Aside from toxicity, distribution of a drug into the CNS is one of the most pressing 
challenges faced when developing a neurological therapeutic, with as little as 2% of small-
molecule drugs successfully crossing the BBB7.  
   The BBB is made up of three compartments that form a huge physical barrier between the 
brain and the rest of the body8. The first boundary is a layer of compact endothelial cells 
covering capillaries and microvessels that contact with brain tissue6. Tight intracellular 
junctions between the endothelial cells control the passage of large molecules, while 
astrocytes mediate correct transportation across the BBB. This first layer has the largest 
surface area for exchange and directly connects the blood and the brain6. It is often 
considered the true barrier and is the main consideration of CNS penetration. The two other 
layers are, an epithelial cell layer forming a barrier between blood and cerebrospinal fluid 
(BCSFB) and an aranoid epithelial barrier between CSF and subdural space8.  
     The BBB exists to ensure the safety and homeostasis of the CNS. Specialised ion channels 
regulate ionic gradients needed for correct synaptic signalling9. Protein transporters, such as 
p-glycoprotein transporters (p-gp), are able to eject any molecules that could be harmful to 
the CNS, as well as excess levels of neurotransmitters3. The lipid bi-layer of the BBB is 
permeable to small lipophilic molecules, gases, and naturally occurring chemicals, such as 
hormones and neurotransmitters8. Small drugs (e.g. propofol) also may passively diffuse 
through the BBB. It is recommended that drug candidates have low MW and good lipophilicity 
in order to pass into the CNS10. Candidates with high Papp are able to diffuse across the BBB 
with greater ease, while those with low substrate affinity for p-gp transporters are much less 
likely to be transported out of the CNS3.  
      The high correlation between MPO score and drugs with high Papp and low p-gp affinity, 
suggests that MPO may be used to predict CNS penetration. It was decided that MPO would 
be used to evaluate compounds in this project. The physiochemical properties were generated 
in silico and the MPO algorithm was applied. Hits with an acceptable score (MPO ≥ 4) and 
good selectivity for GlyRα1 (E50=1µM) were selected for further development. 
 
3.1.3 Drug Development Process 
     The research and development process of a new drug is generally divided into three 
phases; drug discovery, pre-clinical development and clinical trials11. The process is 
summarised in Figure 3.1, wherein the ‘drug discovery’ phase is detailed in blue. The whole 
process can take as long as 15-20 years and can end-up costing billions of dollars, with the 
 most time and money spent during the clinical testing stage12. In the last decade, it has been 
estimated that as few as 11% of drug candidates will move into pre-clinical development, 
while on average only 1% of drugs are approved for market per year7;13. 
      Toxicity and poor ADME profiles account for more than half of drug candidates failing14. 
During pre-clinical development, failure is can be costly; however during clinical trials where 
time, money and reputation have been greatly invested, failure can be devastating.   
Therefore it is far more advantageous to thoroughly refine drug candidates during lead 
optimisation, where the stakes are much lower. The focus of early drug development is largely 
composed of generating candidates with high efficacy at the target and optimising good 
physiochemical properties.  In recent years, the incorporation of pharmacokinetic and safety 
profiling alongside pharmacodynamic testing has become increasingly commonplace15.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4 ADME Testing 
        The study of pharmacokinetic alongside, pharmacodynamic testing helps build a better 
picture of how a drug will act in a living organism16. ADME and toxicity studies during lead 
optimisation are useful, not only in refining a drug candidate but foreshadowing any potential 
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Figure 3.1. Outline of our drug development process: The drug development process often begins 
with the identification and validation of a biological target. A series of ‘hit’ compounds that may 
interact with the chosen target are synthesised. These compounds are assessed in silico for drug-
likeness. Successful compounds will be tested for target efficacy. Lead compounds that demonstrate 
good target selectivity will then be optimised using data gathered from in vitro and in vivo 
metabolism and pharmacokinetics. A lead compound is then validated in an animal model of disease 
(i.e. neuropathic pain). Optimised drug candidates can then move into pre-clinical development.  
 pitfalls further down the development pipeline. Toxicity and pharmacokinetics can be 
integrated into lead optimisation in a number of ways. Absorption and distribution can be 
measured using cell permeability assays; Caco-2 permeability Papp (optimal value >1x10
-6 cm-
1)17 is a good measure of absorption through intestinal epithelium. Metabolic stability  can be 
interpreted as intrinsic clearance from sub-cellar microsomal fractions or whole hepatocyte 
studies (desired Clint <30µL/min/mg protein)
17.  Rat models of metabolism are extremely 
useful for measuring ADME in a working biological system. Pharmacokinetic parameters in rats 
include, clearance (Cl), volume of distribution (Vd), maximal plasma concentration (Cmax), peak 
plasma concentration time (Tmax), plasma half-life (T1/2) and bioavailability (F%)
15. However, 
animal models should be used sparingly due to economical and ethical reasons. Toxicity is 
often measured as viability in various cell lines (no effect at EC50)
17. Most notability, Hep G2 
cells are commonly used to investigate hepatoxicity, a major cause of toxicity–related 
failure18. Hepatoxicity can also be the result of negative drug-drug interactions (DDIs). Such 
interactions are usually a consequence of induction or inhibition of metabolising enzymes. 
Cytochrome P450 (CYP) inhibition (EC50 >10µM) is a popular way to identify adverse DDIs
17; 18.  
    These techniques can be used to further optimise compounds that have passed initial target 
validation screening with an acceptable MPO score. Candidates that show drug-like properties 
in various ADME and toxicity tests can then be further validated in an animal model of pain.  
 
 
 
 3.1.5 Pharmacodynamic Testing for Neuropathic Pain Drugs  
   A drug candidate may exhibit high potency at the target receptor, along with a favourable 
PK profile and good drug-like physiochemical properties but it is vital to validate 
effectiveness in an animal model of the target disease. There are numerous methods of 
inducing pain and measuring analgesia in animal models19. In this project, neuropathic pain 
behaviours, allodynia and hyperalgesia were induced using the Chung lesion model of 
neuropathic pain. 
     The Chung lesion was developed as a more controlled model of peripheral nerve injury20. 
Traditionally models of peripheral nerve injury involved the ligation or partial axotomy of the 
sciatic nerve. The sciatic nerve is one of the largest in body and is derived from many spinal 
nerves including those in the lumbar and sacral segments. Therefore direct injury to the 
sciatic nerve will have a large impact on the PNS and will result in a greater variability of 
developed neuropathic pain behaviours 19.  Chung et al. developed a pain that involved the 
ligation of a spinal nerve rather than axotomy20. Traditionally the Chung lesion model targets 
either the lumbar spinal nerve 5 or 6, in this project however, the left sciatic nerve was 
selected for ligation (see Appendix III)19. In order to reduce the number of animals used, only 
a select number of the most promising candidates were chosen to be tested in the Chung 
lesion model. Candidate efficacy was tested against the drugs currently used to treat chronic 
pain. The effect of the candidate on mechanical allodynia was measured by foot withdrawal 
threshold (g) in response to gradually increasing innocuous mechanical stimulus21. While 
hyperalgesia was measured the by paw withdrawal latency (s) from a constant source 
 noxious cold (10°C)21. All neuropathic pain model testing was carried out under the 
supervision of Prof. McMahon at King’s College London, UK.  
 
3.2  Lead Generation  
3.2.1 Amino-alkyl Analogues      
      MPO evaluation of the bi-phenyl analogues indicates that these compounds are unlikely to 
cross the BBB. Breakdown of the MPO scores highlighted a major issue with high ClogP and 
ClogD. The addition of common solubilising substitutions, such as morpholine and other 
heterocyclic amines (Figure 3.2), should reduce the ClogP and ClogD whilst retaining good 
TSPA22. Some of the bi-phenyl analogues already featured a morpholine ring and still 
maintained poor solubility. It is probable that this was caused by the inclusion of the phenyl 
ring. Removal of the ring will reduce the steric hindrance of the structure and hopefully 
improve the physiochemical properties of the analogues.  
 
 
 
 
 
     
     Review of the literature lead to the discovery of an earlier study, wherein propofol 
analogues containing morpholine rings were tested for efficacy at GABAAR. These amino-alkyl 
Figure 3.2. Structure of morpholine.22 
 propofol analogues were developed by Cooke et al., with the intention of improving the 
solubility of propofol23. The analogues were able to cause sedation, but the effect was not 
reversed by the inclusion of a GABAAR antagonist, TBPS (t-butyl bicyclo-phosphorothionate)
23. 
This suggests that the hypnotic activity of these analogues is not mediated through GABAAR. 
In addition to having no activity at GABAAR, the amino-alkyl analogues also demonstrated 
superior solubility. Moreover, these analogues were not tested for activity at GlyRs, so there is 
a possibility that heterocyclic amine analogues may be able to potentiate glycine currents 
without activing GABAAR. On this basis it was decided that a series of amino alkyl analogues 
would be synthesised (Figure 3.3).  
 
 
  
 
    
   These analogues exhibited slightly improved physiochemical properties over their 
predecessors. Unfortunately the aq. Solubility, pKa and ClogP were still too high, whilst the 
TPSA had fallen below an acceptable range. MPO evaluation predicted that none of the 
compounds would be capable of BBB penetration. As a final testing measure, the compounds 
were tested for target efficacy but none were able to activate glycine receptors under the cut-
off concentration of 1µM.  
Figure 3.3. Amino-alkyl analogue scaffold. 
      As part of this rationale a series of analogues based on 2,6-di-tert-butylphenol were also 
synthesised. 2,6-di-tert-butylphenol is a non-sedative propofol analogue (Figure 3.4) that is 
able to potentiate glycine to a greater extent than propofol and is unable to activate GABAARs 
24;25.  
 
 
 
     
  The 2,6-di-tert-butylphenol analogues were synthesised and analysed for their MPO scores. 
The physiochemical properties of these analogues were worse. In both analogue sets, the 
structures containing morpholine had the most favourable individual physiochemical 
properties. The MPO evaluation for the two morpholine analogues is detailed in Table 3.2. 
In addition to poor in vitro activity the amino-alkyl compounds also carry the risk of forming 
toxic metabolites. Benzyl amines are able to form quinone methides, a reactive electrophilic 
metabolite that can interact with many biological nucleophiles (e.g. proteins). Blocking 
metabolism at the methylene position with a carbonyl group may prevent the formation of 
quinone methides. The introduction of a polar carbonyl could also improve pKa, TSPA and 
ClogP. 
 
Figure 3.4. The structure of 2,6-Di-tert-butylphenol. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Parameter T0 Score Parameter T0 Score 
ClogP = 3.60 0.70 ClogP = 4.67 0.17 
ClogD = 2.70 0.65 ClogD = 3.50 0.25 
TPSA = 32.70 Å 0.63 TPSA = 32.70 Å 0.63 
    MW = 277.4 Da 1.00 MW = 305.45 Da 1.00 
HBD = 1 0.83 HBD = 1 0.83 
pKa = 10.89 0.00 pKa = 12.01 0.00 
CNS MPO = 3.8 CNS MPO = 2.9 
 
Table 3.2. MPO score of amino-alkyl analogues: Breakdown of MPO score for two best performing 
analogues of the amino-alkyl series. Both analogues contained a morpholine. The 2,6-Di-tert-
butylphenol analogue had a lower MPO score and higher ClogP compared to the propofol analogues. 
While the propofol analogue did not have a ClogP value that would normally be considered 
acceptable, the T0 score contributed highly to its overall MPO score. 
*MPO data was provided by the Department of Chemistry.  
 3.2.2 Amide Analogues 
       The replacement of the phenyl ring with a benzyl morpholine group did improve the 
physiochemical properties of the compounds, although it had little effect on receptor 
selectivity. The amino-alkyl analogues may also produce toxic metabolites in the form of 
quinones. The introduction of a carbonyl will result in the creation of an amide analogue. In 
this analogue series the vulnerable benzyl link is protected, potentially making the compounds 
more metabolically stable. Furthermore, the carbonyl group should influence the solubility 
and polarity of the compound (e.g. reduced ClogP and increase TPSA).  
 
  
 
 
 
 
 
 
 
 
 
LT-01-25 
 
LT-01-26 
Parameter T0 Score Parameter T0 Score 
ClogP = 3.10 0.95 ClogP = 3.54 0.73 
ClogD = 2.80 0.60 ClogD = 2.50 0.85 
TPSA = 49.8 Å 1.00 TPSA = 43.78 Å 1.00 
    MW = 291.1 Da 1.00 MW = 304.43 Da 1.00 
HBD = 1 0.83 HBD = 1 0.83 
pKa = 10.10 0.00 pKa = 10.14 0.00 
CNS MPO = 4.3 CNS MPO = 4.4 
Gly EC50 = 0.35 nM Gly EC50 = 1.2 pM 
 
Table 3.3. MPO evaluation of amide analogues, LT-01-25 and LT-01-26 
*Data from the Department of Chemistry. 
      All the amide analogues showed a marked improvement in their physiochemical 
properties. Although, only two compounds, LT-01-25 and LT-01-26 were able achieved a MPO 
score above 4 (Table 3.3). While the MPO scores were extremely close, the individual scores 
show that LT-01-26 has a better ClogD value. ClogD is a very important parameter, as it is a 
measure of ClogP in relation to physiological pH changes26. Within this series only LT-01-25 
and LT-01-26 were able to activate GlyR at a much lower concentration than propofol. As seen 
in Table 3.3, LT-01-26 had a lower EC50 value and it showed not activity at GABAAR, unlike LT-
01-25, which had a minor effect (GABAAR EC50= 30µM).  Following the success of MPO 
evaluation and high potency for the target receptor, LT-01-25 and LT-01-26 were chosen to 
undergo in vitro and in vivo PK/PD testing.  
 
3.2.3 Tert-butyl Amide Analogues 
       Amide analogues of 2,6-di-tert-butylphenol were also synthesised. Based on the progress 
seen with the amide morpholine analogues, the addition of a carbonyl may decrease the 
ClogP, ClogD and pKa of the original tert-butyl analogues. The new amide analogues did show 
an improvement in regards to ClogP, TSPA and pKa, nevertheless the predicted parameters 
were still not within an acceptable range. Following MPO evaluation, none of the tert-butyl 
amide analogues were able to reach the desired score of ≥4. The highest scoring analogues, 
LT-01-88 and LT-01-89, are shown in Table 3.4.  
     The tert-butyl amide analogues were tested for GlyR efficacy. Due to unstable cell lines it 
was not feasible to test every compound. Based on poor MPO score LT-01-88 did not undergo 
 electrophysiological testing. LT-01-89, on the other hand, was one of the three compounds 
chosen to be tested at GlyRα1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Table 3.4 shows that the predicted drug-likeness of the tert-butyl amide analogues is not 
as promising as the amide morpholine compounds. Even so, LT-01-89 did show a good level of 
selectivity, in keeping with that of the amide morpholine analogues, LT-01-25 and LT-01-26. It 
was determined that LT-01-89 would be investigated further. Although LT-01-88 was not 
 
LT-01-88 
 
LT-01-89 
Parameter T0 Score Parameter T0 Score 
ClogP = 5.13 0.0 ClogP = 4.10 0.45 
ClogD = 3.70 0.15 ClogD = 4.70 0.00 
TPSA = 40.54 Å 1.00 TPSA = 49.77 Å 1.00 
 MW = 317.47 Da 1.00 MW = 319.44 Da 1.00 
HBD = 1 0.83 HBD = 1 0.83 
pKa = 10.70 0.00 pKa = 10.52 0.00 
CNS MPO = 3.0 CNS MPO = 3.3 
- Gly EC50 = 0.46 nM 
 
Table 3.4. MPO evaluation of tert-butyl amide analogues, LT-01-88 and LT-01-89. 
*Information provided by the Department of Chemistry (Gly EC50 value for LT-01-88 not available). 
 selected for GlyRα1 efficacy, the analogue was included in microsomal stability studies with 
LT-01-25, LT-01-26 and LT-01-89. 
 
 
3.3  Pharmacological Testing of Amide Analogues 
 
3.3.1 Metabolic Stability  
      In comparison to earlier propofol analogues in this project, the amide compounds have 
shown a huge improvement in their drug-like properties. Three of these analogues, LT-01-25, 
LT-01-26 and LT-01-88 were able to successfully modulate GlyRs. These compounds, as well as 
another analogue, LT-01-88, were selected to undergo the same microsomal stability testing 
as a previous analogue, LT-01-45. The major site of CYP metabolism has also been blocked by 
a para-substitution. The newly substituted carbonyl group will help protect the benzyl link, 
another possible site of metabolism (Figure 3.5).  
 
 
 
 
 
 
 
 
Figure 3.5. Potential sites of CYP mediated metabolism are blocked in amide morpholine analogues. 
Expected site 
of CYP 
metabolism 
Expected site of 
CYP metabolism 
blocked 
       The analogues were tested with the same protocol used for LT-01-45 in rat and human 
liver microsomes (RLM and HLM). The compounds were incubated at 37°C for 60 minutes. 
Samples were taken at 0, 10, 30 and 60 min. The samples were analysed using LC-MS. 
Microsomal stability results are shown in Figure 3.6 (LT-01-25), Figure 3.7 (LT-01-26), Figure 
3.8 (LT-01-88) and Figure 3.9 (LT-01-89). Microsomal parameters are shown in Table 3.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6a. Microsomal stability data for LT-01-25 in rat liver microsomes:  LT-01-25 (1µM) was 
incubated for 60 minutes in rat liver microsomes (1mg/mL protein). Each individual experiment was 
carried out in duplicate. A control without essential co-factor, NADPH was also carried out. The data 
is expressed as mean (± SEM) (n=6). Data comparison between drug and control incubation was 
carried out using one tailed T-Test (P=0.08). Total turnover was 5% (±0.09). 
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       The total turnover for LT-01-25 in rats was 5% (±0.09). For human microsomes the 
turnover was slightly higher in at 8% (±0.17). There was no statistical significance between the 
controls and the incubations at 60 minutes (RLM P=0.08, HLM P=0.06). The half-life in both 
species was exceptionally long, with the compound estimated to last over 8 hours. The 
microsomal clearance was well within an acceptable range (RLM = 0.9 µL/min/mg and HLM = 
1.3 µL/min/mg). The predicted intrinsic clearance was nearly 10-fold lower than that of 
propofol. LT-01-25 was the most microsomal stable analogue tested at this point in the 
project. Its stability can be attributed to the carbonyl group, which prevents the hydroxylation 
by CYPs and helps maintain favourable drug-like properties.  
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Figure 3.6b. Microsomal stability data for LT-01-25 in human liver microsomes:  LT-01-25 (1µM) was 
incubated for 60 minutes human liver microsomes (1mg/mL protein). Each individual experiment was 
carried out in duplicate. A control without essential co-factor, NADPH was also carried out. The data 
is expressed as mean (± SEM) (n=6). Data comparison between drug and control incubation was 
carried out using one tailed T-Test (P=0.06) and the total turnover 8% (±0.17). 
    In contrast, the other amide analogue, LT-01-26 had a dramatically different microsomal 
profile. Despite the fact that LT-01-26 is more potent at the drug target, it is far less stable 
than LT-01-25. After 60 minute most of analogue had been broken-down by rat microsomes, 
leaving a mere 7% (±0.02) of the starting amount remaining. Following statistical analysis, the 
difference between the test incubation and control was significant (P=0.05). The intrinsic 
clearance was still lower that propofol, however the microsomal clearance was well above the 
margin for highly metabolised drugs (recommended ClCYP ≤ 26.88 mL/min/kg).  
 
 
 
 
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50 60
%
 R
e
m
ai
n
in
g 
Time (min) 
LT-01-26 (1um RLM)
LT-01-26 (-NADPH
RLM Ctrl)
Figure 3.7a. Microsomal stability data for LT-01-26 in rat liver microsomes: The data is expressed as 
mean (± SEM) (n=6). Data comparison between drug and control incubation was carried out using one 
tailed T-Test (RLM P=0.05 and HLM P=0.09). The total turnover at 60 minutes was 88% (±0.01). 
       In human microsomes, LT-01-26 fared considerably better. The overall turnover was 32% 
(±0.09) and was not statistically different to the control (P=0.09). The half-life is estimated to 
be over 2 hours, although this was still the shortest of all the analogues tested so far. The 
microsomal and intrinsic clearance values were also the highest, but were still within a 
satisfactory range. The rapid metabolism of LT-01-26 is probably the result of the exposed N-
methyl group that replaced the morpholine of LT-01-25. The data indicates that the 
morpholine should be maintained for good stability. 
Figure 3.7b.Microsomal stability data for LT-01-26 in human liver microsomes: The data is 
expressed as mean (± SEM) (n=6). Data comparison between drug and control incubation was carried 
out using one tailed T-Test (P=0.09). After 60 minutes the turnover in comparison to the control was 
32% (±0.09). 
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Figure 3.8. Microsomal stability data for LT-01-88 in rat (above) and human (below) liver 
microsomes: The data is expressed as mean (± SEM) (n=6). Data comparison between drug and 
control incubation was carried out using one tailed T-Test (RLM P=0.04 and HLM P=0.06). The 
turnover in RLM was 25% (±0.15) and 17% (±0.07) in HLM. 
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Figure 3.9. Microsomal stability data for LT-01-89 in rat (above) and human (below) liver 
microsomes: The data is expressed as mean (± SEM) (n=6). Data comparison between drug and 
control incubation was carried out using one tailed T-Test (RLM P=0.04 and HLM P=0.06). LT-01-89 
had an overall turnover of 25% (±0.15) in RLM and 9% (±0.11) in HLM. 
       The tert-butyl analogues expressed similar microsomal profiles, though LT-01-89 showed 
marginally higher stability. This could parallel of the differences scene with LT-01-25 and LT-
01-26, where the morpholine is contributing to greater stability. In rats, the maximum 
turnover for both compounds was 25% (±0.15). Statistical analysis showed a significant 
difference (P=0.04) between the control and test incubation, despite the overall turnover 
being lower than LT-01-26 in human microsomes, a value that was not statistically significant. 
This is most likely due to higher general stability of the tert-butyl analogues in the control 
incubation.  LT-01-89 had a lower turnover in HLM (9% ±0.11) than LT-01-88 (17% ±0.07). The 
half-life for both compounds was high, LT-01-88 (RLM = 173 mins, HLM = 223 mins) and LT-01-
89 (RLM = 165 mins, HLM = 407 mins). The microsomal clearance was within a metabolically 
stable range and the intrinsic clearance values were lower than propofol. As seen with the 
amide analogues, the compound containing morpholine, LT-01-89 had a more favourable 
microsomal profile.  
     There is a vast difference in the metabolic stability of the two amide analogues can be 
seen. LT-01-25 was the most stable analogues, whilst LT-01-26 was almost completely 
metabolised by rat CYPs. The tert-butyl analogues underwent some metabolic breakdown, 
with both compounds sharing similar microsomal turnover with the bi-phenyl analogue, LT-
01-45. The microsomal parameters were calculated using the formulas used to calculate the 
parameters for LT-01-45. The values for the amide and tert-butyl analogues is summarised in 
Table 3.5 
 
  
 
 
 
 
 
 
 
    Based on the microsomal data above, it is clear that LT-01-25 has the most desirable 
metabolic stability, followed by LT-01-89. It was decided that these compounds would be 
tested in rat and human hepatocytes. With major sites of CYP metabolism blocked in these 
analogues, studying the metabolism in microsomes can only provide limited information. It is 
vital that other routes of metabolism are studied. The used of whole hepatocytes allows for 
simultaneous testing of multiple metabolic pathways, including the main route of propofol 
metabolism, glucuronidation.  
      Whole hepatocytes are extremely useful for in-depth metabolic studies without the use of 
animals. Unfortunately, difficulty securing large quantities of functional cells places a major 
restriction the practicality of hepatocytes. It was decided that only two analogues, LT-01-25 
and LT-01-89 would be sent for testing. Hepatocyte testing was carried out by ChemPartners. 
The compounds (1µM) were incubated for 120 minutes. Samples were taken at 0, 15, 30, 60 
and 120 min. The hepatocyte parameters are presented in Table 3.6.  
 
 
T1/2 (min) ClCYP(µL/min/mg) Clint (mL/min/kg) 
RLM HLM RLM HLM RLM HLM 
LT-01-25 770 533 0.9 1.3 1.6 1.75 
LT-01-26 46 126 15 5.8 26.88 6.9 
LT-01-88 173 223 4.0 3.1 7.2 3.9 
LT-01-89 165 407 4.2 1.7 7.5 2.1 
 
Table 3.5. Microsomal pharmacokinetic parameters of amide analogues: Microsomal stability-
time plots were used to generate the parameters for LT-01-25, LT-01-26, LT-01-88 and LT-01-89. 
 
  
 
 
 
 
 
 
 
      The data provided by ChemPartners shows that LT-01-25 undergoes substantially more 
metabolism in human hepatocytes than microsomes. It is likely that glucuronidation of the 
phenol is responsible. In LT-01-89, the hydroxyl group is protected by additional methyl 
groups, so the compound is more resistant to conjugation. The values for rat hepatocytes are 
lower than the microsomal value, but remain better than LT-01-89. The in vitro metabolic 
profiles of both compounds are encouraging; however these analogues need to undergo more 
detailed testing to fully understand their pharmacokinetic properties.  
 
3.3.2 In vivo Metabolism  
       Determining pharmacokinetic parameters through in vivo metabolic studies is an essential 
part of lead optimisation. Whilst microsomes are useful for high-throughput screening and 
hepatocytes involve multiple metabolic pathways, they are not sufficient replacements for a 
 
T1/2 (min) Clint (mL/min/kg) 
Rat Human Rat Human 
LT-01-25 429 59 7.55 28.69 
LT-01-89 324 2387 9.99 0.72 
 
Table 3.6. Metabolic stability of LT-01-25 and LT-01-89 in rat and human hepatocytes: The 
compounds were incubated in rat and human hepatocytes at a concentration of 1μM. Samples were 
collected at 0, 15, 30, 60 and 120 minutes (n=2) (See Appendix V). 
*Data from ChemPartners. 
 living organism. Many internal and external factors (e.g. genetics and diet) may intersect and 
contribute to the absorption, distribution or metabolism of a compound. Studying the in vivo 
metabolism of a drug candidate, allows the pharmacokinetics to be viewed in context of living 
system. This will allow for a more accurate prediction of metabolism in man. When working 
with animals, it is important to maintain ‘the 3Rs’ (Replace, Reduce, Refine); as part of this 
philosophy only select number of compounds were chosen for the following studies.  
      The first analogue to be tested was LT-01-25. The selection was based on the strong 
metabolic profile generated through microsomal stability experiments. LT-01-25 was 
administrated orally at 10mg/Kg. The dose was based on information provided by 
ChemPartners in earlier metabolic studies.  Rats were given free access to food and water. 
Blood was collected, under anaesthesia, from the tail vein at 0.25, 0.5, 1, 3, 5, 7 and 24 hrs 
post oral dosing. The analogue was formulated in 10% DMSO, 10% solutol, and 80% saline 
(0.9%). This vehicle was taken from the protocol used by ChemPartners in earlier 
pharmacokinetic studies. Another group of rats were dosed intravenously at 5mg/Kg and 
blood samples were collected at 0.08, 0.25, 0.5, 1, 3 and 6 hrs post dose from the tail vein. To 
improve fluidity of the vehicle for i.v administration, the formulation was modified to 10% 
DMSO, 20% solutol and 70% d.H2O. The samples were analysed using LC-MS and the data 
presented as drug concentration in plasma against time (Figures 3.10 and 3.11). 
 Figure 3.10. Metabolism of LT-01-25 in rats following 10mg/Kg dose (P.O): Rats were dosed orally at 
10mg/kg. Fasted rats has restricted access to food 12 hours prior to dosing.LT-01-25 was formulated in 
10% DMSO, 10% solutol, and 80% saline (0.9%). Blood was collected, under anaesthesia, from the tail 
vein at 0.25, 0.5, 1, 3, 5, 7 and 24 hrs post oral dosing. Plasma concentration (ng/mL) levels were 
calculated from AUC values and represented as mean values (±SEM) (n=4). 
 
     The pilot experiment showed initial absorption was poor and fell quickly before slowing 
rising over the course of a few hours (Figure 3.10). This indicates that enterohepatic 
circulation of LT-01-25 may be taking place. Enterohepatic circulation is a process wherein 
biliary excretions from the liver are re-absorbed through the intestine27. Re-circulation is 
commonly categorised by multiple concentration peaks. The cycling of a drug can lead to a 
prolonged pharmacological response and the build of toxic drugs/metabolites27. 
Enterohepatic circulation can be influenced by a number of factors including, physiochemical 
properties, diet, genetics, disease and interactions with other drugs27. In this case the most 
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 likely causes are the properties of LT-01-25 itself, or food. To investigate the impact of food on 
metabolism a group of rats were denied access to food for 12 hours prior to oral dosing. Food 
access was returned immediately following administration of the drug. 
      Food appeared to have a significant impact on the absorption of the drug. In the fasted 
group the peak concentration was more than two-fold higher and achieved within the first 
hour. The plasma concentration fell quite rapidly after the peak. In contrast, the non-fasted 
group showed much slower absorption on average over the course of 8 hours. After 24 hours 
the concentration in both groups was too low to be accurately quantified. 
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Figure 3.11. Metabolism of LT-01-25 in rats following 5mg/Kg dose (I.V): Rats were dosed 
intravenously at 5mg/kg. LT-01-25 was formulated in 10% DMSO, 20% solutol, and 70% H2O. Blood 
was collected under anaesthetic from the tail vein at 0.08, 0.25, 0.5, 1, 3 and 6 hrs post dose. 
Plasma concentration (ng/mL) levels were calculated from AUC values and represented as mean 
values (±SEM) (n=4). 
        A much greater exposure in the plasma was seen following I.V dosing. The peak was 
reached instantly and the compound was quickly cleared until roughly 3 hours, where the 
plasma concentrated appeared to plateau. 
   As the initial pharmacokinetic profiles of LT-01-25 were promising, it was decided to test 
the analogue in an alternate vehicle. It is important to consider the use of different 
vehicles, as they can have an effect on absorption and thus metabolism28. DMSO, in 
particular, is useful for compounds with poor solubility but it can have an effect on the 
absorption and distribution of a drug 29. In addition, DMSO has been associated with minor 
inflammation and local toxicity30. A standard suspension vehicle (SSV) made up of 0.5% 
sodium carboxymethylcellulose, 0.5% benzyl alcohol, 0.4 Tween 80 and 98.6% saline was 
selected. LT-01-25 was formulated in SSV and administrated to fasted and non-fasted rats. 
The sample protocol was used to collect, prepare and analyse the samples. The 
concentration-time plot is shown in Figure 3.12.  
 
  
 
 
 
 
 
      Changing the vehicle from 10% DMSO to SSV appeared to have a positive effect on the 
exposure of the analogue in the plasma. Absorption in the fasted group was slightly slower, 
although the peak concentration was higher. Formulating LT-01-25 in SSV seems to have 
diminished the effect of food. The differences in plasma concentration between the two 
groups in not as distinct as with the original formulation. This suggests that DMSO may have 
been affecting intestinal re-absorption. Pharmacokinetic parameters were generated using PK 
Solutions software and the values for LT-01-25 have been collected in Table 3.7. 
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Figure 3.12. Metabolism of LT-01-25 in rats following 10mg/Kg dose (P.O) in an alternative vehicle: 
Rats were dosed orally at 10mg/kg. Fasted rats has restricted access to food 12 hours prior to 
dosing.LT-01-25 was formulated in SSV (0.5% sodium carboxymethylcellulose, 0.5% benzyl alcohol, 0.4 
Tween 80 and 98.6% saline). Blood was collected under anaesthetic from the tail vein at 0.25, 0.5, 1, 3, 
5, 7 and 24 hrs post oral dosing. Plasma concentration (ng/mL) levels were calculated from AUC values 
and represented as mean values (±SEM) (n=3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      The overall pharmacokinetic profile of LT-01-25 was encouraging. On average the Cmax was 
high in all the test groups (>1500ng/mL). In most cases the peak plasma concentration was 
reached within an hour, with the exception of non-fasted rats dosed with the DMSO 
containing vehicle (Tmax = 240mins). This is thought to be the result of re-absorption in the 
intestine.  Interestingly non-fasted rats dosed with the SSV formulation exhibited the shortest 
Tmax (15mins), suggesting that DMSO may aggravate enterohepatic circulation. The clearance 
Parameters 
10% DMSO (P.O) – 10mg/Kg SSV (P.O) – 10mg/Kg 
FASTED NON-FASTED FASTED NON-FASTED 
AUC (hr*ng/mL) 8532.8 20421.4 18130 19032.8 
Cmax (µg/mL) 2.4  1.7  2.6 2.1 
Tmax (min) 18 240 60 15 
T1/2 (min) 84  84  84 217 
CL (L/min/Kg) 1.9 0.5 0.5 0.5 
Vd (L/Kg) 2.3 0.97  1.1 2.7 
 
Parameters 
I.V P.O Relative 
Bioavailability 
F (%) 5mg/Kg 10mg/Kg 
AUC (hr*ng/mL) 1275.4 20421.4  
81.6 
Cmax (µg/mL) -  1.7 
Tmax (min) - 240 
t1/2 (min) 90 84 
Cl (L/hr/Kg) 3.2 0.5 
Vd (L/Kg) 1.01 0.97 
 
Table 3.7. Pharmacokinetic parameters of LT-01-25: Pharmacokinetic parameters were 
generated from the data presented in Figures 3.10-12. Parameters calculated using PK Solutions 
in a one-compartmental analysis. 
 was almost with a recommended range of 10-40 mL/min/kg, while the distribution was well 
within an acceptable range. Based on good absorption it was decided that future PK 
experiments would be carried out using SSV. Food appeared to have less of an impact when 
SSV was used, so it was also decided that rats would no longer be fasted.  
      As the second most metabolically stable compound, LT-01-89 was also selected to undergo 
in vivo PK testing. LT-01-89 (10mg/Kg) was formulated in SSV and administrated orally in non-
fasted rats. LT-01-89 was also given as an intravenous dose at 5mg/Kg in 10% DMSO, 20% 
solutol and 70% d.H2O. Blood was collected at the same time points used for LT-01-25 and the 
samples were analysed using LC-MS. The data is expressed below in Figure 3.14 and Table 3.8 
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Figure 3.13a. Metabolism of LT-01-89 in rats: Rats were dosed orally at 10mg/Kg (SSV). Blood 
samples were taken at 0.25, 0.5, 1, 3, 5, 7 and 24 hrs post dose.  Plasma concentration levels (ng/mL) 
were calculated from AUC values and represented as mean (±SEM) (n=3). 
  
 
        
 
        LT-01-89 was absorbed fairly slowly (Tmax = 180min) and the peak plasma concentration 
was much lower that LT-01-25 (Cmax = 720ng/mL). The clearance was much higher than LT-
01-25 but still fell with an acceptable range, whereas the Vd was within a desire range 
(7.2L/Kg). The relative bioavailability was 49%, a passable value but not on par with LT-01-25, 
which had a relative bioavailability of 81.6%. Generally, LT-01-89 had an adequate 
pharmacokinetic profile, however the absorption and distribution was poor when compared 
to LT-01-25.   
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Figure 3.13b. Metabolism of LT-01-89 in rats: Rats were dosed intravenously at 5mg/Kg (10% 
DMSO, 10% solutol and 80% saline). Blood samples were taken at 0.08, 0.25, 0.5, 1, 3 and 6 hrs post 
dose.  Plasma concentration levels (ng/mL) were calculated from AUC values and represented as 
mean (±SEM) (n=2). 
  
 
 
 
 
 
 
 
 
  
     LT-01-26 also underwent brief in vivo metabolic testing. Despite being readily broken-down 
in rat liver microsomes, LT-01-26 remains the most potent analogue. Following the same 
protocol as LT-01-25 and LT-01-89, this analogue was only tested in non-fasted rats at 
10mg/Kg (P.O) in SSV. The results are shown in Figure 3.14. The pharmacokinetic parameters 
are shown in relation to LT-01-25 and LT-01-89 in Table 3.9. 
     The peak concentration for LT-01-26 was reached quickly (<30min), however the total 
exposure in the plasma was poor (500ng/mL). This suggests that while LT-01-26 is rapidly 
absorbed, the majority of the dose undergoes extensive first-pass metabolism. This is 
supported by the high turnover seen in rat liver microsomes and would account for the low 
pharmacokinetic values. Low plasma concentrations and high hepatic metabolism means that 
LT-01-26 is unlikely to achieve sufficient exposure at the drug target.   
Table 3.8. Pharmacokinetic parameters of LT-01-89: Pharmacokinetic parameters were generated 
from the data presented in Figures 3.13. Parameters calculated using PK Solutions using a one-
compartmental analysis. 
Parameters 
I.V P.O Relative 
Bioavailability 
F (%) 5mg/Kg 10mg/Kg 
AUC (min*µg/mL) 92.2 455.3 49 
Cmax (µg/mL) -  0.72 
Tmax (min) - 180 
t1/2 (min) 90 216 
Cl (L/min/Kg) 0.3 0.5 
Vd (mL/Kg) 7.1 7.2 
 
  
 
 
 
      
 
 
 
 
 
Parameters LT-01-25 LT-01-26 LT-01-89 
AUC(min*µg/mL) 1140 273 455.3 
Cmax (µg/mL) 2.1 0.5 0.72 
Tmax (min) 15 18 180 
t1/2 (min) 217 72 216 
CL (L/hr/kg) 0.5 2.2 0.5 
Vd (mL/Kg) 2.7 3.7 7.2 
1
101
201
301
401
501
601
0 4 8 12 16 20 24
P
la
sm
a 
C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
 
 
Time (hr) 
LT-01-26 : Oral, SSV, 10mg/kg
Figure 3.14. Metabolism of LT-01-26 in rats: Rats were dosed orally at 10mg/Kg in SSV. Blood samples 
were collected at 0.25, 0.5, 1, 3, 5, 7 and 24 hrs post dose. Plasma concentration (ng/mL) levels were 
calculated from AUC values and represented as mean values (±SEM) (n=2). 
 
Table 3.9. Pharmacokinetic parameters of amide propofol analogues: LT-01-25, LT-01-26 and LT-01-89 
were formulated in SSV and administered to rats at 10mg/Kg (P.O). Pharmacokinetic parameters 
calculated using PK Solutions in a one-compartmental analysis. 
      Out of the three analogues tested, LT-01-25 had the most promising PK profile. High drug 
exposure and bioavailability may compensate for LT-01-25 being less potent at GlyRα1 than 
LT-01-26. The only tert-butyl analogue tested, LT-01-89 had poor exposure in the plasma due 
to ineffectual absorption and was the least potent at GlyR, making it the least suitable as a 
drug candidate. Throughout the in vivo pharmacokinetic studies no obvious signs of toxicity 
were observed. Although this is encouraging, it is possible that the analogues could be 
interacting negatively with metabolising enzymes. It is thought that metabolism related 
toxicity is mostly caused by the inhibition of CYPs. As such, the inhibition of CYPs should be 
investigate as part of lead optimisation.  
 
3.3.3 Cytochrome P450 and Toxicity  
        As few as 5% of drugs will successfully enter the market following clinical trials, with 
almost 50% of drugs failing due to a poor safety profile31. In many of these cases toxicity can 
be linked to drug metabolism32. As the majority of metabolism takes place in the liver,  this 
type of toxicity usually manifests as drug-induced liver injury (DILI). DILI is complex disease 
with many contributing factors including genetic, pharmacological and environmental33. It is 
also a major cause of drug withdrawal34. Although the full mechanism underlying DILI is not 
understood in its entirety, metabolising enzymes, particularly CYPs are thought to play a 
significant role35. DILI is believed to occur in three phases, a drug-specific stage (e.g. formation 
of a reactive metabolite), cellular specific stage (e.g. oxidative stress, immune response) and 
finally the pro-death stage (e.g. activation of necrotic signalling)33.  
     A common trigger of the immune response involved in DILI is believed to be the formation 
of metabolic adducts36. These adducts act as neo-antigens initiating an immune attack on 
healthy hepatocytes37. The liver has a high number of innate immune cells (e.g. Kupffer, 
natural killer cells) and adaptive cells (e.g. T-cells). These cells are responsible for the 
breakdown of red blood cells (Kupffer) and hepatocytes (natural killer cells) following extreme 
cellular stress33. The role of the immune system in DILI is supported by the long-onset (1-8 
weeks) and symptoms (rash and fever) that are usually associated with DILI36.   
     Certain drugs and their metabolites may form metabolic intermediate complexes or protein 
adducts with CYPs18. Conjugation with CYPs inhibits their activity and impacts the metabolism 
of other drugs. CYPs are responsible for metabolising more than 70% of approved drugs, 
preventing this action can have serious ramifications especially if build-up of a particular drug 
can lead to an overdose38. CYP adduct driven DILI occurs through oxidative stress and 
mitochondrial dysfunction36. The formation of adducts trigger the activation of MAP kinases. 
These kinase cascades converge into the P-JNK pathway which promotes oxidative stress and 
causes MPT33. MPT is the swelling and subsequent rupture of mitochondria. The ruptured 
mitochondria release Ca2+ and apoptotic factors into the cell, thus causing cell death37.  
    The prevention of unforeseen CYP induced DILI is an extremely important consideration in 
choosing a drug candidate. One of the easiest methods for HTS of adverse drug-CYP 
interactions is to study enzyme inhibition. This can be done through various methods; the 
most accessible method is the use of fluorescent based screening kits39.   
 
 3.3.4 Cytochrome P450 Inhibition Screening of Amide Analogues 
      Testing for CYP inhibition is something that can be done with relative ease at early 
developmental stages, saving time and resources at later stages. In this instance, inhibition of 
CYPs was measured using a fluorescence assay provide by Life Sciences, UK40. In this assay a 
substrate is tagged with fluorescent dye and incubated with the compound and a one of five 
CYP isoforms; CYP1A2, CYPC9, CYP2C19, CYP2D6 and CYP3A4. These five isoforms are believed 
to be responsible for 90% negative CYP interactions39. Upon metabolism the dye is released 
and emits fluorescence. The level of fluorescence is used as a direct measure of inhibition (Fig 
3.15)40. 
 
 
 
 
 
 
 
 
     Using a 96-well plate, 40µL of test compound (0.1µM, 1µM and 10µM) was added to 
individual wells in triplicate. A master pre-mixed containing, reaction buffer, desired 
Baculosomes® and regeneration system was prepared and 50µL was added to each well. The 
plate was incubated at room temperature for 10 minutes. A mixture containing reaction 
buffer, NADP+ and Vivid™ Substrate was pre-made. The reaction was started by addition of 
Figure 3.15. Conversion of non-fluorescent substrate to highly fluorescent metabolite by CYP450: 
CYP enzymes transform the tagged substrate into a free dye that emits fluorescence. Compounds 
that inhibit CYPs will inhibit this reaction, resulting in no fluorescence39. 
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10µL of substrate mixture to each well, making a final volume of 100µL. The plate was 
incubated in a Varioskan™ flash multimode plate reader at 37.1°C for 60 minutes. Data was 
collected using SkanIt™ Software. The results at the highest testing concentration (µ10M) for 
each CYP isoform are presented in Figures 3.16a-e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16a. Inhibition of CYP1A2 by LT-01-25, LT-01-26 and LT-01-89: CYP1A2 baculosomes 
incubated with test compounds (10µM) for 60 mins in a fluorescent plate reader (37.1°C). Inhibition 
was measured by the maximum fluorescence at 60 mins. A vehicle control (1.25% DMSO) and positive 
control (α-Naphthoflavone, 10µM) were also tested as a comparison for inhibition. Data is presented as 
mean ±SEM (n=3). Statistical analysis was carried out between the positive control and test compounds 
using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). 
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Figure 3.16b. Inhibition of CYP2C9 by LT-01-25, LT-01-26 and LT-01-89: CYP2C9 baculosomes incubated 
with test compounds (10µM) for 60 mins in a fluorescent plate reader (37.1°C). Inhibition was measured 
by the maximum fluorescence at 60 mins. A vehicle control (1.25% DMSO) and positive control 
(Sulfaphenazole, 30µM) were also tested as a comparison for inhibition. Data is presented as mean ±SEM 
(n=3). Statistical analysis was carried out between the positive control and test compounds using one-
tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). 
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Figure 3.16c. Inhibition of CYP2C19 by LT-01-25, LT-01-26 and LT-01-89: CYP2C19 baculosomes 
incubated with test compounds (10µM) for 60 mins in a fluorescent plate reader (37.1°C). Inhibition was 
measured by the maximum fluorescence at 60 mins. A vehicle control (1.25% DMSO) and positive 
control (Miconazole, 30µM) were also tested as a comparison for inhibition. Data is presented as mean 
±SEM (n=3). Statistical analysis was carried out between the positive control and test compounds using 
one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). 
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Figure 3.16d. Inhibition of CYP2D6 by LT-01-25, LT-01-26 and LT-01-89: CYP2D6 baculosomes 
incubated with test compounds (10µM) for 60 mins in a fluorescent plate reader (37.1°C). Inhibition 
was measured by the maximum fluorescence at 60 mins. A vehicle control (1.25% DMSO) and 
positive control (Quinidine, 10µM) were also tested as a comparison for inhibition. Data is presented 
as mean ±SEM (n=3). Statistical analysis was carried out between the positive control and test 
compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). 
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Figure 3.16e. Inhibition of CYP3A4 by LT-01-25, LT-01-26 and LT-01-89: CYP3A4 baculosomes 
incubated with test compounds (10µM) for 60 mins in a fluorescent plate reader (37.1°C). Inhibition 
was measured by the maximum fluorescence at 60 mins. A vehicle control (1.25% DMSO) and 
positive control (Ketoconazole, 10µM) were also tested as a comparison for inhibition. Data is 
presented as mean ±SEM (n=3). Statistical analysis was carried out between the positive control and 
test compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). 
      The analogues, along with a vehicle and positive control, were incubated with selected CYP 
isoforms. Fluorescence was used to measure CYP activity following a successful reaction. The 
positive controls were chosen in accordance to the protocol provided in the CYP inhibition 
assay kit from Life Technologies and are FDA recommended controls41. These drugs are known 
to inhibit CYPs. The structures of the positive controls are shown in Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
     In these experiments, the vehicle control (1.25% DMSO) was taken as 0% inhibition. 
Inhibitory activity of the analogues was viewed as a percentage difference from the vehicle 
control. For statistical analysis the positive control was used as a comparison. The difference 
between the analogues and positive controls was statistically significant for all five CYP 
α-Naphthoflavone 
(CYP1A2 inhibitor) 
Sulfaphenazole 
(CYP2C9 inhibitor) 
Miconazole 
(CYP2C19 inhibitor) 
Quinidine 
(CYP2D6 inhibitor) 
Ketoconazole 
(CYP3A4 inhibitor) 
Figure 3.17. Positive controls used in CYP inhibition screening assay: These drugs are known 
inhibitors of CYP. They are recommended by the FDA for use as positive controls in CYP studies40. 
 isoforms tested. If the level of fluorescence generated in the positive controls is assumed to 
be maximum inhibition of the enzyme then each analogue demonstrated considerably less 
inhibition.  
    Overall the analogues did not have a great effect on CYP activity. The highest incidence of 
inhibition was seen with CYP2D6 treated with LT-01-89 (38% ±0.19 inhibition). LT-01-25 also 
caused some reduction in metabolic activity (33% ±0.23), whereas LT-01-26 was seen to have 
very little effect (5.5% ±0.30). CYP3A4 also showed some mild inhibition, again with LT-01-26 
having the least effect (LT-01-25 = 30.7% ±0.02, LT-01-26 = 7.6% ±0.32 and LT-01-89 = 31% 
±0.02). Similar inhibitory activity occurred with CYP2C19, although LT-01-89 was now the least 
potent compound (LT-01-25 = 32% ±1.87, LT-01-26 = 30% ±1.64 and LT-01-89 = 12% ±3.36). 
The analogues had little to no effect on CYP1A2 and CYP2C9. The levels of inhibition for both 
isoforms fell below 10%, with the exception of LT-01-26, which inhibited CYP1A2 by 16% 
(±1.18), in comparison to the vehicle control.  
    The FDA guidelines state that a weak CYP inhibitor has an IC50 ≥ 10µM
42. In these 
investigations the maximum inhibition caused by analogues over the course of an hour was 
did not fall below 50%, therefore accurate IC50 values could not be determined. However, 
none of the analogues were able to achieve more than 40% inhibition at 10µM, suggesting 
that these compounds are weak inhibitors of CYP41.  
   The pharmacokinetic testing of the amide analogues has helped establish excellent 
metabolic profiles for each compound. Data from CYP inhibition screening suggests that these 
compounds are unlikely to form adducts with CYPs or prevent the metabolism of other drugs. 
 While each analogue shows promise, LT-01-25 has the best PK profile overall. The final major 
test to determine whether LT-01-25 is the most suitable drug candidate is validation in an 
animal model of chronic pain.  
 
3.3.5 Validation in a Model of Neuropathic Pain 
    The amide analogues were testing in the Chung lesion of neuropathic pain model. These 
studies were carried out using fasted, male, Wistar rats at the King’s College London (UK) 
under the supervision of Prof. Stephen McMahon. The protocol for these experiments can be 
seen in the appendix. Neuropathic pain developed over a week following surgery. The rats 
were then orally dosed at three concentrations; 3mg/Kg, 10mg/Kg and 30mg/Kg. Behavioural 
tests for mechanical allodynia and cold hyperalgesia, were conducted at 1, 3, 6 and 24 hours 
post-dose. Mechanical allodynia was tested using von Frey hairs and cold hyperalgesia using a 
cold plate (10°C). The positive control used was the sodium channel blocker, lamotrigine 
(30mg/Kg P.O.) and the vehicle control was 10% DMSO, 10% solutol and 80% Saline (0.9%). 
The formulated pro-drug of 4-chloropropofol (30mg/Kg) was also tested against LT-01-25 
(Figure 3.18a-b). Analgesia was measured at percentage reversal from the baseline taken prior 
to dosing.  
 
  
       
 
 
 
 
 
 
 
     
 
 
      LT-01-25 was able to attenuate mechanical allodynia to a greater degree than lamotrigine 
at the same dose (30mg/Kg). The maximum reversal (90%) was seen at 3 hours, this value was 
the same for both 10mg/Kg and 30mg/Kg. In contrast, lamotrigine was only to achieve at 60% 
reversal, this was the same for lowest dose of LT-01-25 (3mg/Kg). LT-01-25 also outperformed 
4-chloropopofol, which produced a 70% reversal at 3 hours.  
Figure 3.18a. The effect of LT-01-25 on mechanical allodynia in the Chung lesion neuropathic pain 
model: Fasted, male, Wistar rats were treated with LT-01-25 at 3, 10 and 30mg/Kg (Vehicle = 10% 
DMSO, 10% solutol, 80% saline). Lamotrigine and formulated pro-drug 4-chloropropofol (30mg/Kg) 
were used as comparisons. Mechanical allodynia was measured as paw withdrawal latency after 
pressure applied with von Frey hairs. The data is presented as mean ± SEM (n=6) percentage reversal 
of the pre-dose baseline. Statistical analysis between LT-01-25 and the lamotrigine control was carried 
using out one-way ANOVA, comparison and Tukey’s HSD test for time-matched vehicle group (* = P ≤ 
0.05, ** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
  
 
 
 
 
 
 
 
 
 
 
     
     At the highest dose, LT-01-25 had a more dramatic effect on cold hyperalgesia. The highest 
reversal (95%) was achieved at 1 hour by LT-01-25 (30mg/Kg). Lamotrigine and 4-
chloropropofol produced approx. 70% reversal at the same time point. The analgesic effect 
persisted over the course of 6 hours. At the 6 hour point, LT-01-25 exhibited double the 
analgesic effect produced by lamotrigine and 4-chloropropofol. This is consistent will the long-
half, low clearance and high metabolic stability of LT-01-25. LT-01-89 was tested under the 
Figure 3.18b. The effect of LT-01-25 on cold hyperalgesia in the Chung lesion model of neuropathic 
pain: Fasted, male, Wistar rats were treated with LT-01-25 at 3, 10 and 30mg/Kg (Vehicle = 10% DMSO, 
10% solutol, 80% saline). Lamotrigine and formulated pro-drug 4-chloropropofol (30mg/Kg) were used 
as controls. Cold hyperalgesia was measured as paw withdrawal latency from a source of noxious cold 
(10°C). The data is presented as mean ± SEM (n=6) percentage reversal of the pre-dose baseline. 
Statistical analysis between LT-01-25 and the lamotrigine control was carried using out one-way 
ANOVA, comparison and Tukey’s HSD test for time-matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, 
*** = P 0.001). 
*Data provided by King’s College London. 
 
 
 same conditions as LT-01-25, however the formulated 4-chrolopropopofol was removed as it 
was deemed unnecessary. The results are shown below in Figure 3.19a-b.  
 
 
 
 
 
 
 
 
 
 
 
       
      LT-01-89 was able to achieve peak analgesia quicker than LT-01-25 (1 hour), this is 
surprising as LT-01-89 has much longer Tmax (3 hours). The level of reversal was not as high 
(75%), which is in keeping with the much lower Cmax of LT-01-89 (720ng/mL).  LT-01-89 was 
able to produce greater reversal in comparison to lamotrigine (65%) at the same dose and 
Figure 3.19a. The effect of LT-01-89 on mechanical allodynia in the Chung lesion model of 
neuropathic pain: Fasted, male, Wistar rats were treated with LT-01-89 at 3, 10 and 30mg/Kg (Vehicle 
= 10% DMSO, 10% solutol, 80% saline). Lamotrigine (30mg/Kg) was used as a positive control. 
Mechanical allodynia was measured as paw withdrawal threshold from application of von Frey hairs. 
The data is presented as mean ± SEM (n=6) percentage reversal of the pre-dose baseline. Statistical 
analysis between LT-01-89 and lamotrigine was performed using a one-way ANOVA, comparison and 
Tukey’s HSD test was used for time-matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
 time point. The effect of LT-01-89 steadily falls after over the course of 6 hours, where the 
reversal was roughly 20%. This is likely due to the high clearance and low bioavailability of LT-
01-89.  
 
 
 
 
 
 
 
 
 
 
 
      
    The effect of LT-01-89 on cold hyperalgesia was very similar to what as was seen for 
allodynia. The maximum reversal was 70% at 1 hour, this gradually diminished to 10% after 6 
hours. The analogue was also able to match the reversal of the positive control. For LT-01-26, 
Figure 3.19b. The effect of LT-01-89 on cold hyperalgesia in the Chung lesion neuropathic pain model: 
Fasted, male, Wistar rats were treated with LT-01-89 at 3, 10 and 30mg/Kg (Vehicle = 10% DMSO, 10% 
solutol, 80% saline). The positive control was lamotrigine (30mg/Kg). Cold hyperalgesia was measured as 
paw withdrawal latency from a source of noxious cold (10°C). The data is presented as mean ± SEM 
(n=6) percentage reversal of the pre-dose baseline. Statistical analysis between LT-01-89 and the 
positive control was carried out using out one-way ANOVA, comparison and Tukey’s HSD test for time-
matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
 the positive control was changed to gabapentin (30mg/Kg), as it is considered the ‘gold 
standard’ comparison for novel analgesics and has known side-effects than lamotrigine43. The 
data for LT-01-26 in presented above in Figure 3.20a-b. 
 
 
 
 
 
 
 
 
 
 
 
 
       In the allodynia behavioural tests, the peak effect (75% reversal) for LT-01-26 was seen at 
3 hours at both concentrations (10 and 30mg/Kg). Initial analgesia, at 1 hour, was greater in 
the higher dose (10mg/Kg = 55%, 30mg/Kg =65%).  The analgesic effect quickly fell, resulting 
Figure 3.20a. The effect of LT-01-26 on mechanical allodynia in the neuropathic Chung lesion pain 
model: Fasted, male, Wistar rats were treated with LT-01-25 at 3, 10 and 30mg/Kg (Vehicle = 10% 
DMSO, 10% solutol, 80% saline). Gabapentin (30mg/Kg) was used as a positive control. Mechanical 
allodynia was measured as paw withdrawal threshold from application of von Frey hairs. The data is 
presented as mean ± SEM (n=6) percentage reversal of the pre-dose baseline. Statistical analysis 
between LT-01-89 and lamotrigine was performed using a one-way ANOVA, comparison and Tukey’s 
HSD test was used for time-matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
 in only 10%-20% reversal at 6 hours. The swift descent in reversal is most probably caused by 
the extensive metabolism of LT-01-26, indicated by its short half-life. LT-01-26 was able to 
attenuate mechanical allodynia better than gabapentin at ten-fold lower dose. 
 
 
 
 
    
Figure 3.20b. The effect of LT-01-26 on cold hyperalgesia in the Chung lesion model of neuropathic 
pain: Fasted, male, Wistar rats were treated with LT-01-26 at 3, 10 and 30mg/Kg (Vehicle = 10% 
DMSO, 10% solutol, 80% saline).The positive control was gabapentin (30mg/Kg). Cold hyperalgesia 
was measured as paw withdrawal latency from a source of noxious cold (10°C). The data is presented 
as mean ± SEM (n=6) percentage reversal of the pre-dose baseline. Statistical analysis between LT-01-
26 and the lamotrigine control was carried using out one-way ANOVA, comparison and Tukey’s HSD 
test for time-matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
      The analgesic effect of LT-01-26 on hyperalgesia was similar to what was seen in 
mechanical allodynia. The initial reversal at 1 hour was high; this rose to a maximum reversal 
of 105% at 3 hours before rapidly falling to 15% at 6 hours. Even so, LT-01-26 was able to 
achieve greater reversal than gabapentin at a lower dose (10mg/Kg).  
   At 24 hours all compounds, regardless of dose or behavioural testing returned to the pre-
dose baseline. This is consistent with the extremely low plasma concentrations seen at 24 
hours in the PK studies. All three analogues were able to attenuate pain in neuropathic pain 
model; LT-01-25 and LT-01-26 were far more effective than currently prescribed analgesics, 
whilst LT-01-89 was able to match the analgesic effect. As LT-01-89 was not as effective as LT-
01-25 and LT-01-26 in the Chung lesion model, so it was decided that it wouldn’t undergo 
further pharmacological testing. The maximum percentage reversal for each compound can 
be seen in Table 3.10 and Table 3.11. 
 
 
 
 
 
 
 
Compound/Dose (mg/Kg) Max % Reversal Time (hr) 
LT-01-25 (3 mg/Kg) 65% 3 hrs 
LT-01-25 (10 mg/Kg) 90% 3 hrs 
LT-01-25 (30 mg/Kg) 90% 3 hrs 
   
LT-01-26 (3 mg/Kg) 20% 3 hrs 
LT-01-26 (10 mg/Kg) 70% 3 hrs 
LT-01-26 (30 mg/Kg) 75% 3 hrs 
   
LT-01-89 (3 mg/Kg) 35% 1 hrs 
LT-01-89 (10 mg/Kg) 65% 1 hrs 
LT-01-89 (30 mg/Kg) 75% 1 hrs 
 
Table 3.10. Maximum percentage reversal of mechanical allodynia in the Chung lesion model of 
neuropathic pain: LT-01-25, LT-01-26 and LT-01-89 were tested at three concentrations in the Chung 
lesion pain model. Data is presented as a percentage reversal of the pre-dose baseline in mechanical 
allodynia behavioural tests. The highest reversal values are highlighted. 
  
 
 
 
 
 
 
 
 
3.3.6 Additional Pharmacology 
       Along with good drug-like properties and a strong metabolic profile, validation in an 
animal model of disease is one of the most important aspects in lead optimisation. There are a 
number of in vitro pharmacological tests frequently included in early drug development that 
have yet to be discussed. These assays can be carried out as part of lead optimisation and 
ensure a greater chance of success further down the development pipeline.  
      Many of these guidelines have already being tested as part of the optimisation process 
previously mentioned in this project. The remaining criteria are associated to ADME and 
safety. The first two recommendations are directly related to distribution. The first is protein 
Compound/Dose (mg/Kg) Max % Reversal Time (hr) 
LT-01-25 (3 mg/Kg) 55% 1 hrs 
LT-01-25 (10 mg/Kg) 88% 1 hrs 
LT-01-25 (30 mg/Kg) 95% 1 hrs 
   
LT-01-26 (3 mg/Kg) 20% 1 hrs 
LT-01-26 (10 mg/Kg) 90% 3 hrs 
LT-01-26 (30 mg/Kg) 105% 3 hrs 
   
LT-01-89 (3 mg/Kg) 65% 1 hrs 
LT-01-89 (10 mg/Kg) 70% 1 hrs 
LT-01-89 (30 mg/Kg) 70% 1 hrs 
 
Table 3.11. Maximum percentage reversal of cold hyperalgesia in the Chung lesion model of 
neuropathic pain: LT-01-25, LT-01-26 and LT-01-89 were tested at three concentrations in the Chung 
lesion pain model. Data is presented as a percentage reversal of the pre-dose baseline in mechanical 
allodynia behavioural tests. The highest reversal values are highlighted. 
 binding in the plasma. It is recommended that the total amount of drug bound to proteins 
does not exceed 99.5%, to guarantee a minimum exposure of free drug. The quantity of free 
drug within the CNS is measured by brain CSF levels. Protein binding and CSF experiments 
were carried out by ChemPartners using fasted, male, Wistar rats dosed orally with 3mg/Kg 
(10% DMSO, 10% solutol, 80% Saline). Establishing ADME of a drug candidate can be 
extremely useful in predicting toxicological risk, however metabolism does not account for all 
possible toxicities. 
    There are three commonplace assays that must be performed as part of drug safety 
profiling. The first is the use of hERG (human ether a-go-go related gene) to measure the risk 
of cardiotoxicity44. Cells can be transfected with hERG to express inward rectifying voltage-
gated potassium channels, normally found in the heart44. Inhibition of these channels causes 
long QT intervals, which can lead to fatal tachyarrhythmias such as Torsade de Pointes; many 
TCAs, for example Amitriptyline, are associated with QT interval prolongation45. Drugs should 
not antagonise these channels below a concentration of 10µM. hERG toxicity was tested by 
ChemPartners using Chinese hamster ovary cells (CHO-K1) were transfected with hERG and 
incubated with the test compounds at a 10 point concentration range. This assay was carried 
out by ChemPartners.  
     Aside from cardiotoxicity, hepatoxicity also be established. Incubation with hepG2 liver 
cells is a common and efficient means of determining cellular toxicity. A drug must not exhibit 
cytotoxicity at a concentration that is lower than 50x EC50
17. The test compounds were 
incubated (37°C) with hepG2 cells across a concentration range (maximum concentration = 
500µM).  
      The mutagenic properties of a drug candidate should also be assessed. A well-used method 
of testing drug-induced mutagenesis is the Ames assay. Within this assay, histidine dependant 
Salmonella strains containing a variety of mutations in the histidine. These mutations make 
the bacteria vulnerable to mutagenesis46. The strains are grown on an agar plate containing 
trace amounts of histidine46. Mutated bacteria will become histidine independent and 
flourish. If few colonies are seen, then the test compound is considered non-mutagenic46. In 
this project compounds (250µg/mL) were incubated (37°C) for 48 hours with TA98 and TA100 
strains. The Ames assay and MTT cytotoxicity were conducted by Cyprotex. The protocols for 
each assay can be found in Appendix VIII, IX and X. The desired testing criteria used to drive 
lead optimisation is this project can be seen in Table 3.12.  
       
  
Parameter Recommendation LT-01-25 LT-01-26 
Physiochemical    
•Aq. Sol (mg/mL) 0.01 - 0.5mg/mL (pH7.4) 0.025mg/mL (pH7.4) - 
•LogP ≤4 3.10 3.54 
•LogD 1-3 2.88 2.50 
•MW (Da) ≤450 291 304 
•TPSA (Å) 40-90 49.80 43.78 
•HBD ≤3 1 1 
•pKa 3-9 10.10 10.14 
•MPO 4≥ 4.3 4.4 
Selectivity    
*GlyRα1 EC50 ≤1µM 0.35nM 1.2pM 
◊GABAAR EC50 ≥ 100x GlyRα1 EC50 ≥30µM (1000x) ≥30µM (1000x) 
Pharmacokinetics    
Oral Bioavailability (%) ≥20 81.6 - 
T1/2 (Rat Liver Microsomes)  ≥60 min 770 min 46 min 
*T1/2 (Human Hepatocytes)  ≥30 min 59 min - 
*Brain CSF 
3x GlyRα1 EC50 
(at 2/3 hrs, 1-3mg/Kg) 
10x GlyRα1 EC50 - 
*Protein Binding  ≤99.5% 62% 38% 
Toxicity     
*hERG toxicity  IC50 ≥ 10µM IC50 ≥ 10µM - 
+
HepG2 toxicity 
No tox at 50x GlyRα1 
EC50 
No tox below 500µM - 
+AMES genotoxicity negative negative - 
CYP Inhibition  IC50 ≥ 10µM IC50 ≥ 10µM IC50 ≥ 10µM 
 
Table 3.12. Target testing criteria for LT-01-25 and LT-01-26.  
  •Data provided by Department of Chemistry ◊ GABAAR EC50 value from BioFocus *Data provided by 
ChemPartners + Data provided by Cyprotex 
      From Table 3.12 it is clear that LT-01-25 meets every desired testing criteria with the 
exception of pKa, which is slightly too high; the sample problem applies to LT-01-26 as well. In 
addition, LT-01-26 also demonstrated poor metabolic stability in microsomes. LT-01-26 is still 
undergoing metabolic testing in human hepatocytes, as well as toxicity testing so it cannot be 
said with complete confidence that LT-01-25 is a more suitable lead; however results from 
microsomal studies and neuropathic pain testing show that LT-01-25 has better metabolic 
stability and thereby has a stronger analgesia effect in a model of neuropathic pain.  The 
remaining problem with LT-01-25 is its high pKa; drugs acting in the CNS should have a pKa 
value below 9, whereas LT-01-25 has a value above 1047. Despite this, LT-01-25 was effective 
in the pain model, suggesting that the compound is able to penetrate the CNS. It was decided 
that further investigation into structural optimisation would be carried out.  
 
3.4  Lead Optimisation 
3.4.1 LT-01-25 Analogues  
      The introduction of electronegative substitutes, such as amines, methyl groups and various 
heterocycles, can not only reduce the pKa of a compound but may have a positive impact on 
efficacy, metabolism and bioavailability. The current lead compound, LT-01-25, has met every 
desired criteria with the exception of pKa. As part of the lead optimisation process, a series of 
analogues based around LT-01-25 were synthesised and tested for efficacy at the target. 
    Out of the new analogue series only a small number maintained activity at GlyRα1. The first 
attempt at structure optimisation involved the addition of a single methyl group at various 
 positions in the morpholine ring. Over 50% of drugs on the market contain at least one methyl 
group and numerous endogenous ligands also contain many methyl groups, making them a 
common building-block in drug design48. The inclusion of a methyl can improve the 
physiochemical properties of a compound, particularly solubility. Furthermore there is 
evidence to suggest that methyl groups may increase affinity for the desired target by 
reducing the energy required for binding, thus boosting potency and selectivity. Methyl 
groups should be used cautiously as they are vulnerable to metabolic attack48.  
 
 
 
 
 
 
 
 
 
 
 
Table 3.13. MPO evaluation of LT-02-39. 
*Data was provided by the Department of Chemistry.  
 
 
 
LT-02-39 
Parameter T0 Score 
ClogP = 3.6 0.7 
ClogD = 3.9 0.05 
TPSA = 49.77 Å 1.00 
MW = 305.41 Da 1.00 
HBD = 1 0.83 
pKa = 10.08 0.00 
CNS MPO = 3.6 
GlyRα1 EC50 = 60pM 
 
      The only monomethyl analogue to successful activate GlyRα1 below 1µM was LT-02-39 
shown in Table 3.13. This analogue was far more potent than LT-01-25 (EC50 = 0.35 nM), with 
an EC50 value in the picomolar range. Some activity was seen at GABAAR (EC50= 30µM), 
although the massive difference in EC50 concentration between GlyRα1 and GABAAR, shows 
great level of selectivity for the target. There was a very minor decrease in pKa, unfortunately 
the value is still >10. The ClogD increased, which cause the overall MPO scored to fall below 
the optimal value of 4. This indicates that LT-02-39 may have difficulty crossing the BBB. As LT-
02-39 shares many structural similarities with LT-01-25, it was decided that more dramatic 
modification would be tested. 
    The morpholine ring was removed and replaced with an azetidine ring. Azetidine rings are 
heavily influenced by surrounding functional groups49. In the case of LT-02-50 the ring is 
attached to fluorine (Table 3.14). As the most electronegative element, fluorine is often used 
as a means of reducing pKa. Fluorine may also stabilise surrounding functional groups and 
form extremely strong bonds with carbon due to its powerful electron withdrawing effect. The 
replacement of hydrogen with fluorine can also affect the pharmacology of a compound, 
improving absorption, distribution and metabolism50.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
      
         The addition of fluorine brought the pKa down to 9.77, which is just within the desired 
range. The ClogD increased, meaning that the MPO score was lower than that of LT-01-25 
(MPO=4.3) however the score does imply good CNS penetration (CNS MPO ≥4). LT-02-50 also 
demonstrated higher efficacy at GlyRα1. Unlike LT-01-25, this compound showed no affinity 
for GABAAR at the highest testing concentration 30µM, confirming excellent selectivity for the 
target. This may relate to the readiness of fluorine to form hydrophobic bonds within the 
binding pocket of receptors50    
Table 3.14. MPO evaluation of LT-02-50. 
*MPO data provided by the Department of Chemistry.  
 
 
LT-02-50 
 
Parameter T0 Score 
ClogP = 3.3 0.85 
ClogD = 3.57 0.22 
TPSA = 40.54 Å 1.00 
MW = 279.35 Da 1.00 
HBD = 1 0.83 
pKa = 9.77 0.11 
CNS MPO = 4.0 
GlyRα1 EC50 = 1.2pM 
 
      The third approach was to replace the morpholine ring with a spirocyclic group (Table3.15). 
While morpholines are useful for improving solubility they can often become metabolic 
hotspots. Spirocyclic compounds are considered to be highly metabolically stability and are an 
established alternative to morpholines51. In terms of solubility, lipophilicity and pKa, many 
spirocycles can emulate the properties of carbonyls52.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      The spirocyclic analogue did have a lower pKa that LT-01-25, but it was still above the 
recommended value for CNS penetration. As seen with LT-02-39 and LT-02-50, changes to the 
 
 
 
LT-02-53 
 
Parameter T0 Score 
ClogP = 3.3 0.85 
ClogD = 3.93 0.04 
TPSA = 49.77 Å 1.00 
MW = 303.34 Da 1.00 
HBD = 1 0.83 
pKa = 10.10 0.00 
CNS MPO = 3.7 
GlyRα1 EC50 = 1.6pM 
 
Table 3.15. MPO evaluation of LT-02-53. 
*MPO data was provided by the Department of Chemistry.  
 morpholine ring increases the ClogD, which has effected on the overall MPO. LT-02-53, 
achieved a score of 3.7, which is just below the desired value of 4. On a positive note, this 
compound showed substantial improvement in efficacy at GlyRα1, and there was no activity 
seen at GABAAR. 
      Piperazine, along with morpholines and spirocycles, is a structural motif that is frequently 
used in drug design. Similarly to spirocycles, compounds featuring piperazine, may have an 
advantage over morpholines in terms of physiochemical properties and metabolic stability52.  
The piperazine analogue, LT-02-86, can be seen in Table 3.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LT-02-86 
Parameter T0 Score 
ClogP = 3.1 0.96 
ClogD = 1.92 1.00 
TPSA = 52.57 Å 1.00 
MW = 290.40 Da 1.00 
HBD = 1 0.83 
pKa = 10.14 0.00 
CNS MPO = 4.8 
GlyRα1 EC50 = 137aM 
 
Table 3.16. MPO evaluation of LT-02-86. 
*MPO data was provided by the Department of Chemistry.  
      Unfortunately no progress was seen in the pKa value of LT-02-86. Piperazine substitution 
resulted in a slight increase in pKa. On the other hand, the ClogP and ClogD were vastly 
improved, bringing the CNS MPO scored to 4.8, one of the highest values out of all the 
analogues.  LT-02-86 also produced an exceptionally strong response at GlyRα1. The EC50 
value was in the attomolar concentration range, potentially making extremely potent 
compared LT-01-25. 
     So far the optimisation of LT-01-25 has been focussed on alterations to the morpholine 
ring. It is already known that the basic phenolic structure of propofol must be maintained for 
GlyRα1 activity. Phenols are hugely common in pharmacological agents; meaning that any 
compound containing a phenol runs the risk of acting off-target and causing toxicity. 
Furthermore phenols provide a perfect platform for metabolic conjugation53. On this basis, 
the use of phenols in novel drug design is discouraged. For these analogues, it would be ideal 
to find a suitable replacement that retains the pharmacological effect but has a reduced risk 
of off-target toxicity and improved metabolic stability.  
   Bioisosteres are functional groups that have similar biological responses but different 
chemical structures. Numerous studies have shown that heterocyclic phenol bioisosteres, 
particularly containing amines can be used to recreate the properties of phenols. In a study by 
Wright et al. (2000), phenolic analogues were designed as NMDA antagonists. In order to 
improve the poor PK of these analogues, a series of phenol bioisosteres were produced, these 
compounds showed great bioavailability and potency53.  In another study, phenolic oestrogen 
receptor ligands were replaced with phenol bioisosteres (Figure 3.21). Again these 
heterocyclic bioisosteres displayed improved potency, absorption and metabolic stability54.  
  
 
 
 
 
 
       Based on the rationale and evidence from these studies, it was decided the effect of 
phenol bioisostere substitution would be investigated in this project. A bioisostere of LT-01-25 
was synthesised and tested (Table 3.17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phenol Phenol Bioisostere 
     Figure 3.21. Structures of phenol and the phenol bioisostere scaffold from Wilkening et al. (2006). 
 
 
 
RKA-018 
 
Parameter T0 Score 
ClogP = 2.21 1.000 
ClogD = 2.50 0.750 
TPSA =  53.93 Å 1.000 
MW = 287.36 Da 1.000 
HBD = 1.00 0.833 
pKa = 13.10 0.000 
CNS MPO = 4.6 
GlyRα1 EC50 = 4.2nM 
 
Table 3.17. MPO evaluation of RKA-018. 
*MPO data was provided by the Department of Chemistry.  
  
     The EC50 concentration for RKA-018 was lower than that of LT-01-25; however the phenol 
bioisostere was not as potent as the other analogues discussed above. The pKa was 
significantly increased however the low ClogP and ClogD gave RKA-018 the second highest 
MPO score in the project.  
      The purpose of LT-01-25 optimisation was to improve the physiochemical properties, 
particularly pKa. For the most part, the substitutions provided molecules with good all-around 
properties. Many of the structural groups used also had a positive impact on efficacy at 
GlyRα1. Other well-known effects that have been reported are better absorption, higher 
bioavailability and less metabolic breakdown. To determine whether these substitutions have 
a positive impact on pharmacokinetics, they were tested using rat and human liver 
microsomes. 
 
3.4.2 Metabolic Stability  
    As the metabolic profile of the lead compound, LT-01-25 is already desirable; it would be 
interesting to see whether in can be further enhanced. The new analogues that were 
successful able activate GlyRα1 below 1µM were selected to be incubated with rat and liver 
microsomes following the same protocol applied to LT-01-25. The data for LT-02-39 (Figure 
3.22), LT-02-50 (Figure 3.23), LT-02-53 (Figure 3.24), LT-02-86 (Figure 3.25) and RKA-018 
(Figure 3.26) is presented and discussed below.  
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Figure 3.22. Microsomal stability data for LT-02-39 in rat (above) and human (below) liver 
microsomes:  LT-02-39 (1µM) was incubated for 60 minutes in rat and human liver microsomes 
(1mg/mL protein). Each individual experiment was carried out in duplicate. A control without essential 
co-factor, NADPH was also carried out. The data is expressed as mean (± SEM) (n=6). Data comparison 
between drug and control incubation was carried out using one tailed T-Test (RLM P=0.03 and HLM 
P=0.06). Total turnover in RLM was 48% (±0.007) and 32% (±0.08) in HLM. 
   The monomethyl analogue, LT-02-39 was the only analogue of its set that showed potency at 
the target receptor. The EC50 value was in the picomolar range, making the compound far 
more potent that LT-01-25. However, LT-02-39 underwent a fair amount of metabolic 
breakdown, predominantly in rats with some metabolism occurring in human microsomes. 
The total turnover in rats was 48% (±0.007) in comparison to the control; in humans this value 
was a bit lower at 32% (±0.08). The half-life in both species was moderately low at 86 minutes 
(RLM) and 96 minutes (HLM).  
   In humans the microsomal clearance (ClCYP) was 7.2µL/min/mg protein, this is close the 
recommended cut off at 8.2 µL/min/mg protein. The intrinsic was calculated as 9 mL/min/Kg; 
this is similar to the estimated clearance of propofol in HLM (11-15 mL/min/Kg). The rat 
microsomal clearance was 8x higher compared to LT-01-25. Increase in metabolic breakdown 
is most probably due to the inclusion of the methyl group in the morpholine ring. While, LT-
02-39 is more potent than LT-01-25, high rate of microsomal breakdown will probably result 
in poor exposure at GlyRα1. The pharmacological response is likely to be weaker and short-
lived, similar to what is seen with LT-01-26; a compound that was more biological potent but 
less metabolically stable, therefor not as effective in the neuropathic pain model.  
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Figure 3.23. Microsomal stability data for LT-02-50 in rat (above) and human (below) liver 
microsomes: The data is expressed as mean (± SEM) (n=6). Data comparison between drug and 
control incubation was carried out using one tailed T-Test (RLM P=0.04 and HLM P=0.04). LT-02-50 
had an overall turnover of 46% (±0.02) in RLM and 90% (±0.60) in HLM. 
       Fluorine is often used as a means of improving PK, so it would be expected that the 
fluorine azetidine analogue would be the most stable compound. However, LT-02-50 
underwent nearly complete metabolism in human microsomes leaving only 10% (±0.6) of the 
original amount remaining after 60 minutes. The half-life was extremely low (47 minutes) and 
ClCYP was 14.7 µL/min/mg protein, this is almost double the maximum recommended value 
(8.2 µL/min/mg protein).  The Clint (18.5 mL/min/Kg) exceeded the estimated value for 
propofol. LT-02-50 fared better in rats, with a total breakdown of 46% (±0.02). It should be 
noted that the compound showed much more degradation (approx.14%) in the control 
incubations, suggesting that the compound itself may not be stable. This could have 
contributed to the high levels of breakdown. Even with high efficacy at the target, poor 
stability and extensive metabolism will ultimately impact analgesic performance.  
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       The spirocyclic compound, LT-02-53 was exceedingly stable in human microsomes, 
showing only 9% (±0.06) metabolism at 60 minutes in comparison to the control. The 
analogue has a long half-life (407 minutes) and clearance values (ClCYP = 7.7 µL/min/mg 
protein and Clint = 2.1 mL/min/Kg) were comparable to that of LT-01-25 and LT-01-89. 
Unfortunately, such stability was not sustained across species. In rat microsomes, a total 
turnover of 38% (±0.02) was seen. The half-life (106 minutes), ClCYP (6.5 µL/min/mg protein) 
and Clint (11.7 mL/min/Kg) were better than those of LT-02-39 and LT-02-50.  
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Figure 3.24. Microsomal stability data for LT-02-53 in rat (above) and human (below) liver 
microsomes: The data is expressed as mean (± SEM) (n=6). Data comparison between drug and 
control incubation was carried out using one tailed T-Test (RLM P=0.06 and HLM P=0.08). LT-02-53 
had an overall turnover of 38% (±0.02) in RLM and 9% (±0.06) in HLM. 
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Figure 3.25. Microsomal stability data for LT-02-86 in rat (above) and human (below) liver 
microsomes: The data is expressed as mean (± SEM) (n=6). Data comparison between drug and 
control incubation was carried out using one tailed T-Test (RLM P=0.05 and HLM P=0.06). LT-02-86 
had an overall turnover of 40% (±0.74) in RLM and 34% (±0.07) in HLM. 
         The metabolic profile of LT-02-86 is very similar to that of LT-02-39. The piperazine 
compound has a somewhat higher metabolic resistance in rat microsomes, perhaps due to the 
replacement of the N-methyl with an NH function with the piperazine ring system. The half-
life in humans (95 minutes) was almost identical to that of LT-02-39, as was the ClCYP 
(7.3µL/min/mg protein) and Clint (9 mL/min/Kg). LT-02-86 was more stable in rats with an 
overall turnover of 40% (±0.74) and a half-life of 103 minutes. Both clearance values were 
within a desired range, although they were much higher than LT-01-25. Although LT-02-86 
demonstrated extraordinary efficacy at GlyRα1, the high CYP metabolic rate is likely to lessen 
exposure and weaken the analgesic effect in an animal model of pain. However the compound 
is very stable in humans, suggesting that results from in vivo pharmacodynamic testing in rats 
might not be truly reflective of the pharmacological response in man.  
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    As with, LT-02-53, the phenol bioisostere, RKA-018 showed good metabolic resistance in 
humans and underwent some metabolism in rat microsomes. RKA-018 was not as stable as 
LT-02-53 but still demonstrated better stability than the other LT-01-25 analogues tested. The 
overall metabolism was 36% (±0.10) in rats and 13% (±0.02) in humans. As expected, the half-
life was longer in humans (330 minutes) than rats (135 minutes). The clearance values were 
well within the desired ranges and lower than that of propofol.  It is probable that CYP 
metabolism in taking place at the methyl group within the phenolic bioisostere. The 
microsomal parameters for each analogue are collected in Table 3.18.  
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Figure 3.26. Microsomal stability data for RKA-018 in rat (above) and human (below) liver 
microsomes: The data is expressed as mean (± SEM) (n=6). Data comparison between drug and control 
incubation was carried out using one tailed T-Test (RLM P=0.03 and HLM P=0.07). RKA-018 had an 
overall turnover of 36% (±0.10) in RLM and 13% (±0.02) in HLM. 
  
 
 
 
      
 
      Surprisingly none of the LT-01-25 analogues, showed improved microsomal stability over 
the original lead compound, however all the compounds showed excellent metabolic stability. 
In accordance with microsomal clearance guidelines all the compounds, bar LT-02-50, fall into 
the low clearance category for both species. Although, LT-02-50 demonstrated moderate 
human microsomal clearance, the value was at the lower end of the classification bracket 
(Table 3.19).  
 
 
 
 
     While these compounds all showed increase potency, extensive metabolism may hinder 
their effectiveness at reducing pain in a living organism. However the microsomal data only 
 
 
T1/2 (min) ClCYP(µL/min/mg) Clint(mL/min/Kg) 
RLM HLM RLM HLM RLM HLM 
LT-02-39 86 96 8 7.2 14 9 
LT-02-50 70 47 9.9 14.7 17.7 18.5 
LT-02-53 106 407 6.5 1.7 11.7 2.1 
LT-02-86 103 95 6.7 7.3 12 9 
RKA-018 135 330 5.1 2.1 9.1 2.6 
 
Table 3.18. Microsomal pharmacokinetic parameters of LT-01-25 analogues 
 
Table 3.19. Microsomal clearance classification55.  
 
 
Microsomal Clearance (µL/min/mg) 
Low Moderate High 
Human < 8.6 8.6 - 47.0 > 47.0 
Rat < 13.2 13.2 – 71.9 > 71.9 
 
 provides information about one metabolic pathway. The major route of metabolism in LT-01-
25 is thought to be glucuronidation. There is a possibility that these analogues have better 
resistance to phase II metabolism. The analogues were sent to ChemPartners for testing. 
Fasted, male, Wistar rats were dosed orally at 10mg/Kg (10% DMSO, 10% solutol and 80% 
saline). The pharmacokinetic parameters were calculated based on concentration levels in the 
plasma. The parameters are shown in Table 3.20. LT-02-39 is currently undergoing testing, so 
a full data-set is not yet available and LT-02-53 and RKA-018 are waiting to be tested. 
    
    
     From the data of the analogues that have completed testing, it is clear that these 
compounds are rapidly absorbed (Tmax ≤1). Unfortunately the exposure in the plasma for LT-
02-50 (Cmax = 995ng/mL) and LT-02-86 (Cmax = 664ng/mL), this could be consequence of 
extensive CYP metabolism. The bioavailability of LT-02-50 and LT-02-86 was lower than that of 
LT-01-25. Based on microsomal data, it is likely that LT-02-53 and RKA-018 will exhibit similar 
PK profiles.  
Table 3.20. Pharmacokinetic parameters of LT-01-25 analogues 
*Parameters provided by ChemPartners 
 
 
 
 
 
 
 
LT-02-39 
 
 
 
LT-02-50 
 
 
 
LT-02-86 
Tmax (min) 40 30 60 
Cmax (ng/mL) 3723 995 664 
T1/2 (min) 154.2 154.8 184.8 
CL (mL/hr/kg) -- 1.64 2.11 
F (%) -- 38.8 74 
 
     As with LT-01-26 and LT-01-89, the analgesic effect of these analogues is likely be fast acting 
but short-lived. In addition these analogues are extremely potent, so the initial 
pharmacological response could be higher than LT-01-25, but high clearance will mean the 
effect is brief. To be certain how efficacy and metabolism impact analgesia, these analogues 
must be tested in the same animal model of neuropathic pain. 
 
3.4.3 Testing in the Chung Lesion Model of Neuropathic Pain 
 
      The analogues of LT-01-25 were sent to King’s College London to be tested in the Chung 
lesion model of neuropathic pain. Testing was carried using fasted, male Sprague-Dawley rats 
following the same protocol used in previous Chung lesion experiments. As before the rats 
were dosed orally at three concentrations (3, 10 and 30mg/Kg) formulated in 10% DMSO, 10% 
solutol and 80% saline. Gabapentin and lamotrigine (30mg/Kg P.O) were used as controls. The 
data is presented as a percentage reversal of the pre-dose baseline, representing a 
neuropathic pain state. Mechanical allodynia was measured via paw withdrawal thresholds in 
response to mechanical pressure and cold hyperalgesia was measured as paw withdrawal 
latencies from a cold stimulus (10°C). The results of LT-02-50 can be seen below in Figure 3.27. 
 
 
 
 
 
  
 
 
Figure 3.27. The effect of LT-02-50 on mechanical allodynia (top) and cold hyperalgesia (bottom) in  
the Chung lesion neuropathic pain model: Fasted, male, Sprague-Dawley rats were treated with LT-02-
50 at 3, 10 and 30mg/Kg (Vehicle = 10% DMSO, 10% solutol, 80% saline). Gabapentin (30mg/Kg) was 
used as a control analgesic. Mechanical allodynia is measured as paw withdrawal threshold from 
application of von Frey hairs and cold hyperalgesia is measured as paw withdrawal latency from a source 
of noxious cold (10°C). Data is presented as mean ± SEM (n=6) percentage reversal of the pre-dose 
baseline. Statistical analysis between LT-02-50 and gabapentin was carried out using one-way ANOVA, 
comparison and Turkey’s HSD test for time-matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 
0.001). 
*Data from King’s College London. 
 
 
      While, LT-02-50, was able to outperform gabapentin at 3 hours with a 20% reversal of 
mechanical allodynia (10 and 30mg/Kg), the compound was considerably less effective than 
LT-01-25, which produced 90% reversal at the same dose and time. LT-02-50 appeared to 
have little effect on cold hyperalgesia. The analogue was not able to achieve greater reversal 
than gabapentin; the maximum reversal of gabapentin was 85% at 1 hour. At the same dose 
(30mg/Kg), LT-02-50 produced 25% reversal (maximum) at 3 hours. The analgesic effect in a 
living organism is not reflective of the outstanding potency exhibited in electrophysiology 
testing at recombinant GlyRα1 (EC50 =1.2pM). This is most likely the result of low 
bioavailability (38.8%). LT-02-50 was extensively metabolised in rat liver microsomes, with a 
short half-life (70 minutes) and high clearance (9.9mL/min/mg protein). The maximum 
concentration seen in the plasma of rats was 995ng/mL. Despite being highly selective for the 
target, the availability of free drug is low, this could possibly be the result of high phase I 
metabolism. This is illustrated in the lower analgesic response seen in the neuropathic pain 
model.  
     It should also be noted, that the control gabapentin had little effect on mechanical 
allodynia. This was also case in the experiments carried out on LT-01-26. During testing with 
LT-01-25 and LT-01-89, lamotrigine was used as a control. Lamotrigine was much more 
effective in treating mechanical allodynia than gabapentin. There was little difference 
between the two control drugs in cold hyperalgesia. It was decided that LT-02-39 (Figure 
3.28a-b) would be tested against lamotrigine, as it is appeared to be stronger analgesic in this 
particular pain model.  
  
 
 
 
 
      LT-02-39 responded much better than LT-02-50. In mechanical allodynia the maximum 
reversal (85%) was seen at 3 hours following a 30mg/Kg dose. Under the same conditions, 
lamotrigine achieved 50% reversal. The analgesic effect of LT-02-39 was very close to that of 
LT-01-25 (90% maximum reversal, 3 hours, 30mg/Kg). 
Figure 3.28a. The effect of LT-02-39 on mechanical allodynia in the Chung lesion model of 
neuropathic pain model: Fasted, male, Sprague-Dawley rats were treated with LT-02-39 at 3, 10 
and 30mg/Kg (Vehicle = 10% DMSO, 10% solutol, 80% saline). The positive control was 
lamotrigine (30mg/Kg). Mechanical allodynia is measured as paw withdrawal threshold from 
application of von Frey hairs. Data is presented as mean ± SEM (n=6) percentage reversal of the 
pre-dose baseline. Statistical analysis between LT-02-39 and lamotrigine was carried out using 
one-way ANOVA, comparison and Turkey’s HSD test for time-matched vehicle group (* = P ≤ 0.05, 
** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
  
 
 
 
 
 
 
 
 
 
 
      
     Interestingly, LT-02-39 out-performed both the control and LT-01-25 in cold hyperalgesia. 
At 3 hours, LT-02-39 reversed paw withdrawal latency by 110% (30mg/Kg). In comparison, 
lamotrigine reached 70% reversal. LT-01-25 and LT-02-39 both demonstrated 90% reversal at 
1 hour, however the effect produced by LT-01-25 gradually diminished over time, whereas LT-
02-39 peaked at 3 hours before falling sharply. Although the maximum reversal generated by 
LT-02-39 was much higher than LT-01-25, the same effect could not be maintained at lower 
Figure 3.28b. The effect of LT-02-39 on cold hyperalgesia in the Chung lesion neuropathic pain 
model: Fasted, male, Sprague-Dawley rats were treated with LT-02-39 at 3, 10 and 30mg/Kg (Vehicle 
= 10% DMSO, 10% solutol, 80% saline). The positive control was lamotrigine (30mg/Kg). Cold 
hyperalgesia is measured as paw withdrawal latency from a source of noxious cold (10°C). Data is 
presented as mean ± SEM (n=6) percentage reversal of the pre-dose baseline. Statistical analysis 
between LT-02-39 and lamotrigine was carried out using one-way ANOVA, comparison and Turkey’s 
HSD test for time-matched vehicle group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 0.001). 
*Data provided by King’s College London. 
 
 
 doses. Whilst, LT-01-25 showed some analgesia at 3mg/Kg (maximum reversal = 15% at 3 
hours), LT-02-39 did not have any effect on mechanical allodynia or cold hyperalgesia. The 
powerful, yet short-lived effect of LT-02-39 makes the compound an unreliable analgesic as 
the effect is dependent on high dose, resulting in good exposure at the target. LT-02-53 has 
good efficacy at GlyRα1 (EC50 = 60pM) and is efficiently absorbed (Cmax = 3723ng/mL, Tmax=40 
minutes) however the compound has at least 50% metabolic breakdown by CYPs and has high 
intrinsic clearance in rats (Clint= 9mL/min/Kg), close to that of propofol. The maximum 
percentage reversal of allodynia and hyperalgesia for LT-02-39 and LT-02-50 is summarised in 
Table 3.21. 
 
 
   
     
 
 
 
 
 
 
 
Compound/Dose (mg/Kg) Max % Reversal Time (hr) 
LT-02-39 (3 mg/Kg) 5% 3 hrs 
LT-02-39 (10 mg/Kg) 55% 3 hrs 
LT-02-39 (30 mg/Kg) 85% 3 hrs 
   
LT-02-50 (3 mg/Kg) 0% 3 hrs 
LT-02-50 (10 mg/Kg) 20% 3 hrs 
LT-02-50 (30 mg/Kg) 20% 3 hrs 
 
Table 3.21. Maximum percentage reversal of mechanical allodynia (top) and cold hyperalgesia (bottom) 
in the Chung lesion model of neuropathic pain: LT-02-39 and LT-02-50 were tested at three concentrations 
in the Chung lesion pain model. Data is presented as a percentage reversal of the pre-dose baseline in 
mechanical allodynia behavioural tests. The highest reversal values are highlighted. 
Compound/Dose (mg/Kg) Max % Reversal Time (hr) 
LT-02-39 (3 mg/Kg) 0% 3 hrs 
LT-02-39 (10 mg/Kg) 65% 3 hrs 
LT-02-39 (30 mg/Kg) 110% 3 hrs 
   
LT-02-50 (3 mg/Kg) 5% 3 hrs 
LT-02-50 (10 mg/Kg) 25% 3 hrs 
LT-02-50 (30 mg/Kg) 20% 3 hrs 
 
   The data for LT-02-53, LT-02-86 and RKA-018 is not currently available as these studies are 
on-going. Based on the metabolic profiles of these compounds it is possible that any analgesic 
effect will be short-lived, although there is a chance that increase potency will lead to greater 
maximum reversal that LT-01-25. Alongside, testing in the Chung lesion model of neuropathic 
pain, these compounds were undergoing other methods of testing, including the investigation 
into the inhibition of CYP isoforms.  
 
3.4.4 Cytochrome P450  Inhibition Screening 
       Identifying compounds that may inhibit CYPs is a significant part of understanding drug 
safety. Previously tested analogues did not produce more than 40% inhibition at 10µM when 
incubated with five major CYP isoforms; CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.  As 
part of the analogue design, functional groups that are commonly associated with protein 
adduct formation and enzyme inhibition, for example quinones, have been avoided. It is 
unlikely that these compounds will be strong CYP inhibitors based on their structure and 
previous testing results of the amide analogues.  CYP inhibition is measured as fluorescence 
released following successful metabolic reaction. The data for CYP1A2 is presented below 
(Figure 3.29) as the level of fluorescence taken at the experimental end-point of 60 minutes. 
Only the values for the highest testing concentration (10µM) are shown, however the test 
compounds were also tested at 1µM and 0.1µM.   
  
 
 
      
        Comparisons made to the vehicle control (no inhibition) were calculated as a percentage 
difference, while statistical comparisons were made between the test compounds and the 
positive controls (high inhibition). The difference between the positive control, α-
Naphthoflavone (94% ±0.03 inhibition) and all of the analogues tested was highly statistically 
significant (P≤0.01). None of the analogues caused 50% inhibition and therefore would be 
considered weak CYP inhibitors (IC50 > 10µM)
56.  LT-02-50, showed the highest level of 
inhibition (45% ±0.58). Fluorine substitutions are not usually associated with negative CYP-
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LT-02-39 (10µM)
LT-02-50 (10µM)
LT-02-53 (10µM)
LT-02-86 (10µM)
RKA-018 (10µM)
Figure 3.29 Inhibition of CYP1A2 by analogues of LT-01-25: CYP1A2 baculosomes incubated with test 
compounds; LT-02-39, LT-02-50, LT-02-53, LT-02-86 and RKA-018 (10µM) for 60 mins in a fluorescent 
plate reader (37.1°C). Inhibition was measured by the maximum fluorescence at 60 mins. A vehicle 
control (1.25% DMSO) and positive control (α-Naphthoflavone, 10µM) were also tested as a 
comparison for inhibition. Data is presented as mean ±SEM (n=3). Statistical analysis was carried out 
between the positive control and test compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, 
*** = P ≤ 0.001). 
 drug interactions57. LT-02-50 was rapidly metabolised by CYP in microsomal incubations, as 
such there may be a relation between extensive metabolism and low levels of fluorescence. 
The least inhibitory analogue was LT-02-39, demonstrating only 7% (±0.99) inhibition. RKA-
018 also had a relatively minor inhibitory effect (13% ±1.04), while both LT-02-39 and LT-02-53 
produced roughly 26% inhibition compared to the vehicle control. 
Figure 3.30 Inhibition of CYP2C9 by analogues of LT-01-25: CYP2C9 baculosomes incubated with test 
compounds; LT-02-39, LT-02-50, LT-02-53, LT-02-86 and RKA-018 (10µM) for 60 mins in a fluorescent 
plate reader (37.1°C). Inhibition was measured by the maximum fluorescence at 60 mins. A vehicle 
control (1.25% DMSO) and positive control (Sulfaphenazole, 30µM) were also tested as a comparison 
for inhibition. Data is presented as mean ±SEM (n=3). Statistical analysis was carried out between the 
positive control and test compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 
0.001). 
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LT-02-50 (10µM)
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LT-02-86 (10µM)
RKA-018 (10µM)
      LT-02-50 had little to no effect on CYP2C9, causing only 2% (± 4.58) inhibition (Figure 3.30), 
this is a complete contrast to the level of inhibition seen with CYP1A2. This might suggest that 
CYP2C9 is not a major metabolising enzyme of LT-02-50. By the same token, LT-02-39 
inhibited CYP2C9 by 40% (±4.62), whereas it was the least inhibitory analogue of CYP1A2. LT-
02-86 also had a very minor effect on CYP2C9 (4% ±1.08), as did RKA-018 (11% ±4.08). LT-02-
53 had a moderate impact (40% ±4.77) but would still be considered a weak CYP inhibitor.  
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Vehicle Control
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LT-02-53 (10µM)
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Figure 3.31 Inhibition of CYP2C19 by analogues of LT-01-25: CYP2C19 baculosomes incubated with 
test compounds; LT-02-39, LT-02-50, LT-02-53, LT-02-86 and RKA-018 (10µM) for 60 mins in a 
fluorescent plate reader (37.1°C). Inhibition was measured by the maximum fluorescence at 60 mins. 
A vehicle control (1.25% DMSO) and positive control (Miconazole, 30µM) were also tested as a 
comparison for inhibition. Data is presented as mean ±SEM (n=3). Statistical analysis was carried out 
between the positive control and test compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, 
*** = P ≤ 0.001). 
      The results for CYP2C19 are shown in Figure 3.31. In this case, one analogue, LT-02-39 did 
produce over 50% inhibition (52% ±0.04). The IC50 was calculated as 9.4µM using a percentage 
inhibition-concentration plot. While this is not ideal, the IC50 value is very close to the upper 
range for a moderate inhibitor (IC50 = 1-10µM)
55. The structure of LT-02-39 contains no 
functional groups that would suggest CYP inhibition, so this result is unusual. As with CYP2C9, 
LT-02-50 caused almost no inhibition (2% ±1.17). The second strongest inhibitor was LT-02-53 
(43% ±1.54), followed by RKA-018 (33% ±1.89). LT-02-86 showed some mild inhibitory activity 
(17% ±5.85), which is in keeping with the results from CYP1A2 and CY2C19.  
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Figure 3.32 Inhibition of CYP2D6 by analogues of LT-01-25: CYP2D6 baculosomes incubated with 
test compounds; LT-02-39, LT-02-50, LT-02-53, LT-02-86 and RKA-018 (10µM) for 60 mins in a 
fluorescent plate reader (37.1°C). Inhibition was measured by the maximum fluorescence at 60 mins. 
A vehicle control (1.25% DMSO) and positive control (Quinidine, 10µM) were also tested as a 
comparison for inhibition. Data is presented as mean ±SEM (n=3). Statistical analysis was carried out 
between the positive control and test compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, 
*** = P ≤ 0.001). 
     LT-02-86 had the smallest effect on CYP2D6, causing only 15% (±0.37) inhibition. The 
monomethyl analogue, LT-02-39, produced 21% (±0.56) inhibition of CYP2D6. The other 
analogues, LT-02-50, LT-02-53 and RKA-018 caused marginal inhibition. LT-02-50 inhibited 
CYP2D6 by 28% (±0.16), as did RKA-018 (38% ±0.21). LT-02-53 demonstrated slightly less 
inhibition at 35% (±0.39). All of these values were significantly different to the positive control 
quinidine, which caused 60% (±0.11) inhibition at the same concentration.  
 
 
 
** 
** 
** ** 
** 
** 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
Fl
u
o
re
sc
e
n
ce
 a
t 
6
0
 m
in
u
te
s 
 
Vehicle Control
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Figure 3.33 Inhibition of CYP3A4 by analogues of LT-01-25: CYP3A4 baculosomes incubated with test 
compounds; LT-02-39, LT-02-50, LT-02-53, LT-02-86 and RKA-018 (10µM) for 60 mins in a fluorescent 
plate reader (37.1°C). Inhibition was measured by the maximum fluorescence at 60 mins. A vehicle 
control (1.25% DMSO) and positive control (Ketoconazole, 10µM) were also tested as a comparison 
for inhibition. Data is presented as mean ±SEM (n=3). Statistical analysis was carried out between the 
positive control and test compounds using one-tailed T-Test (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 
0.001). 
       As with CYP2D6, LT-02-86 was the least inhibitory analogue of CYP3A4, resulting in 7% 
(±0.29) inhibition. RKA-018 inhibited CYP3A4 by 17% (±0.28), making the bioisostere analogue 
the second weakest inhibitor of this isoform. LT-02-39 and LT-02-50 both results in roughly 
24% inhibition. The strongest CYP3A4 inhibitor was the spirocyclic analogue, LT-02-53 (30%± 
0.19). 
    With the exception of LT-02-39 causing moderate inhibition of CYP2C19 (IC50=9.4µM), all of 
the analogues can be considered weak enzyme inhibitors of five chief CYP isoforms. These 
analogues, along with LT-01-26, are currently undergoing more intensive drug safety testing, 
such as the Ames test and hERG toxicity.  
 
3.4.5 Summary  
     A series of propofol analogues were synthesised as positive allosteric modulators of SSGRs. 
For drugs acting in the CNS, ensuring a high probability of BBB penetration is one of the most 
vital aspects of drug design. Using a mutliparameter algorithm created by Pzifer, the likelihood 
of drugs successfully entering the CNS can be assessed (CNS MPO ≥ 4). The MPO scoring 
system was used to determine which analogue would be taken into further testing.  
    After various different structural scaffolds, including bi-phenyls and amino-alkyls, a group of 
analogues based around the inclusion of an amide morpholine ring produced a desire MPO 
score. In addition, three of these analogues, LT-01-25, LT-01-26 and LT-01-89 had high efficacy 
at the target receptor (GlyRα1). These compounds were incubated with microsomes to assess 
 phase I metabolic breakdown. LT-01-25, was particular stable, whereas its sister compound, 
LT-01-26 was almost completely metabolised. The analogues were also tested in rats to 
determine the in vivo pharmacokinetic. Initial experiments were carried out using LT-01-25 in 
both fasted and non-fasted rats. The effect of different formulations was also investigated. LT-
01-25 had the strongest pharmacokinetic profile, demonstrating the best absorption, lowest 
clearance and highest bioavailability.  The analogues were also screened for negative CYP 
interactions. None of the analogues caused more than 40% inhibition at 10µM, making them 
weak inhibitors of CYP enzymes.  
    LT-01-25, LT-01-26 and LT-01-89 were then tested against gabapentin and lamotrigine, two 
drugs currently used to treat chronic pain, in the Chung lesion model of neuropathic pain. 
Gabapentin is typically dosed following a regime starting at 300mg per day, increasing the 
frequency of the dose to 3 times per day. In some cases, dosing can reach as high as 3600mg 
per day for sufficient pain relief58. In comparison, lamotrigine is recommended to be taken 
once a day at 200mg-400mg59. All three compounds outperformed to the two control 
analgesics at a low dose of 30mg/Kg. Out the analogues, LT-01-25, once again produced the 
most promising results. This compound was able to reverse neuropathic pain behaviours, 
allodynia and hyperalgesia, to a greater extent than the other analogues. LT-01-26 was also 
fairly effective; however LT-01-89 fell short of expectations. At this point it was decided that 
only LT-01-25 and LT-01-26 would be taken into further testing.  
    While LT-01-26 is currently undergoing additional pharmacological testing, such as CSF 
exposure and hepatic cytotoxicity, the results for LT-01-25 have been presented above. At 
present, LT-01-25 has met every desired criteria laid out for upcoming drugs, with the 
 exception of pKa, which is considered too high for successful CNS penetration. In order to 
reduce to pKa, whilst retaining positive testing results a number of LT-01-25 were produced. 
The design of these analogues was driven by literature research into the replacement of 
morpholines and phenols within drug optimisation. Five analogues, LT-02-39, LT-02-50, LT-02-
53, LT-02-86 and RKA-018, were remarkably potent at GlyRα1. Only two of these compounds, 
LT-02-50 (MPO=4.0) and LT-02-86 (MPO=4.4) achieved a desirable MPO score. The 
compounds were tested in rat and human liver microsomes. Most of the compound shared 
similar stability with LT-01-25 and LT-01-89. However, LT-02-50 and LT-02-39 both had half-
lives below 100 minutes, shorter than the value for all the other analogues. LT-02-50 showed 
particular poor microsomal metabolism, even having higher clearance than propofol. LT-02-50 
also demonstrated poor absorption and bioavailability in rats. LT-02-86 had far better 
bioavailability, although not as high as LT-01-25. In the Chung lesion model, LT-02-39 
outperformed both the control analgesic and LT-01-25, but this effect was short-lived and only 
occurred at the highest testing concentration. In comparison, LT-02-50 was unable to 
attenuate allodynia and  hyperalgesia. This compound was  far less effective than LT-01-25, 
despite showing greater efficacy at GlyRα1; extensive metabolism is most likely to blame. The 
structural optimisation of LT-01-25 lead to both positive and negative pharmacological 
changes. To fully understand which analogue would make the most suitable drug candidate, 
the testing results for all analogues should be reviewed together.     
 
 
 3.5  References  
1. Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. (2010). Moving beyond rules: the 
development of a central nervous system multiparameter optimization (CNS MPO) 
approach to enable alignment of druglike properties. ACS Chem Neurosci 1, 435-49. 
2. Segall, M. D. (2012). Multi-parameter optimization: Identifying high quality compounds 
with a balance of properties. Current Pharmaceutical Design 18, 1292-1310. 
3. Mahar Doan, K. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., 
Serabjit-Singh, C. J., Adkison, K. K. & Polli, J. W. (2002). Passive permeability and P-
glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS 
marketed drugs. J Pharmacol Exp Ther 303, 1029-37. 
4. Pajouhesh, H. & Lenz, G. R. (2005). Medicinal Chemical Properties of Successful Central 
Nervous System Drugs. NeuroRx 2, 541-553. 
5. Alavijeh, M. S., Chishty, M., Qaiser, M. Z. & Palmer, A. M. (2005). Drug Metabolism and 
Pharmacokinetics, the Blood-Brain Barrier, and Central Nervous System Drug 
Discovery. NeuroRx 2, 554-571. 
6. Pangalos, M. N., Schechter, L. E. & Hurko, O. (2007). Drug development for CNS 
disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6, 
521-32. 
7. Pardridge, W. M. (2005). The Blood-Brain Barrier: Bottleneck in Brain Drug 
Development. NeuroRx 2, 3-14. 
8. Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R. & Begley, D. J. (2010). 
Structure and function of the blood–brain barrier. Neurobiology of Disease 37, 13-25. 
9. Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. J Cereb Blood 
Flow Metab 32, 1959-1972. 
10. Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., 
Villalobos, A. & Will, Y. (2010). Defining Desirable Central Nervous System Drug Space 
through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes. 
ACS Chemical Neuroscience 1, 420-434. 
11. Li, Y. T. & Yu, J. Y. (2010). 40th International Conference on Computers and Industrial 
Engineering: Soft Computing Techniques for Advanced Manufacturing and Service 
Systems, CIE40 2010. 
12. Nicolaou, K. C. (2014). Advancing the drug discovery and development process. 
Angewandte Chemie - International Edition 53, 9128-9140. 
13. Milardi, D. & Pappalardo, M. (2015). Molecular dynamics: New advances in drug 
discovery. European Journal of Medicinal Chemistry 91, 1-3. 
14. Kola, I. & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? 
Nature reviews Drug discovery 3, 711-716. 
15. Wang, J. & Urban, L. (2004). The impact of early ADME profiling on drug discovery and 
development strategy. DDW DRUG DISCOVERY WORLD 5, 73-86. 
16. Gallo, J. M. (2010). Pharmacokinetic/Pharmacodynamic‐Driven Drug Development. 
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 
77, 381-388. 
 17. Hughes, J. P., Rees, S. S., Kalindjian, S. B. & Philpott, K. L. (2011). Principles of early 
drug discovery. British Journal of Pharmacology 162, 1239-1249. 
18. Castellino, S., O'Mara, M., Koch, K., Borts, D. J., Bowers, G. D. & MacLauchlin, C. (2012). 
Human metabolism of lapatinib, a dual kinase inhibitor: Implications for 
hepatotoxicity. Drug Metabolism and Disposition 40, 139-150. 
19. Kim, K. J., Yoon, Y. W. & Chung, J. M. (1997). Comparison of three rodent neuropathic 
pain models. Experimental Brain Research 113, 200-206. 
20. Chung, J. M., Kim, H. K. & Chung, K. (2004). Segmental spinal nerve ligation model of 
neuropathic pain. Methods in molecular medicine 99, 35-45. 
21. Kim, S. H. & Chung, J. M. (1992). An experimental model for peripheral neuropathy 
produced by segmental spinal nerve ligation in the rat. Pain 50, 355-363. 
22. Leung, S. C., Gibbons, P., Amewu, R., Nixon, G. L., Pidathala, C., Hong, W. D., Pacorel, 
B., Berry, N. G., Sharma, R., Stocks, P. A., Srivastava, A., Shone, A. E., 
Charoensutthivarakul, S., Taylor, L., Berger, O., Mbekeani, A., Hill, A., Fisher, N. E., 
Warman, A. J., Biagini, G. A., Ward, S. A. & O’Neill, P. M. (2012). Identification, Design 
and Biological Evaluation of Heterocyclic Quinolones Targeting Plasmodium falciparum 
Type II NADH:Quinone Oxidoreductase (PfNDH2). Journal of Medicinal Chemistry 55, 
1844-1857. 
23. Cooke, A., Anderson, A., Buchanan, K., Byford, A., Gemmell, D., Hamilton, N., McPhail, 
P., Miller, S., Sundaram, H. & Vijn, P. (2001). Water-soluble propofol analogues with 
intravenous anaesthetic activity. Bioorganic and Medicinal Chemistry Letters 11, 927-
930. 
24. Ahrens, J., Haeseler, G., Leuwer, M., Mohammadi, B., Krampfl, K., Dengler, R. & Bufler, 
J. (2004). 2,6 di-tert-butylphenol, a nonanesthetic propofol analog, modulates 
alpha1beta glycine receptor function in a manner distinct from propofol. Anesth Analg 
99, 91-6. 
25. Ahrens, J., Leuwer, M., de la Roche, J., Foadi, N., Krampfl, K. & Haeseler, G. (2009). The 
non-anaesthetic propofol analogue 2,6-di-tert-butylphenol fails to modulate GABA(A) 
receptor function. Pharmacology 83, 95-8. 
26. Cernak, T., Dykstra, K., Levorse, D., Verras, A., Balkovec, J., Nargund, R. & DeVita, R. 
(2011). Synthesis of oxaspiropiperidines as a strategy for lowering logD. Tetrahedron 
Letters 52, 6457-6459. 
27. Roberts, M. S., Magnusson, B. M., Burczynski, F. J. & Weiss, M. (2002). Enterohepatic 
circulation: physiological, pharmacokinetic and clinical implications. Clin 
Pharmacokinet 41, 751-90. 
28. Pestel, S., Martin, H. J., Maier, G. M. & Guth, B. (2006). Effect of commonly used 
vehicles on gastrointestinal, renal, and liver function in rats. Journal of 
Pharmacological and Toxicological Methods 54, 200-214. 
29. Jacob, S. W. & Herschler, R. (1986). Pharmacology of DMSO. Cryobiology 23, 14-27. 
30. Willson, J. E., Brown, D. E. & Timmens, E. K. (1965). A toxicologic study of dimethyl 
sulfoxide. Toxicology and Applied Pharmacology 7, 104-112. 
31. Hartung, T. (2013). Food for Thought Look Back in Anger – What Clinical Studies Tell Us 
About Preclinical Work. ALTEX 30, 275-291. 
 32. Li, A. P. (2009). Overview: Evaluation of metabolism-based drug toxicity in drug 
development. Chemico-Biological Interactions 179, 1-3. 
33. Stephens, C., Andrade, R. J. & Lucena, M. I. (2014). Mechanisms of drug-induced liver 
injury. Current Opinion in Allergy and Clinical Immunology 14, 286-292. 
34. Regev, A. (2014). Drug-induced liver injury and drug development: industry 
perspective. Semin Liver Dis 34, 227-39. 
35. Choi, J. M., Oh, S. J., Lee, J. Y., Jeon, J. S., Ryu, C. S., Kim, Y. M., Lee, K. & Kim, S. K. 
(2015). Prediction of Drug-Induced Liver Injury in HepG2 Cells Cultured with Human 
Liver Microsomes. Chem Res Toxicol 28, 872-85. 
36. Ju, C. & Reilly, T. (2012). Role of immune reactions in drug-induced liver injury (DILI). 
Drug Metab Rev 44, 107-15. 
37. Williams, C. D. & Jaeschke, H. (2012). Role of innate and adaptive immunity during 
drug-induced liver injury. Toxicology Research 1, 161-170. 
38. Lavandera, J. V., Parera, V. E., Batlle, A. & Buzaleh, A. M. (2006). CYP2D6 
Polymorphisms in Patients with Porphyrias. Molecular Medicine 12, 259-263. 
39. Cohen, L. H., Remley, M. J., Raunig, D. & Vaz, A. D. N. (2003). In vitro drug interactions 
of cytochrome p450: An evaluation of fluorogenic to conventional substrates. Drug 
Metabolism and Disposition 31, 1005-1015. 
40. Nayadu, S., Behera, D., Sharma, M., Kaur, G. & Gudi, G. (2013). Fluorescent probe 
based CYP inhibition assay: A high throughput tool for early drug discovery screening. 
International Journal of Pharmacy and Pharmaceutical Sciences 5, 303-307. 
41. Gad, S. C. Preclinical Development Handbook: ADME and Biopharmaceutical 
Properties. [electronic book]. Online access via Linkfinder: EBSCO eBook Clinical 
Collection (EBSCOhost), John Wiley & Sons Incorporated. 
42. Nassar, A. F., Hollenberg, P. F. & Scatina, J. (2009). Drug metabolism handbook. 
[electronic book] : concepts and applications. Online access with purchase: Wiley-
Blackwell online books, Hoboken, New Jersey : Wiley-Blackwell, 2009. 
43. Wodarski, R., Clark, A. K., Grist, J., Marchand, F. & Malcangio, M. (2009). Gabapentin 
reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. 
Eur J Pain 13, 807-11. 
44. Huang, X.-P., Mangano, T., Hufeisen, S., Setola, V. & Roth, B. L. (2010). Identification of 
Human Ether-à-go-go Related Gene Modulators by Three Screening Platforms in an 
Academic Drug-Discovery Setting. Assay and Drug Development Technologies 8, 727-
742. 
45. Vieweg, W. V. & Wood, M. A. (2004). Tricyclic antidepressants, QT interval 
prolongation, and torsade de pointes. Psychosomatics 45, 371-7. 
46. Mortelmans, K. & Zeiger, E. (2000). The Ames Salmonella/microsome mutagenicity 
assay. Mutat Res 455, 29-60. 
47. Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. (2010). Moving beyond rules: The 
development of a central nervous system multiparameter optimization (CNS MPO) 
approach to enable alignment of druglike properties. ACS Chemical Neuroscience 1, 
435-449. 
 48. Schönherr, H. & Cernak, T. (2013). Profound Methyl Effects in Drug Discovery and a 
Call for New C H Methylation Reactions. Angewandte Chemie International Edition 52, 
12256-12267. 
49. Deyrup, J. A. (2008). Aziridines. In Chemistry of Heterocyclic Compounds, pp. 1-214. 
John Wiley & Sons, Inc. 
50. Park, B. K., Kitteringham, N. R. & O'Neill, P. M. (2001). Metabolism of fluorine-
containing drugs. In Annual Review of Pharmacology and Toxicology, Vol. 41, pp. 443-
470. 
51. Burkhard, J. A., Wuitschik, G., Rogers-Evans, M., Müller, K. & Carreira, E. M. (2010). 
Oxetanes as versatile elements in drug discovery and synthesis. Angewandte Chemie - 
International Edition 49, 9052-9067. 
52. Burkhard, J. A., Wagner, B., Fischer, H., Schuler, F., Müller, K. & Carreira, E. M. (2010). 
Synthesis of azaspirocycles and their evaluation in drug discovery. Angewandte Chemie 
- International Edition 49, 3524-3527. 
53. Wright, J. L., Gregory, T. F., Kesten, S. R., Boxer, P. A., Serpa, K. A., Meltzer, L. T., Wise, 
L. D., Espitia, S. A., Konkoy, C. S., Whittemore, E. R. & Woodward, R. M. (2000). 
Subtype-selective N-methyl-D-aspartate receptor antagonists: Synthesis and biological 
evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. Journal of Medicinal Chemistry 
43, 3408-3419. 
54. Wilkening, R. R., Ratcliffe, R. W., Fried, A. K., Meng, D., Sun, W., Colwell, L., Lambert, S., 
Greenlee, M., Nilsson, S., Thorsell, A., Mojena, M., Tudela, C., Frisch, K., Chan, W., 
Birzin, E. T., Rohrer, S. P. & Hammond, M. L. (2006). Estrogen receptor β-subtype 
selective tetrahydrofluorenones: Use of a fused pyrazole as a phenol bioisostere. 
Bioorganic and Medicinal Chemistry Letters 16, 3896-3901. 
55. http://www.cyprotex.com/admepk/in-vitro-metabolism/microsomal-stability. 
56. http://www.cyprotex.com/admepk/in-vitro-metabolism/cytochrome-p450-inhibition. 
57. Fuhr, U., Strobl, G., Manaut, F., Anders, E. M., Sorgel, F., Lopez-de-Brinas, E., Chu, D. T.,   
Pernet, A. G., Mahr, G., Sanz, F. & et al. (1993). Quinolone antibacterial agents: 
relationship between structure and in vitro inhibition of the human cytochrome P450 
isoform CYP1A2. Mol Pharmacol 43, 191-9. 
58. Backonja, M. & Glanzman, R. L. (2003). Gabapentin dosing for neuropathic pain: 
Evidence from randomized, placebo-controlled clinical trials. Clinical Therapeutics 25, 
81-104. 
59. Wiffen, P. J., Derry, S. & Moore, R. A. (2011). Lamotrigine for acute and chronic pain. 
Cochrane Database Syst Rev 16. 
 
  
 
 
Chapter 4 
Conclusions 
  
 Table of Contents 
 
4.1 Conclusions ............................................................................................ 193 
4.1.1 Summary of Lead Optimisation ............................................................ 193 
    4.1.2 Further Development ........................................................................   213 
4.2 References ............................................................................................. 214 
 
 
  
 4.1 Conclusions 
4.1.1 Summary of Lead Optimisation 
      This project was focussed on the lead optimisation of positive allosteric modulators of 
SSGRs. These compounds are being developed with the aim to produce a new therapeutic for 
the treatment of chronic pain. Chronic pain is a condition that is thought to affect roughly 
about 20% of adults in Europe1. It is a disease that can develop as part of old age, as a by-
product of degenerative diseases or aa the result of external factors, such a surgical nerve 
injury or chemotherapy2. Any pain that persists for more than six months or occurs without a 
clear stimulus can be classified as chronic pain. The three main characteristics of chronic pain 
are allodynia, hyperalgesia and spontaneous activity.  According to recent surveys, only one 
third of chronic pain sufferers in the UK seek therapy and more than half of these patients will 
discontinue their treatments due to insufficient pain relief and adverse-effects1. Many of 
these issues may arise because the drugs prescribed were intended to treat chronic pain and 
have merely been adapted to this purpose. There is a great need for new treatments that are 
specifically designed to target the underlying mechanisms of chronic pain.  
    SSGRs containing the α3 subunit are known to be down-regulated in animal models of 
neuropathic pain. It is also known that drugs can produce analgesia by potentiating glycine 
currents3. Positive allosteric modulators acting on GlyRα1 may able to compensate for the 
inhibitory glycinergic activity that is reduced in chronic pain. Potential modulators were 
developed from the anaesthetic propofol, which is able to activate glycine receptors at high 
concentrations. Propofol normally causes sedation through the modulation of inhibitory 
 GABAARs, which are co-localised with GlyRs within the spinal cord. Research has shown than 
activation of GlyRs over GABAARs can produce analgesia without sedation
4. It has also been 
reported that halogenated analogues of propofol show a greater degree of selectivity for 
GlyRs over GABAARs
5; 6. Upon this rationale, a series of propofol analogues was synthesised 
and tested at recombinant GlyRs containing the α1 subunit.  
     Throughout lead optimisation, seven analogues stood out as the most promising drug 
candidates. The structures of the lead compound, LT-01-25 and six back-up compounds are 
shown in Figure 4.1. Although LT-01-25 was not the most potent analogue nor did it have the 
highest MPO score, overall it proved to be the most effective compound in attenuating 
allodynia and hyperalgesia in models of neuropathic pain.  
 
 
 
 
 
 
     
 
LT-01-25 LT-01-26 LT-02-39 LT-02-50 
LT-02-53 LT-02-86 RKA-018 
Figure 4.1. Structures of propofol analogues with the most promising candidate profiles.   
       Many of the analogues created within the project exhibited higher efficacy at GlyRα1 than 
propofol. Unfortunately many of these compounds also displayed high ClogP, ClogD and pKa. 
Following the ‘rule of five’, these analogues would be considered to have poor drug-like 
properties7. It is recommended that drugs acting in the CNS have physiochemical properties 
within a particular range. The MPO algorithm created by Pzifer can be used to assess to the 
likelihood of CNS penetration8. Lead candidates should have an MPO score above 4 and must 
elicit the desired response at the target receptor (GlyRα1 EC50 = 1µM). The seven analogues 
that had the best MPO assessment profiles are shown in Table 4.1. 
 
 
     Through the use of MPO evaluation, five analogues in the project were able to meet the 
desired MPO score (≥4). Two additional analogues, LT-02-53 and LT-02-39, did not have a 
desirable MPO score but were including in optimising because of their extreme potency at 
GlyRα1. The first two analogues to produce successful MPO profiles were the amide 
Parameter LT-02-86 RKA-018 LT-01-26 LT-01-25 LT-02-50 LT-02-53 LT-02-39 
ClogP 3.10 2.21 3.54 3.10 3.30 3.30 3.60 
ClogD 1.92 2.50 2.50 2.80 3.57 3.93 3.90 
TPSA (Å) 52.27 53.93 43.78 49.8 40.54 49.77 49.77 
MW (Da) 290.40 287.36 304.43 291.1 279.35 303.34 305.41 
HBD 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
PKa 10.14 13.10 10.10 10.14 9.77 10.10 10.08 
MPO Score 4.8 4.6 4.4 4.3 4.0 3.7 3.6 
 
Table 4.1. The physiochemical properties and MPO scores for positive allosteric modulators of GlyRs: 
Propofol analogues designed as positive allosteric modulators of GlyRs. The analogues are ranked by 
CNS MPO score. The individual parameters are coloured coded in accordance with the recommended 
values for dugs acting in the CNS8. 
*Physiochemical parameters and MPO scores were provided by the Department of Chemistry.  
 
 
 
 analogues, LT-01-25 and LT-01-26. The amide analogues, particularly LT-01-25, generated very 
promising results in other aspects of optimisation. 
      The pKa of these analogues was considered too high for successful penetration of the BBB 
however the compounds tested in the Chung model were able to attenuate neuropathic pain 
and LT-01-25 demonstrated good exposure within the CSF. MPO evaluation revealed that 
despite high pKa the compounds can still access the CNS. Table 4.1 shows that the analogues 
with the highest pKa values, LT-02-86 and RKA-018 had the best MPO scores as a result of low 
ClogP and ClogD. This emphasises the usefulness of MPO evaluation in the assessment of new 
analogues.  
    Good potency at the GlyRα1 was one of the first and most significant measures carried out 
during the optimisation of these GlyR modulators. Target efficacy was measured through the 
use of electrophysiology. The test compounds were exposed to recombinant GlyRα1 in the 
presence of glycine (10µM) and the current response was recorded. In order to continue 
optimisation the analogues must have an EC50 value below 1µM. To ensure good selectivity, 
the analogues were also tested at GABAAR; none of the analogues were able to activate 
GABAR below 30µM. While many compounds showed sufficient activity at GlyRα1, only the 
testing results for the seven analogues shown in Table 4.1 are presented below (Table 4.2). 
 
 
 
  
      
 
 
 
 
     
      All the analogues with a MPO score above 4, were successfully able to potentiate glycine 
currents to a greater extent than propofol (EC50 = 4.8µM
9). The most potent compound was 
the piperazine analogue, LT-02-86, which was able to activate GlyRs at attomolar (10-18M) 
concentration; LT-02-86 also produced the best MPO profile. On this basis, LT-02-86 would 
make a more suitable lead compound than LT-01-25, which was the second least potent 
compound and had less favourable physiochemical properties.  
     MPO assessment and GlyRα1 efficacy testing are extremely useful tools to determine 
which compounds are best suited to be taken into further testing. The aim of lead 
optimisation is to generate a drug candidate that will eventually be used by patients; 
therefore it is important to keep in mind the numerous external and internal factors that may 
have an effect of success of a drug. As such, extraordinary potency at the isolated drug target 
may not translate to an effective therapeutic in humans. Drug metabolism and 
Analogue GlyRα1 EC50 
LT-02-86 137aM 
LT-01-26 1.2pM 
LT-02-50 1.2pM 
LT-02-53 1.6pM 
LT-02-39 60pM 
LT-01-25 350pM 
RKA-018 4.2nM 
 
Table 4.2. Ranked GlyRα1 EC50 values of propofol analogues: The propofol analogues that displayed 
the highest efficacy at the target receptor.  
*GlyRα1 data was collected at the University of Tübingen. 
 pharmacokinetics play a huge role in how a drug acts within in a living organism. The first step 
in studying pharmacokinetics as part of lead optimisation is to determine phase I metabolism 
by CYPs.  
    Propofol analogues were incubated with both rat and human liver microsomes. The goal of 
these experiments was to test the extent by which the analogues are broken-down by CYPs. 
These analogues are designed to be administered orally, and so they must be absorbed from 
the GI tract, but first they must pass through the liver where they will come into contact with 
CYPs. Compounds that are microsomally stable will be absorbed into the blood rather than 
being broken-down, meaning there is more free drug available to move into the CNS. From 
the data collected in microsomal incubations, the half-life, clearance by CYPs and intrinsic 
clearance values were calculated. The microsomal parameters for the seven lead candidate 
analogues are shown in Table 4.3 and Table 4.4  
     
        
RLM T1/2 (min) ClCYP (µL/min/mg) Clint (mL/min/kg) 
LT-01-25 770 0.9 1.6 
RKA-018 135 5.1 9.1 
LT-02-53 106 6.5 11.7 
LT-02-86 103 6.7 12 
LT-02-39 86 8 14 
LT-02-50 70 9.9 17.7 
LT-01-26 46 15 26.88 
 
Table 4.3. Microsomal parameters of lead analogues in rat liver microsomes: The analogues are 
ranked from most to least metabolically stable. A long half-life and low clearance indicates a low level 
of CYP mediated metabolism. 
      LT-01-25 was by far the most stable compound when incubated with rat liver microsomes. 
The amide morpholine analogue had an extremely long half-life and underwent very little 
microsomal break-down. RKA-018, the least potent analogue also demonstrated good rat 
microsomal stability. LT-02-86, which had the best MPO and EC50 values, experienced some 
CYP mediated metabolism. The analogue with the highest incidence of break-down in rat 
microsomes was LT-01-26. This analogue was almost completely metabolised in rats and had 
a very short half-life. LT-01-26 produced the second best response at the GlyRα1 and had one 
of the highest MPO scores; however poor metabolic stability would make it an unsuitable lead 
candidate. Interestingly, this analogue demonstrated much better stability in human liver 
microsomes.  
 
 
 
 
 
 
 
      Differences in microsomal stability between rat and human liver microsomes are most 
likely caused by variations in CYP isoform expression for each species10. In human 
Table 4.4. Microsomal parameters of lead analogues in human liver microsomes: The analogues are 
ranked from most to least metabolically stable. A long half-life and low clearance indicates a low level 
of CYP mediated metabolism. 
HLM T1/2 (min) ClCYP (µL/min/mg) Clint (mL/min/kg) 
LT-01-25 533 1.3 1.75 
LT-02-53 407 1.7 2.1 
RKA-018 330 2.1 2.6 
LT-01-26 126 5.8 6.9 
LT-02-39 96 7.2 9 
LT-02-86 95 7.3 9 
LT-02-50 47 14.7 18.5 
 
 microsomes, LT-01-25 was still the most stable, although the differences in the stability 
between the analogues were much smaller. The least stable compound was LT-02-50, a 
spirocyclic analogue with a low MPO score. LT-02-50 had a much higher clearance value than 
propofol, the analogue was also extensively metabolised in rat microsomes. This analogue 
would be considered a highly metabolic compound11. LT-01-26 did not undergo the same 
level of breakdown in human microsomes. In fact, this analogue was fairly metabolically 
stable. The most potent analogue, LT-02-86 was significantly metabolised in humans. This 
means that LT-02-86 is likely to have much lower exposure in the CNS.  
      Based on the data from CYP phase I metabolism testing, LT-01-25 has the most potential 
as a lead candidate. However, hydroxylation by CYPs is just one of two main routes of 
propofol metabolism; the other major metabolic pathway is glucuronidation of the phenol 
group. The most effective way to test for alternate routes of metabolism is through in vivo 
metabolism. Measuring metabolism in a living system not only allows conjugative 
biotransformation to be investigated but also how external factors such as diet and 
formulation, along with numerous internal factors may affect ADME as a whole.  
       The amide analogues, LT-01-25 and LT-01-26 were administered orally (10mg/Kg) to male, 
Wistar rats. Pilot experiments carried out using LT-01-25, explored the effect of fasting on 
metabolism; LT-01-25 appeared to undergo enterohepatic circulation, resulting in slow 
absorption. In the original vehicle (10% DMSO, 10% solutol and 80% saline), fasting prior to 
dosing had a huge effect on absorption. The calculated Cmax and Tmax were much higher in 
fasted rats, indicating that food does slow absorption. The original vehicle contained DMSO, 
which can have an effect on absorption and is thought to have mild inflammatory properties. 
 An alternate SSV was chosen (0.5% sodium carboxymethylcellulose, 0.5% benzyl alcohol, 0.4 
Tween 80 and 98.6% saline). Fasting appeared to have less of an impact when the SSV was 
used. The new vehicle seemed to slow absorption slightly; though the overall exposure in the 
plasma was higher than seen in the DMSO containing vehicle. The SSV is considered to be 
more innocuous than DMSO and the effect on metabolism, however small, was positive. It 
was decided that LT-01-26 would be formulated in the SSV rather than the original vehicle. In 
addition, extensive hepatic re-circulation was not seen in experiments using SSV, so LT-01-26 
was not tested in fasted rats. The pharmacokinetic parameters for LT-01-25 and LT-01-26 are 
shown in Table 4.5. 
 
 
 
 
 
 
 
    LT-01-26 was absorbed a little slower than LT-01-25; however the maximum exposure in 
the plasma is almost 4x less. This could possibly be due to large amounts of CYP mediated 
metabolism reducing the amount of free drug available for absorption. The pharmacokinetic 
 
Parameters LT-01-25 LT-01-26 
AUC (min*µg/mL) 1140 273 
Cmax (µg/mL) 2.1 0.5 
Tmax (min) 15 18 
t1/2 (min) 217 72 
CL (mL/hr/kg) 0.5 2.2 
Vd (L/Kg) 2.7 3.7 
 
Table 4.5. Pharmacokinetic parameters of amide propofol analogues: LT-01-25 and LT-01-26 were 
administered orally to non-fasted, male, Wistar rats (10mg/Kg, SSV). Pharmacokinetic parameters 
calculated using PK Solutions, in an one-compartmental analysis. 
 parameters for LT-01-26 tie in with the microsomal parameters. As seen with microsomal 
incubations the half-life of LT-01-25 was much higher than that of LT-01-26. The clearance 
and distribution for both compounds are within the desired range. Low exposure in plasma 
would suggest low exposure within the CNS, while LT-01-26 is more potent and more drug-
like, it may be not be as effective in a living organism.  
     For the remaining analogues, in vivo metabolism was carried out by ChemPartners’ DMPK 
group. In these studies, fasted, male, Wistar rats were dosed orally at 10 mg/Kg. The original 
DMSO based vehicle was used. These studies are currently being conducted; as such a 
complete data set for each analogue is not available. The pharmacokinetic parameters that 
have been provided by ChemPartners, at present, are shown in Table 4.6, LT-01-25 was also 
tested to give a comparison under the same experimental conditions.  
 
 
 
 
 
 
       
 
 
 
LT-01-25 LT-02-39 LT-02-50 LT-02-86 
Tmax (min) 30 40 30 60 
Cmax (ng/mL) 4.6 3.7 0.9 0.6 
T1/2 (min) 2.5 154.2 154.8 184.8 
CL (L/hr/kg) 0.43 -- 1.64 2.11 
F (%) 85.9 -- 38.8 74 
 
Table 4.6. Pharmacokinetic parameters provided by ChemPartners: Fasted, male, Wistar rats were 
dosed at 10mg/Kg (P.O. 10% DMSO, 10% solutol, 80% saline). Data collection and analysis was carried 
out by ChemPartners. 
 
 
     The in vivo metabolic studies carried out by ChemPartners show that LT-01-25 has the 
highest bioavailability of all the compounds. This value is also close to the bioavailability 
calculated from in house metabolism experiments (81.9%). LT-02-86, the most potent 
compound at the target, had a high bioavailability as well; however the exposure in plasma 
was far lower than that of LT-01-25. This analogue also took twice as long to reach maximum 
plasma concentration, suggesting slow absorption; poor absorption could be the result of CYP 
break-down. LT-02-50, a compound that underwent almost complete microsomal breakdown, 
also demonstrated low plasma concentration levels. The compound was absorbed as quickly 
as LT-01-25, suggesting that poor exposure in this case is due to the rapid metabolism by 
CYPs.   
      One compound that did demonstrate high plasma exposure was the monomethyl 
analogue, LT-02-39. This compound was highly metabolised by CYPs, due to the vulnerable 
methyl group, so it is interesting that the plasma concentration level is so high. It is possible 
that LT-02-39 is a highly permeable compound. This analogue was not absorbed as efficiently 
as LT-01-25, but it was much better than LT-02-50 and LT-02-86. A complete data-set is not 
yet available for LT-02-39, as such the bioavailability and potential exposure at the target 
cannot be commented on.  LT-02-53 and RKA-018 are waiting testing, so no data is available 
for these analogues. These compounds were stable in rat liver microsomes, beaten by only 
LT-01-25, so it is probable that they will have similar in vivo pharmacokinetic profiles.   
    
       Along with pharmacokinetics, establishing safety pharmacological profiles is becoming a 
significant part of early drug development. Toxicity is one of the major causes of failure at 
both pre-clinical and clinical stages. Metabolism related toxicity plays a substantial role in 
drug candidate failure. This type of toxicity can be caused by the build-up of toxic drugs or by 
the formation of enzyme adducts. The inhibition of CYPs can be indicated in both of these 
processes; CYPs are responsible for more than 70% of marketed drugs. If these vital enzymes 
are inhibited then, there could be a build-up leading to overdose. Drug and their metabolites 
may also inhibit an enzyme through conjugation; this could trigger the necrotic pathways that 
lead to the death of healthy hepatocytes. Investigating CYP inhibition is something that can be 
carried out during lead optimisation and will help refine the safety profiles of drug candidates.  
    The seven candidate analogues were testing using fluorescence based CYP inhibition kit 
developed by Life Technologies. In this kit, a substrate tagged with dye is incubated with 
different CYP isoforms and the test compound. Successful metabolism causes the dye to emit 
fluorescence; the level of fluorescence is used as a measure of metabolism. A vehicle control 
and positive control are used for comparison. The vehicle control is taken as no inhibition, 
while the positive control (a known CYP inhibitor) is taken as high inhibition. The data 
presented in Table 4.7, is the percentage inhibition from the vehicle control. The five isoforms 
tested are thought be responsible for most CYP related toxicity.  
 
 
 
  
 
 
     
       Weak CYP inhibitors are classed as drugs with an IC50 above 10µM
12. None of the 
analogues were able to produce more than 50% inhibition across all CYP isoforms, with the 
exception of LT-02-39. LT-02-39 inhibited CYP2C19 by 63% at 10µM. Using an inhibition-
concentration plot the IC50 was calculated to be 9.4µM. This means that LT-02-39 is 
considered a moderate inhibitor on CYP2C19, however the value is extremely close to the 
recommended IC50 ≥ 10µM
12. LT-02-39 underwent substantial CYP metabolism, which may be 
contributing to high inhibition percentage by occupying the catalytic sites, thus reducing the 
amount of enzymes free to metabolise the tagged substrate.  
Compound CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Positive Control 94% 59% 97% 70% 74% 
LT-01-25 7% 2% 32% 30% 30% 
LT-01-26 16% 15% 29% 3% 6% 
LT-02-39 7% 42% 63% 21% 24% 
LT-02-50 45% 2% 2% 38% 24% 
LT-02-53 13% 40% 43% 35% 30% 
LT-02-86 26% 40% 43% 15% 7% 
RKA-018 26% 11% 33% 38% 17% 
 
Table 4.7. Inhibition of five major CYP isoforms by propofol analogues: Five major CYP isoforms 
associated with negative enzyme-drug interactions were incubated with analogues of propofol.  A 
recommended inhibitor of each isoform was used a positive control. The data is expressed as 
percentage inhibition from the vehicle control (interpreted as no inhibition) at the highest testing 
concentration (10µM). Drugs that produced more than 50% inhibition are highlighted. 
       There was no obvious pattern to the mild inhibition produced by the other analogues. 
Some isoforms were barely affected, whilst others experienced some inhibition. LT-01-25 and 
LT-01-26 appeared to have the least inhibitory effect across all analogues. LT-01-26 only 
resulted in more than 20% inhibition in one isoform, CY2C19. While, the highest level of 
inhibition caused by LT-01-25 was 32% in the same isoform. LT-02-53 and RKA-018 caused at 
least 10% across all analogues, making them the most inhibitory analogues on average. LT-02-
53 was only able to achieve less than 10% in CYP1A2. The same was true for LT-02-86 acting 
on CYP3A4. While most of the analogues would be considered weak inhibitors, LT-01-25 and 
LT-01-26 proved to be the lowest inhibition overall. The data suggests that these analogues 
will not trigger DILI through the formation of protein adducts nor will they cause negative 
drug-drug interactions through the inhibition of phase I metabolism. Additional safety testing 
is still ongoing, notably the genotoxicity Ames test, hepatoxicity and hERG cardiotoxicity. At 
present only LT-01-25 has a complete safety profile. 
     The next key aspect of the lead optimisation process is to prove effectiveness in an animal 
model of the target disease. The end-goal of any lead optimisation process is to produce a 
compound that will eventually be used as a drug in the treatment of a particular disease. 
Everything from potency at the isolated receptor to pharmacokinetics can ultimately affect 
how a drug acts within the body. The usefulness and safety of a drug within man cannot be 
entirely predicted through the use of individual pharmacological testing. These tests are 
beneficial for selecting the most promising candidates, to ensure that animals are not used 
needlessly. However it is essential that a drug be tested against the target disease in a living 
organism. 
     Chronic pain can develop as a result of numerous diseases and injuries. Spinal nerve 
damage is one of the main contributing factors, as it can be caused by both injury and 
degenerative disease13. Ligation or axotomy of a nerve leads to the rapid development of 
neuropathic pain; an aspect of chronic pain that is extremely difficult to treat14.  It was 
decided that a chronic pain model based on nerve ligation would be the most suitable proof 
of concept model. The Chung lesion model of nerve injury was used to develop a state of 
neuropathic pain. Response to an innocuous stimulus was measured as mechanical allodynia, 
while hyperalgesia was measured as response to a noxious cold. Behavioural baselines were 
taken pre-surgery and pre-dose to ensure that the rats had developed neuropathic pain. Rats 
were tested with the test analogue at three concentrations. The positive controls were either 
gabapentin or lamotrigine, drugs commonly used to treat chronic pain. Analgesia was 
measured as percentage reversal from the pre-dose baseline. The maximum reversal of 
mechanical allodynia and the time taken to achieve it, for the analogues tested so far can be 
seen in Table 4.8. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
     At this time, testing for LT-02-53, LT-02-86 and RKA-018 is still being undertaken. From the 
data available it can be seen that LT-01-25 is able to produce the highest level of analgesia at 
every testing concentration, and did outperform the control analgesic lamotrigine (data not 
shown). Out of the analogues tested in Chung lesion model, LT-01-25 produced lowest 
response at isolated recombinant GlyR, but had the strongest pharmacokinetic profile. It is 
possible that strong metabolic resistance it contributing to high exposure within the CNS, 
allowing LT-01-25 to exert a greater response. LT-02-50 the least metabolically stable 
Compound/Dose (mg/Kg) Max % Reversal Time (hr) 
LT-01-25 (3 mg/Kg) 65% 3 hrs 
LT-01-25 (10 mg/Kg) 90% 3 hrs 
LT-01-25 (30 mg/Kg) 90% 3 hrs 
   
LT-01-26 (3 mg/Kg) 20% 3 hrs 
LT-01-26 (10 mg/Kg) 70% 3 hrs 
LT-01-26 (30 mg/Kg) 75% 3 hrs 
   
LT-02-39 (3 mg/Kg) 5% 3 hrs 
LT-02-39 (10 mg/Kg) 55% 3 hrs 
LT-02-39 (30 mg/Kg) 85% 3 hrs 
   
LT-02-50 (3 mg/Kg) 0% 3 hrs 
LT-02-50 (10 mg/Kg) 20% 3 hrs 
LT-02-50 (30 mg/Kg) 20% 3 hrs 
 
Table 4.8. Maximum percentage reversal of mechanical allodynia in the Chung lesion model of 
neuropathic pain: LT-01-25, LT-01-26, LT-02-39 and LT-02-50 were tested at three concentrations in 
the Chung lesion pain model. Data is presented as a percentage reversal of the pre-dose baseline in 
mechanical allodynia behavioural tests. The highest reversal values are highlighted. 
 compound was one of the most potent compounds at GlyRα1. This effect was not reflected in 
the Chung lesion testing results. Not only was LT-02-50 the least effective compound but it 
was not able to outperform the control analgesic. LT-01-26 and LT-02-39 both performed 
amenably, although the effect was not maintained at lower doses, suggesting low exposure at 
the target.  The effect on cold hyperalgesia was also tested and the results are displayed in 
Table 4.9. 
 
 
 
 
 
 
 
 
 
 
 
     
Compound/Dose (mg/Kg) Max % Reversal Time (hr) 
LT-01-25 (3 mg/Kg) 55% 1 hrs 
LT-01-25 (10 mg/Kg) 88% 1 hrs 
LT-01-25 (30 mg/Kg) 95% 1 hrs 
   
LT-01-26 (3 mg/Kg) 20% 1 hrs 
LT-01-26 (10 mg/Kg) 90% 3 hrs 
LT-01-26 (30 mg/Kg) 105% 3 hrs 
   
LT-02-39 (3 mg/Kg) 0% 3 hrs 
LT-02-39 (10 mg/Kg) 65% 3 hrs 
LT-02-39 (30 mg/Kg) 110% 3 hrs 
   
LT-02-50 (3 mg/Kg) 5% 3 hrs 
LT-02-50 (10 mg/Kg) 25% 3 hrs 
LT-02-50 (30 mg/Kg) 20% 3 hrs 
 
Table 4.9. Maximum percentage reversal of cold hyperalgesia in the Chung lesion model of 
neuropathic pain: LT-01-25, LT-01-26, LT-02-39 and LT-02-50 were tested at three concentrations in the 
Chung lesion pain model. Data is presented as maximum percentage reversal of the pre-dose baseline in 
cold hyperalgesia behavioural tests. The highest reversal values are highlighted.  
 Overall, the analogues were more effective at attenuating hyperalgesia than allodynia; this 
suggests that the glycine receptor may play a more significant role in the malfunction of 
nociceptive neurons rather than non-nociceptive neurons. LT-01-26 and LT-02-39 were both 
able to outperform LT-01-25 in cold hyperalgesia behavioural tests. Although maximum 
reversal was achieved much slower; taking 3 hours as opposed to the 1 hour taken by LT-01-
25. This may be suggestive of slow absorption of LT-01-26 and LT-02-39. The effect was not 
maintained at lower concentrations, where LT-01-25 produced at least 50% reversal at the 
lowest testing concentration. High metabolic stability of LT-01-25 is likely to result in higher 
exposure even at low concentrations, whereas LT-01-26 and LT-02-39 underwent extensive 
metabolism. Therefore, at lower concentrations, metabolic breakdown has considerably more 
impact of the amount of free drug remaining. As with mechanical allodynia, LT-02-50 had a 
minor impact on cold hyperalgesia, once again this analogue was unable to outperform the 
control analgesic. On a whole, LT-01-25 produced the most consistent level of analgesia 
despite not being particularly potent at GlyRα1 compared to the other analogues.  
     The lead optimisation process was driven by criteria set out in the drug target profile (Table 
4.10). The target values in the profile are commonly used in early drug development11; 15. The 
analogues discussed above are still undergoing many of these tests. Only, LT-01-25 has been 
completely tested to these criteria and the analogue has met every desired value, except pKa. 
The concerns about high pKa are directly related to CNS penetration, however testing in a 
neuropathic pain model showed that even at a low dose (3 mg/Kg) was able to attenuate pain 
by at least 50%. This indicates that LT-01-25 is able to successful cross the BBB regardless of 
its high pKa.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     From the data available, all the analogues were able to achieve desired selectivity for 
GlyRα1 over GABAAR. Two analogues, LT-01-26 and LT-02-50, failed to achieve a desired MPO 
Parameter Target 
Physiochemical  
Aq. Sol (mg/mL) 0.01- 0.5mg/mL (pH7.4) 
LogP ≤4 
LogD 1-3 
MW (Da) ≤450 
TPSA (Å) 40-90 
HBD ≤3 
pKa 3-9 
MPO 4≥ 
Selectivity  
GlyRα1 EC50 ≤1µM 
GABAAR EC50 ≥ 100x GlyRα1 EC50 
Pharmacokinetics  
Oral Bioavailability (%) ≥20 
T1/2 (Rat Liver Microsomes)  ≥60 min 
T1/2 (Human Hepatocytes)  ≥30 min 
Brain CSF 
3x GlyRα1 EC50 
(at 2/3 hrs, 1-3mg/Kg) 
Protein Binding  ≤99.5% 
Toxicity   
hERG toxicity  IC50 ≥ 10µM 
HepG2 toxicity 
No tox at 50x GlyRα1 
EC50 
AMES genotoxicity negative 
CYP Inhibition  IC50 ≥ 10µM 
 
Table 4.10. Target testing profile for lead optimisation 
 
 due to high ClogD and pKa. High pKa is a problem that persists across all the analogues, 
however many of them still achieved MPO over 4 and were able to have some effect in the 
Chung lesion model. LT-01-26 had a lower T1/2 in rat liver microsomes that desired and was 
not able to meet the benchmark value. It should be noted that LT-02-50 was just able to beat 
the desired value by 10 minutes. The monomethyl analogue, LT-02-39 was the only analogue 
to have a toxicity alert via inhibition of CYP2C19. Although the IC50 (9.4µM) was very close to 
the desired value. Overall the analogues have produced very favourable testing profiles.  
     Complete testing has not been completed for the other analogues; as such a true 
comparison cannot be made. However, out of the data available, LT-01-25 would appear to 
be the most promising compound. This analogue produced the best pharmacokinetic profile 
and was the most effective and reliable analgesic in the Chung lesion model. While it neither 
was the most potent nor had the highest MPO, it did meet the desired values. There is a 
possibility that compounds like LT-02-86, (highest MPO and GlyRα1 EC50) will achieve a 
greater level of analgesia and have a good safety profile. At present, however, LT-01-25 
remains the leading analogue, primarily because of its strong pharmacokinetic profile and 
high metabolic stability. It is important to note that lead optimisation is not restricted to 
testing criteria set out in Table 4.9. There are many additional tests that can be incorporated 
into early drug development.  
 
 
 
 4.1.2 Further Development  
   While the other analogues are undergoing testing to develop a full target profile, LT-01-25 
was carried into further development, namely effectiveness in an alternate animal model, 
dose-dependent toxicity and response in an ex vivo neuronal network. The neuronal 
electrophysiology studies will focus on wide dynamic range neurons (WDR). WDR neurons can 
exist as both interneurons and projection neurons16. These neurons are typically located in 
laminae V, much deeper than nociceptive primary afferents, however these neurons respond 
to inputs from Aβ, Aδ and C-fibres17. WDR neurons feature a ‘wind-up’ ability, which produces 
a greater response via repetitive stimulus16. These neurons are known to interact with 
inhibitory interneurons and are highly likely to express glycine receptors17. Such experiments 
will allow LT-01-25 to be tested under ‘in vivo like’ conditions, in a way that is more 
mechanism specific than a whole animal pain model18.  
   LT-01-25 is also being prepared for testing in an alternate chronic pain model, more 
specifically a diabetic pain model. Many diseases associated with chronic pain result in some 
form of nerve injury, a major contributor to neuropathic pain. Even so, it is highly important 
to remember that other aspects of disease may affect the development of pain and how a 
drug produces analgesia. Therefore it is extremely useful to test LT-01-25 in various different 
pain models. The diabetic model is a good choice as diabetes effects almost 4 million people 
in the UK and at least one quarter of diabetics experience some degree of chronic pain19.  The 
diabetic pain model also includes changes in metabolism that may be seen in diabetic 
patients20.  
      LT-01-25 is also undergoing in vivo dose-dependent toxicity studies. Assessment of safety 
pharmacology through the use of cell-based assays is useful to identifying highly toxic 
compounds; however the testing concentrations are very low in comparison to ‘real-life’ 
therapeutic doses. In addition, hypothetically a drug may not be completely metabolised 
before the next dose, causing build-up beyond the therapeutic dose. As such, toxicity up to 
and beyond therapeutic doses must be observed in a living organism. LT-01-25 will be tested 
in a dose dependant manner up to an extremely high dose, to measure the potential acute 
toxicity. This study, along with the ones mentioned previously, is just some of the aspects that 
make up the lead optimisation process.  
   This project is part of the early drug development of positive allosteric modulators of SSGRs. 
The work in this thesis has focussed on drug metabolism and pharmacokinetics as a part of 
the lead optimisation process. A strong pharmacokinetic profile can have a huge impact on 
the effectiveness of a drug, as demonstrated by LT-01-25. The development of LT-01-25 and 
other propofol analogues, is still on-going, however based on previous testing results, the 
prospects are highly promising.  
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 Phosphate Buffer (PB) (0.1M) 10mL - PBS 40mL - H2O 
MgCl2 Solution (50mM) 5.08mg - MgCl2 500µL - PB 
Test Compound (20µM)   50µL - 400µM dilution (From 10mM Stock in DMSO) 950µl - PB 
NADPH Solution (1mM) 8.33mg - NADPH 1mL - PB 
 
5.1 Microsomal Stability 
5.1.1 Reagents and Solutions  
     Analogues of propofol were synthesised in University of Liverpool, Department of 
Chemistry (Liverpool, UK). High-Performance Liquid-Chromatography (HPLC) grade solvents, 
H2O, MeOH, EtOAc and ACN, were purchased from Thermo Fisher Scientific (Loughborough, 
UK). MgCl2, dimethyl sulfoxide (DMSO), reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) and formic acid and were purchased from Sigma-Aldrich (Poole, UK). Rat 
and human liver microsomes, pooled from a group of 20 subjects (1mg protein/mL) and 
phosphate buffered saline (PBS - pH 7.4) were purchased from BD Biosciences (Oxford, UK). 
Test compound solutions and microsomes were stored at -80°C. All other reagents and 
solutions were stored at room temperature. Pre-prepared solutions required for the 
incubation assay were made as stated in Table 5.1. 
 
 
 
Table 5.1: Pre-prepared solutions for incubation assay: Test compound and NAPDH solutions were 
made at 10x final concentration, MgCl2 solution was made at 25 x final concentration. PB = 
Phosphate buffer. 
 5.1.2 Incubation assay 
      The reaction mixture consisted of 760µL phosphate buffer (final concentration = 0.1M), 
40µL MgCl2 solution (final concentration = 2mM), 50µL compound (final concentration = 1µM) 
and 50µL microsomes (1mg protein/mL) in a 1.5mL eppendorf. The reaction mix was 
incubated in a shaking incubator (37°C, 250 rpm) for 15 minutes. The reaction was started by 
the addition of 100µL NADPH (final concentration = 1mM) to make the final volume 1mL. The 
reaction was incubated for a further 60 minutes. Aliquots of 150µL were removed at time 
points 0, 10, 30 and 60 minutes. Samples were added to 150µL ice cold stop solution 
containing MeOH:ACN (1:1) and internal standard (IS) (LT-01-89 (26.6ng/mL) or LT-01-25 
(133ng/mL)). LT-01-89 was the main IS, used in the analysis of all the analogues. For LT-01-89 
experimental testing LT-01-25 was used as the IS. Samples were stored at -20°C for a 
minimum of 2 hours. Control reactions lacking NADPH were also carried out. Each reaction 
was carried out in duplicate.  
 
5.1.3 Extraction and Analysis 
     When ready for extraction the samples were thawed at room temperature and centrifuged 
at 13,000 rpm for 10 minutes (4°C). 200µL of the supernatant was removed and added to 
200µL of H2O. 500µL of EtOAc was added and the samples were vortexed then centrifuged at 
10,000 rpm for 1 minute. 400µL of the organic layer was removed and placed in a new 1.5mL 
eppendorf. A further 500µL of EtOAc was added and the process was repeated. The organic 
layer was dried at room temperature using nitrogen gas. The dried samples were stored at -
 20°C until ready for analysis. For analysis by LC-MS the samples were reconstituted with 
200µL MeOH/H2O (1:1). Analysis was carried out using both LC-MS systems; the Accela 
System and Agilent Infinity System. The quantity of a compound was measured by the area 
under the curve (AUC) ratio of the analyte peak and IS peak. Microsomal stability was 
measured as a percentage of t=0. Mean (± standard deviation, SD) values were calculated 
(n=3).  
     Pharmacokinetic parameters, half-life (t1/2), clearance per mg microsomal protein (ClCYP) 
and intrinsic Clearance (Clint) were calculated from the mean (±SD). The parameters were 
calculated using microsomal stability-time plots to determine the gradient, K and applying the 
following formulas1: 
T1/2 = 0.693/K 
ClCYP = [(final volume/microsomal protein concentration) * 0.693]/T1/2 
Clint = (0.693/T1/2) * (1/microsomal protein concentration) * Scaling Factor 
(Table 5.2) 
 
 
 
 
 
 
Table 5.2: Scaling factors used to calculate an approximate intrinsic clearance per Kg: Scaling factor 
was calculated as (microsomal protein per gram of liver) * (liver weight per kilogram of body 
weight)1. 
Species 
Microsomal 
Protein 
Liver Weight 
Scaling Factor 
(per g of Liver) 
(per Kg of Body 
Weight) 
Rat 44.8 40 1792 
Human 48.8 25.7 1254.2 
 
 Vivid® CYP450 Kit 
Reaction 
Buffer  
Vivid® Substrate 
Positive Control (µM) 
(Final concentration) 
Vivid® CYP1A2 Blue I  Vivid® EOMCC Substrate α-napthoflavone (10 µM) 
Vivid® CYP2C9 Green II Vivid® BOMF Substrate Sulfaphenazole (30 µM) 
Vivid® CYP2C19 Blue II Vivid® EOMCC Substrate Miconazole (30 µM) 
Vivid® CYP2D6 Blue I  Vivid® EOMCC Substrate Quinidine (10 µM) 
Vivid® CYP3A4 Red I Vivid® BOMR Substrate Ketoconazole (10 µM) 
 
5.2 Cytochrome P450 Inhibition Assay 
5.2.1 VIVID Cytochrome P450 Inhibition Screening Kit 
Vivid® CYP450 Screening kits2 contained Vivid® CYP450 reaction buffer (50mL, pH 8.0), CYP 
Baculosomes® plus P450 proteins (0.5mL, 0.5nM), Vivid® regeneration system (0.5mL 100x), 
Vivid® substrate (0.1mg) and NADP+ (0.5mL, 10mM). The reaction buffer used was either 
buffer I (200mM) or buffer II (100mM). The appropriate buffer for each screening kit is shown 
in Table 5.3. The baculosomes consisted of recombinant CYP isoform, cytochrome p450 
reductase and human cytochrome b5. The regeneration system was made using 333mM 
glucose-6-phosphate and 30 units/mL glucose-6-phosphate dehydrogenase in 100mM 
phosphate buffer (pH 8.0). The NADP+ was made up in 100mM phosphate buffer (pH8.0).  
Lyophilized Vivid® substrates were reconstituted with ACN as outlined in Table 5.4. 
Baculosomes, regeneration system and NADP+ were stored at -80°C. The substrate was light-
protected and stored at -20°C.  
Table 5.3: Vivid® CYP450 Kit requirements: Adapted from Vivid® CYP450 Screening Kits User Guide2. 
  
 
5.2.2 Materials and Solutions  
    VIVID Cytochrome P450 Inhibition Screening Kit was supplied by Life Technologies (Paisley, 
UK). Positive controls were purchased from Sigma-Aldrich. Black, untreated, clear-bottomed 
96-well plates were purchased from Appleton Woods (Birmingham, UK). Test compound were 
made at 2.5 x final concentration (10 µM, 1 µM, 0.1 µM) in 1.25% DMSO/Reaction Buffer and 
stored at -80°C. The appropriate reaction buffer (Table 5.3) was prepared with H2O (1:1) and 
was stored at room temperature. Dilution and reconstitution information was taken from the 
Vivid® CYP450 Screening Kits User Guide provided by the manufacturer2. 
 
5.2.3 Inhibition Screening Assay 
     In a 96-well plate, 40µL of test compound (0.1µM, 1µM, 10µM) was added to individual 
wells in triplicate. 40µL of vehicle control (1.25% DMSO) and positive control (Table 5.3) was 
Vivid® Substrate 
Volume of acetonitrile 
added (µL) 
Varioskan™ Flash Multimode Reader 
SkanIt™ Programme Excitation/Emission (nm) 
Vivid® EOMCC 
Substrate 
205 CYP2D6BLUE 415/460 
Vivid® BOMF 
Substrate 
110 CYP2C9GREEN 490/520 
Vivid® BOMR 
Substrate 
150 CYP3A2RED 550/590 
 
Table 5.4: Vivid® Substrate requirements: Adapted from Vivid® CYP450 Screening Kits User Guide2. 
 also added in triplicate. A master pre-mixed containing, 4850µL buffer, 50µL desired 
Baculosomes® and 100µL regeneration system was made and 50µL was added to each well. 
The plate was incubated at room temperature for 10 minutes. A mixture containing 885µL 
buffer, 100µL of NADP+ and 15µL of Vivid™ Substrate was prepared. The reaction was started 
by addition of 10µL of substrate mixture to each well, making a final volume of 100µL. The 
plate was incubated in a Varioskan™ Flash Multimode Reader (Thermo Scientific) at 37.1°C for 
60 minutes. Data was collected using SkanIt™ Software (Thermo Scientific) set to kinetic mode 
and fluorescent readings were recorded using the appropriate programme (Table 5.3).  
 
5.3 in vivo Rat Metabolism 
5.3.1 Materials and Animals 
      Sodium carboxymethylcellulose, benzyl alcohol, tween 80, DMSO, Kolliphor® HS 15, NaOH 
and lyophilized rat pooled plasma (containing anticoagulant, 3.8% trisodium citrate) were 
purchased from Sigma-Aldrich, UK. Saline solution (0.9%) was made with 0.9g NaOH in 100mL 
d.H2O. Heparin and isoflurane anaesthetic were supplied by the University of Liverpool. HPLC 
grade solvents, H2O, MeOH and ACN, were purchased from Thermo Fisher Scientific. Male 
Wistar rats (250g-500g) were supplied and housed by University of Liverpool, Biomedical 
Science Unit. Under normal testing conditions rats were given free access to food and water. 
Fasted rats were denied access to food 12 hours prior to dose.  
 
 5.3.2 Formulations 
   The test compounds were formulated in three vehicles. The amount of vehicle was prepared 
as 5mL/Kg per rat. The first vehicle (vehicle 1) consisted of 10% DMSO, 10% solutol 
(Kolliphor® HS 15) and 80% Saline (0.9%). Vehicle 1 was made by heating solutol until it 
become a liquid and then adding DMSO. The mixture was sonicated for 10 minutes. When 
sufficiently mixed saline was added to reach the desired final volume and the solution was 
sonicated for 5 minutes. Vehicle 1 was freshly prepared before each experiment.  The second 
vehicle, Vehicle 2, was a standard Suspension Vehicle (SSV) (vehicle 2) made up using 0.5% 
sodium carboxymethylcellulose, 0.5% benzyl alcohol and 0.4 Tween 80 in 98.6% saline. All 
components were combined and sonicated for 15 minutes. Vehicle 2 was made up prior to 
testing and stored at -4°C for 1 month.  The final vehicle (Vehicle 3) was made using 10% 
DMSO and 20% solutol through the same method as vehicle 1. The desired volume was 
achieved by adding H2O. Vehicle 3 was also freshly prepared before each experiment.    
 
5.3.3 Sample Collection and Preparation  
     Fasted and non-fasted rats were given a 10mg/kg oral dose of the test compound in two 
formulations (Vehicle 1 and Vehicle 2). Blood was collected under anaesthetic from the tail 
vein. Blood (300µL) samples were collected 0.25, 0.5, 1, 3, 5, 7 and 24 hours after dosing in 
pre-heparinised 1.5mL eppendorfs. Throughout the experiment blood samples were stored 
on ice.    
     A 5mg/kg intravenous dose was given to rats via the tail vein under anaesthetic in a single 
formulation (Vehicle 3). Blood (300µL) was taken from the tail vein at 0.08, 0.25, 0.5, 1, 3 and 
6 hours post dose and collected in heparinised eppendorfs. Blood samples were kept on ice 
for the duration of sample collection and stored at -80ᵒC overnight.  
    All blood samples were centrifuged at 13,000 rpm for 15 minutes to separate the plasma. 
100µL of the supernatant (plasma) was removed and added to 300µL of the MeOH:ACN stop 
solution containing IS (LT-01-25 or LT-01-89). The samples were spun for an additional 15 
minutes at 13,000 rpm. For analysis by LC-MS 200µL of the supernatant was taken and placed 
in LC-MS vials. All samples were stored at -80ᵒC. LC-MS analysis was carried out using the 
Accela System. For each analytical run a standard curve in blank plasma was included.  
 
5.3.4 Standard Curves 
    LC-MS instrument methods were tested with calibration curves.  The curves were produced 
in LCQuan™ Quantitative Software (Thermo Scientific). Validation of the curves was 
determined by predicted concentration accuracy below 20%. The test compounds were made 
into a 1mg/mL stock solution in MeOH. A series of serial dilutions in blank plasma were 
carried out to obtain a number of concentrations; 10ng/mL, 100ng/mL, 500ng/mL, 
1000ng/mL, 2000ng/mL and 4000ng/mL. For analysis of in vivo PK samples, standard curves 
were used to extrapolate plasma-concentration levels.  
 
 5.3.5 Pharmacokinetic Analysis 
   Test compound plasma concentration levels were calculated using the standard curve via 
LCQUAN™. Plasma concentration levels and dosing information was then applied to PK 
Solutions software (SummitPK™) to generate PK parameters: The area under the plasma 
concentration–time curve from 0 h to the last sampling time (AUC0-t), the area under the 
plasma concentration–time curve from 0h to infinity (AUC0-1), elimination half-life (T1/2), 
apparent volume of distribution (Vd), maximum concentration reached in plasma( Cmax), the 
time required to reach Cmax (Tmax) and oral clearance (Cl). PK parameters for each individual 
animal were generated and the mean (± standard deviation) was calculated.  Oral 
bioavailability (F) was determined using mean values: 
 
F = (AUCoral/AUCI.v.)×100% 
 
5.4 Liquid-Chromatography Mass-Spectrometry 
5.4.1 Accela System  
     Two liquid-chromatography mass-spectrometry (LC-MS) systems were used to analyse 
samples from microsomal stability and in vivo rat metabolism studies. The LC consisted of a 
variable loop Accela auto-sampler (200 vial capacity (4°C) and Accela LC pump interfaced with 
a TSQ Quantum MS detector. The MS detector was fitted with atmospheric pressure 
ionization (API) ion source and two E2M30 rotary vacuum pumps and a NG1 nitrogen 
generator (Peak Scientific, Scotland, UK) supplying nitrogen and argon. A HyPurity C18 column 
(10cm x 2.1mm, 5µM diameter) was used. All system parts and column were from Thermo 
 Scientific, UK. The mobile phase consisted of ACN and 0.1% FA (H2O) running on a gradient 
(Table 5.5). HPLC grade ACN was purchased from Thermo Fisher Scientific and FA was from 
Sigma Aldrich. The flow rate was set to 300µL/min and the injection volume was 10µL. Data 
was obtained and analysed using Xcalibur™ and LCQuan™ set to positive mode. The 
instrument was tuned to each compound using TSQ Tune™ (Thermo Scientific). 
 
 
 
 
 
 
 
5.4.2 Agilent Infinity System  
    The second system consisted of the following set-up: an Agilent Infinity 1260 auto sampler 
with a 108 vial capacity (RT) and an Agilent Infinity 1260 Quaternary VL. The LC system was 
connected to a hybrid triple quadruple/LIT (linear ion trap) 4000 QTRAP® MS detector with a 
Turbo V™ ion source. Nitrogen and argon gas was supplied by an API Systems gas generator 
from Peak Scientific. The same HyPurity C18 column (10cm x 2.1mm, 5µM diameter) was used 
in both systems. Auto-sampler and pump were provided by Agilent Technologies (Stockport, 
Time (min) ACN FA (0.1%) 
0.00 40% 60% 
2.00 75% 25% 
3.50 90% 10% 
5.00 90% 10% 
5.10 40% 60% 
6.00 40% 60% 
7.00 40% 60% 
 
Table 5.5: Mobile phase gradient using ACN and FA (0.1%) for Accela System. 
 UK). The mass spectrometer detector was supplied by SCIEX (Warrington, UK). The mobile 
phase consisted of ACN and 0.1% FA running on a gradient (Table 5.6). The flow rate was set 
to 300µL/min and the injection volume was 20µL. Data was obtained and analysed with 
Analyst® Software (SCIEX) set in positive mode. 
 
 
 
 
 
 
 
5.4.3 Transition States  
     The Accela System was used to detect and optimise the parent and product ions for each 
compound. The instrument methods were integrated into the Agilent Infinity System (Table 
5.7). In the Accela System the following parameters underwent auto optimisation using TSQ 
Tune™: Spray voltage (V), vaporiser temperature (°C), sheath gas pressure, ion sweep 
pressure, aux gas pressure, capillary temperature (°C), tube lens offset (V) and collision 
energy (V).  
 
Time (min) ACN FA (0.1%) 
0.00 40% 60% 
2.00 75% 25% 
3.50 90% 10% 
5.00 95% 5% 
5.10 40% 60% 
6.10 40% 60% 
9.00 40% 60% 
 
Table 5.6: Mobile phase gradient using ACN and FA (0.1%) for Agilent Infinity System. 
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Compound MW (g/Mol) Parent Ion (m/z) Product Ions (m/z) 
LT-01-25 291 292.2 205.1 163.1 
LT-01-26 304 305.2 214.2 208.5 
LT-01-45 323 324.2 303.9 283.0 
LT-01-88 317 318.1 262.0 233.0 
LT-01-89 319 320.2 233.2 204.2 
LT-02-50 279 280.1 238.1 205.1 
LT-02-53 303 304.2 163.1 126.1 
LT-02-86 290 291.1 205.1 135.0 
LT-02-39 305 306.3 205.2 149.2 
RKA-018 287 286.2 270.3 172.1 
 
Table 5.7: Parent and product ions (m/z) used to detect the compounds. 
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 Appendix I 
Physiochemical Properties and MPO evaluation  
    Aqueous solubility was determined by ChemPartners (n=2). An eight-point (0.02, 0.1, 0.2 
(1:1). The test compound was prepared from a stock solution to a final concentration of 
100µM in 0.1% DMSO (100 mM phosphate buffer). The sample was shaken at 1000 rpm for 1 
hour at room temperature. The sample was then centrifuged for 10 mins at 12000 rpm 
precipitate un-dissolved particles. The supernatant was transferred to a new tube at different 
dilutions (undiluted, 1:10 diluted, 1:100 diluted). 5 µL of supernatants was added to 95 µL 
ACN containing IS. The samples were analysed by LC-MS-MS against the calibration curve. 
Propranolol, ketoconazole and tamoxifen were also tested for solubility comparison. 
       The six physiochemical properties used in MPO assessment were calculated at the 
University of Liverpool, Chemistry Department. ChemDraw software from PerkinElmer 
(Massachusetts, USA) was used to calculate the ClogP, MW and TPSA. The HBD groups were 
determined by the number of hydrogens attached to an electronegative atom (e.g. N or O) 
within the structure. The pKa and ClogD were calculated using ACD/ChemSketch software 
from ACD/Labs (Ontario, Canada).  
     The physiochemical parameters were then used to calculate the MPO score. MPO 
evaluation was carried out using the MPO excel worksheet shown below (Figure 1)1. The 
physiochemical parameters can be inserted into the worksheet to calculate the MPO score.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MPO Calculator for Microsoft Excel™ 
 Appendix II 
GyRα1 Selectivity Electrophysiology Assay  
   Claw frog (Xenopus laevis) oocytes were surgically removed under anaesthetic (0.3% tricaine 
in water). The cells were dissected and stored in sterile-filtered ND96+ medium (96mM NaCl, 
2mM KCl, 1mM CaCl, 1mM MgCl, 5mM HEPES, pH 7.4) containing gentamycin (50µg/mL). The 
oocytes were isolated as described in Grudzinska et al., 20052. Cells were injected with 5ng of 
cRNA, at a volume of 0.05µL, and incubated in the ND96+ medium for 24 hours (18°C) prior to 
electrophysiology experiments. Whole-cell recordings were carried out in solution (115mM 
NaCl, 1mM KCl, 1.8mM CaCl, 10mM HEPES, pH 7.4). A resting potential of -70mV was 
maintained during the experiment. To ensure current quality and 20 % maximal activation 
(EC20), effected currents were measured in response to increasing glycine concentration. The 
test compound was applied in the presence of glycine (EC20). The cells were perfused with test 
compound for 30s before addition of glycine. Over the course the experiment, individual 
oocytes response to glycine (EC20) varied in peak amplitude 8 ± 2 %. All experiments were 
performed at room temperature. 
Currents were measured with Clampfit 9.2 software (Molecular Devices, California USA). The 
data was analysed using KaleidaGraph program (Synergy Software, Pennsylvania, USA) and 
GraphPad Prism (GraphPad Software Inc., California, USA). Current response was plotted 
against drug concentration to establish EC50 parameters. These experiments were carried out 
by Michael Kilb under the supervision of Prof. Bodo Laube at the University of Tübingen. The 
protocol above was provided by Michael Kilb.  
 Appendix III 
Chung Lesion Model of Neuropathic Pain  
    Male Wisar rats (125-149g) were used in proof of concept studies. Neuropathic pain was 
induced by partial ligation of the left sciatic nerve. The rats were anaesthetised (isoflurane/O2 
inhalation). The left sciatic nerve exposed at mid-thigh level through a small incision. The 
nerve was tightly ligated with 7.0 silk. The wound was closed with skin clips. Testing occurred 
12-15 days following surgery to ensure the development of neuropathic pain.  Treatment 
groups were randomised and blinded (n=6). A pre-dose behavioural baseline was taken by 14 
days following nerve ligation before drug treatment. Following drug administration, 
behavioural testing was carried out at 1, 3, 6 and 24 hours post-dose. The drug was tested at 
3, 10 and 30mg/Kg (P.O). A 10mg/Kg vehicle control (10% DMSO, 10% solutol and 80% saline) 
and 30mg/Kg positive control (gabapentin or lamotrigine) was included for comparison. 
     Mechanical allodynia was examined in a model of neuropathic pain by measuring paw 
withdrawal thresholds (PWT) to increasing mechanical force applied to the dorsal surface of 
the rat paw using an Analgesymeter (Ugo-Basile, Milan) equipped with a wedge-shaped probe 
(area 1.75 mm2). The maximum force applied was 250 g and the end-point was taken as 
withdrawal of the ipsilateral hind paw. The withdrawal latency (s) and threshold (g) were 
recorded.  The contralateral paw was also tested, however the data is not shown in this 
thesis.  
    Cold hyperalgesia was measured as paw withdrawal latencies (s) were from a cold-plate set 
at 10°C (Ugo Basile, Milan). Prior to testing, the cold plate was calibrated for 5 minutes at the 
 set temperature. The animals were carefully restrained and each hind paw was placed onto 
the cold-plate. The end point was taken as the withdrawal of the paw and recorded as the 
withdrawal latency for both the ipsilateral and contralateral paw. A maximum cut-off of 30s 
was used for each paw. The experiments were carried out at King’s College London by Clive 
Gentry under the supervision of Prof. Steve McMahon. The protocol described above was 
supplied by Clive Gentry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix IV 
GABAA α1β2γ3 Receptor Profiling 
     Whole-cell recordings were carried on out cells expressing GABAA α1β2γ3 using a 
PatchXpress automated patch clamp system (Molecular Devices). Cell lines were validated via 
direct application of GABA at an increasing dose. The cells were maintained it a holding 
potential -60mV. The internal solution was 90mM KCl, 50mM KF, 11mM EGTA, 10mM HEPES, 
1mM MgCl2 and 2mM Mg-ATP. The external solution used was 137mM NaCl, 4mM KCl, 10mM 
HEPES, 1.8mM CaCl2, 1 mM MgCl2 and 10 mM glucose.    
     The test compound was applied at six concentrations (0.12, 0.37, 1.11, 3.33, 10 and 30µM) 
with and without GABA (2µM) (n=3). The vehicle used was 0.3% DMSO. The cells were treated 
with GABA (30µM) and vehicle to ensure activity of GABAA α1β2γ3 receptors and determine 
the EC20 for GABA. The cells where then washed for 2 mins. Vehicle and GABA (2µM) where 
applied and the cells where washed again for 2 mins. This process was repeated. The cells 
were pre-treated for 1 min with the test compound, and then GABA (2µM) was applied along 
with the testing compound to record the effect on current. The cells were again washed for 2 
mins. Finally propofol (30µM) and GABA (2µM) was applied as a positive control (Figure 2). 
This method was adapted from the data report provided by BioFocus.  
 
     
 
  
 
 
 
 
 
 
 
 
 
 
Figure 2. Example of Compound Testing Regime 
 Appendix V  
Hepatocyte Stability 
     Cryopreserved rat and human hepatocytes were taken from liquid nitrogen storage and 
thawed in a shaking water bath for 2 mins (37°C). The cells were transferred to 50mL of the 
thawing medium (see Table 1 below). The cell pellet was resuspended by the addition of 
Krebs-Henseleit buffer (pre-warmed) buffer containing 5.6g/L HEPES. The mixture was 
centrifuged for 3 minutes (500 rpm). Cell viability and yield was confirmed. If needed the cells 
were diluted to a density of 2x106 cells/mL. 
 
         The test compound (final concentration = 1µM) was prepared as a dosing solution 
containing 990µL of Krebs-Henseleit buffer and 10µL spiking solution (200µM). The spiking 
solution was made-up with 20µL of test compound stock solution (10mM) and 980µL DMSO. 
 
Reagent Initial Concentration Final Concentration 
Quantities of reagents to add 
based on volume needed 
   
50 mL 
Williams E Medium - - 35 mL 
Isotonic Percoll (90% 
Percoll/10% DPBS) 
- 30% 15 mL 
DPBS 10 × 
   
Glutamax 200 mM/100 × 2 mM 500 μL 
HEPES 1 M 15 mM 750 μL 
Fetal Bovine Serum - 5% 2.5 mL 
Human Recombinant 
Insulin 
4 mg/mL 4 μg/mL 50 μL 
10 mM Dexamethasone 
(dissolved in DMSO) 
10 mM 1 μM 5 μL 
 
Table 1. Preparation of Thawing Medium from ChemPartner’s Protocol 
 The dosing solution (50µL) was added to a 96-well plate. The wells were organised into time 
points (0, 15, 60, 120 and 240 mins, n=2). The pre-warmed hepatocyte solution was also 
added to each well (50µL, 2x106 cells/mL). The plate was incubated at 37°C. 
    At designated time points, 100µL of ACN containing IS (Osalmid) was added to the 
corresponding wells. The wells were sealed and the plate was returned to the incubator. This 
was repeated for each time-point. At the final time point the plate was removed from the 
incubator and centrifuged for 15 minutes (4000 rpm, 4°C). The supernatants were removed 
and diluted with ultrapure H2O (2-fold). The samples were analysed by LC-MS. This study was 
conducted by ChemPartners. The protocol is adapted from the data-sheet provided.   
 
 
 
 
 
 
 
 
 
 
 Appendix VI 
CSF and Plasma Exposure 
    Male Sprague-dawley rats (260-290g) were fasted overnight (n=9). Free access to food and 
water was given 4 hours post dose. An oral 3mg/Kg dose of the test compound was 
administered. The testing compound was formulated in 10% DMSO, 10% solutol and 80% 
saline. Blood was collected via cardiac punctures at 2, 3 and 4 hours post dose following 
termination by raising CO2 The blood samples (150µL) were stored into EDTA-2K tubes and 
centrifuged to obtain plasma (2000 G,4°C , 10 min). The CSF samples were collected via direct 
puncture into the cisterna magna using a butterfly needle attached to a syringe. White paper 
was used as a background to monitor colour change during collection. Following a colour 
change, the tubing was quickly clamped and cut just above the clamped site. The clear sample 
was collected into the syringe. All samples were stored at -80°C. 
    For LC-MS analysis, a 30µL aliquot of the plasma samples were added to 150µL ACN 
containing IS (Dexamethasone, 500ng/mL). The mixture was vortexed for 5 mins and 
centrifuged at 14000 rpm for a further 5 mins. For the CSF samples, a 15 µL aliquot of the 
sample was added to 15µL MeOH:H2O (1:1). Then 100µL of the ACN/IS solution was added. 
The mixture was vortexed for 5 mins, then centrifuged at 14000 rpm for 5 mins. These 
experiments were carried out by ChemPartners; the protocol was adapted from the data 
sheet. 
 
 
 Appendix VII 
Plasma Protein Binding Assay 
    Plasma protein binding was tested via equilibrium dialysis (Figure 3)3; 4. Rat plasma and 0.5 
M sodium phosphate buffer were applied to a 96-well plate (380µL). The test compound and 
positive controls were added to the plate (20µL). The test compound (1µM) and positive 
controls (Warfarin and Quinidine, 1µM) were formulated in 0.2% DMSO (in buffer). For 
dialysis sample loading, 100µL of blank dialysis buffer was added to the receiver side of 
dialysis chamber. Then, 100µL of the plasma and testing compounds were applied to the 
donor side of the dialysis chamber.  
 
 
 
 
 
 
      
 
    The dialysis block was covered and was incubated in a shaking incubator (60 rpm, 37°C) for 
5 hours. After incubation 25µL aliquots were taken from both dialysis chambers and placed in 
Figure 3. Simplified Schematic of Equilibrium Dialysis3. 
 a clean 96-well plate (n=2). The relevant matrix (buffer or plasma, 100µL) was also applied to 
the plate. The samples were quenched with 200µL of ice-cold ACN containing IS (Osalmid) and 
vortexed for 10 mins at 600 rpm. The samples were then centrifuged for a further 15 mins 
(6000 G). 50µL of the supernatant was transferred to a new plates and mixed with 50µL Mili-
Q H2O. The plate was covered stored at -20°C until analysis by LC-MS. 
    A second plate was prepared to measure protein binding at t=0. Aliquots (25µL) of plasma 
and testing compound were taken from the original 96-well plate. The same volume of buffer 
was added to each well and the samples were immediately quenched with 200µL of the 
ACN/IS solution. The plate was covered stored at -20°C until analysis by LC-MS. The above 
protocol was adapted from the data sheet provided by ChemPartners.  
 
 
 
 
 
 
 
 
 
 Appendix VIII 
hERG Cardiotoxicity Assay  
    CHO-K1 cells were transfected with hERG cDNA to express hERG channels. The cells were 
cultured in CO2 incubator using a medium containing Ham’s F12, 10% heated fetal bovine 
serum, hygromycin B (100 μg/ml) and geneticin (100 μg/ml). To ensure culture quality only 
colonies with 95% viability and a density of 3-8 × 106 cells/mL were used. During recording 
cells were stored in serum-free HEPES medium for up to four hours. The internal solution was 
120mM KCl, 5mM EGTA, 10mM HEPES, 1.75mM MgCl2, 5.3mM CaCl2 and 4mM Na-ATP. The 
external solution used was 145mM NaCl, 4mM KCl, 10mM HEPES, 2mM CaCl2, 1 mM MgCl2 
and 10 mM glucose.    
    Whole-cell recordings were performed using QPatch automated clamp system (Sophion, 
Sweden). The cells were voltage clamped at resting potential (-80 mV). The hERG current was 
activated by depolarizing at +20 mV for 5 sec. The current was then taken back to -50 mV for 
5 sec to observe the deactivating tail current. The maximum tail current size was used to 
determine hERG current amplitude. The cells were recorded for 120 sec to assess current 
stability. Only stable cells with recording parameters above threshold were selected for the 
drug testing assay.  
    The test compound was tested at six concentrations (0.1, 0.3, 1, 3, 10 and 30µM). The 
vehicle used was 0.1% DMSO (except for 30 µM which was formulated in 0.3% DMSO). The 
positive control was cisapride (0.1, 0.3, 1, and 3µM). The cells were exposed to the vehicle 
solution to establish the baseline. After allowing the current to stabilize for 3 minutes, the test 
 compound was applied. The cells were kept in the test solution until the effect on current 
reached a steady state for 4 mins. For dose response assay, compound was applied to the 
cells from low to high concentration. The cells were washed with vehicle solution after 
testing. The positive control cisapride was applied to the same cell batch. The data was 
analysed using Assay Software (Sophion) and Graphpad Prism. This protocol was taken from 
the data report provided by ChemPartners.  
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix IX 
HepG2 MTT Cytotoxicity Assay 
    Hepatoxicity was measure by the effect on MTT metabolism to formazan5. HepG2 cells 
were applied to a 96-well clear-bottom plate (100µL per well). The plate was incubated at 
37°C for 24 hours. The cells were then dosed the test compound (0.04, 0.1, 0.4, 1.0, 4.0, 10, 
40, 100µM), a positive control (chlorpromazine) and a vehicle control (0.5% DMSO) in 
triplicate. The plate was incubated for a further 72 hours. One hour before the end of the 
incubation period, MTT was added to each well and the plate was dried. The formazan 
precipitate was then re-solubilised using DMSO. 
   The plates are then scanned at 570 nm in a Sunrise™ microplate absorbance reader (TECAN 
Group Ltd, Männedorf, Switzerland). Cell death was indicated by lack of formazan formation. 
Effect of the compounds is measured as a ratio of the vehicle control. HepG2 MTT cytotoxicity 
was performed by Cyprotex (Macclesfield, UK). The above protocol was taken from the data 
report provided by Cyprotex.   
 
 
 
 
 
 
 Appendix X 
AMES Assay 
    Two S. typhimurium strains, TA98 (hisD3052, rfa, uvrB/pKM101) and TA100 (hisG45, rfa, 
uvrB/pKM101) (see Table 2) were exposed to a vehicle control, two positive controls (2-
nitrofluorine/4-nitroquinoline n-oxide and aminoanthracene) and the test compound, LT-01-
25 (8, 16, 31, 62, 125 and 250µg/mL) for 90 minutes in a low histidine medium. The cultures 
were then diluted into a histidine free medium and allotted in to 48 wells of a 348-well plate. 
The plate was incubated at 37°C for 48 hours. Colony growth was indicated by a colour 
change. A visual comparison was made between the vehicle control and test compound. 
Positive response (mutation) was indicated by a minimum 2-fold increase in colony growth 
from the vehicle control (mean ± SEM).  
      Statistical analysis was carried out using an unpaired, one-sided Student’s T-test. 
Experiments were carried out with and without 4.5% S9 (S9 fraction taken from the liver of 
Aroclor-1254 treated rats) to measure the effect of metabolism. A NADPH-regeneration 
system was added in experiments including S9. AMES assay was carried out by Apredica 
(Cyprotex US) in Watertown, MA, USA. The above protocol was taken from the data report 
provided by Apredica.  
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Table 2. Breakdown of S. typhimurium Testing Strains6. 
 
uvrB DNA repair mutation makes strains more vulnerable to DNA damage from UV light 
hisD3052 Mutated allele resulting in a frameshift mutation 
hisG45 Mutated allele resulting in a base-pair substitution 
rfa Mutation that increases cell permeability 
pkM101 Ampicillin resistant plasmid that is highly responsive to mutagens 
 
